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ABSTRACT 
Hepatitis B virus (HBV) is one of the world’s unconquered diseases, with 370 million 
chronically infected globally. HBV replicates in hepatocytes within the liver that exist 
under a range of oxygen tensions from 11% in the peri-portal area to 3% in the peri-
central lobules. HBV transgenic mice show a zonal pattern of viral antigen with 
expression in the peri-central areas supporting a hypothesis that low oxygen regulates 
HBV replication. We investigated this hypothesis using a recently developed in vitro 
model system that supports HBV replication. We demonstrated that low oxygen 
significantly increases covalently closed circular viral DNA (cccDNA), viral promoter 
activity and pre-genomic RNA (pgRNA) levels, consistent with low oxygen boosting 
viral transcription. Hypoxia inducible factors (HIFs) regulate cellular responses to low 
oxygen and we investigated a role for HIF-1α or HIF-2α on viral transcription. A 
combination of HIF inhibitors and silencing of HIF-1α and HIF-2α ablated the effect of 
low oxygen on cccDNA and pgRNA, suggesting a role in regulating HBV transcription. 
This study highlights a new role for hepatic oxygen levels to regulate multiple steps in 
the HBV life cycle and this may impact on future treatments for viral associated 
pathologies. 
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1. INTRODUCTION 
1.1 The Liver as the Site for Hepatitis B Infection 
The liver is a specialised organ that has diverse roles in the storage and conversion of 
energy, blood homeostasis, chemical detoxification and immunity to microbial 
infections. The liver is composed of different cell types: hepatocytes are the most 
dominant cell type comprising up to 70% of the liver, bile duct epithelium and Kupffer 
cells. Hepatocytes and bile duct epithelium are unique to the liver and stem from a 
common progenitor (Fausto, 1990, Thorgeirsson, 1996, Fausto and Campbell, 2003). 
Hepatocytes are the only confirmed target for all members of the Hepatitis B virus 
family (Seeger and Mason, 2000) and limited evidence suggests that bile duct 
epithelial cells, pancreas, kidney and lymphoid cells can be infected by 
hepadnaviruses, however most of this data was obtained using woodchuck or duck 
Hepatitis B virus (HBV) (Halpern et al., 1983, Jilbert et al., 1987, Ogston et al., 1989, 
Nicoll et al., 1997). 
1.1.1 Liver Structure 
The liver can be divided into small sections called lobules, where (Figure 1.1) shows a 
schematic representation demonstrating the role of the liver in blood homeostasis 
(Seeger and Mason, 2000). Blood enters through the portal veins and hepatic arteries 
that make up the hepatic portal triad. Blood then splits into smaller vessels and into the 
sinusoidal spaces, which exist between rows of hepatocytes (Seeger and Mason, 
2000). These rows of hepatocytes are typically one cell thick in mammals. Blood flows 
through spaces that are lined with endothelial cells and Kupffer cells (Kolios et al., 
2006). These enact various functions in cleaning blood, immune responses and 
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breakdown of heme into bile. Blood flow continues to the hepatic central vein and exits 
the liver. This occurs in each lobule separately but ultimately the blood flows into one of 
several surrounding “central” veins (Seeger and Mason, 2000). 
The liver experiences a range of oxygen concentrations from 11% at the hepatic portal 
triad to 3% in the hepatic central vein. This gradient can be divided into 3 zones as 
shown in (Figure 1.2) (Jungermann and Kietzmann, 2000, Adams and Eksteen, 2006, 
Wilson et al., 2014). These zones are created through the directional blood flow 
towards the central veins that result in a physiological oxygen gradient (Wilson et al., 
2014). These zones can also be distinguished based upon carbohydrate metabolic 
functions, which are modulated through the oxygen tension (Jungermann and 
Kietzmann, 2000, Gebhardt et al., 2007). An oxygen concentration of 3% is considered 
a hypoxic environment; therefore, part of a healthy liver is continually exposed to low 
oxygen. 
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Figure 1.1 Anatomy of the liver lobule (Seeger and Mason, 2000) 
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Figure 1.2 Cartoon depicting different zones within a liver lobule (Wilson 
et al., 2014) 
A) A hematoxylin and eosin stain of a liver lobule, which is divided into 3 zones. B) 
Schematic representation of the oxygen gradient within the liver. 
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1.1.2 Liver Differentiation 
Hepatocytes are considered “terminally” differentiated and will remain within the liver 
not dividing for up to 12 months (Seeger and Mason, 2000). However, the capacity of 
the liver to regenerate following injury is remarkable. Following acute injury and 
removal of up to 70% of liver mass, hepatocytes can replicate and generate 
replacements for lost cell mass (Grisham, 1962, MacDonald, 1961, Rhim et al., 1994). 
If required almost the entire cell population can proceed through the cell cycle. 
However, this is not the only method of regeneration. Literature shows that in 
circumstances of severe or chronic injury, hepatocytes can become overwhelmed; at 
this point the hepatic stem cells or oval cells will begin to repair damaged tissues, a 
process known as ductal reaction (Fausto and Campbell, 2003, Thorgeirsson et al., 
1993, Thorgeirsson, 1996, Fausto et al., 2006). The literature suggests that the 
progenitor cells reside within the periportal region of the liver (specifically in the canal 
of Hering Figure 1.1) (Coleman et al., 1993, Dabeva et al., 1993, Evarts et al., 1987, 
Evarts et al., 1989, Thorgeirsson et al., 1993). When proliferation begins they migrate 
towards the central vein along the row of hepatocytes, where they will mature into 
bipotential cells, that proliferate into hepatocytes and finally mature hepatocytes. The 
cells get larger as they proceed towards the central vein (MacDonald, 1961, Fausto, 
1990, Thorgeirsson et al., 1993, Zaret and Grompe, 2008). 
It is unclear whether HBV can target and infect progenitor cells or if viral nucleic acids 
spread during division. One of the problems with current treatments for established 
HBV infections is the persistence of viral DNA in infected hepatocytes, of which up to 
35% can be infected in chronically infected patients (Rodriguez-Inigo et al., 2003). 
Removing the virus requires either total elimination of viral DNA from liver cells or 
complete replacement of infected cells by an uninfected population of progenitor cells. 
Nicholas Ross Baker Frampton Hepatitis B and Hypoxia Student ID: 1301165 
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Hepatocytes provide an incredibly stable and constant environment for hosting HBV 
infections. The regenerative capacity of the liver is amazing, potentially able to replace 
all infected cells with uninfected cells, however this simply does not occur fast enough 
in cells with 6-12 month half life. The virus does not appear to be cytopathic so removal 
of an established chronic infection would be difficult (Seeger and Mason, 2015). 
1.2 Hepatitis B Virus 
1.2.1 HBV Epidemiology and Vaccinology 
HBV is one of the most common infectious diseases globally. There are approximately 
350 million people chronically infected with HBV worldwide and an estimated 2 billion 
people show serological evidence of a past or present HBV infection. The prevalence 
of HBV varies geographically; from high levels (>8%) in African regions and East Asia, 
to intermediate levels (2-7%) in the Middle East and Indian subcontinent and low levels 
(<2%) in Western Europe and North America (Hou et al., 2005, Saeed et al., 2014). 
HBV infects the liver and can cause both acute and chronic disease. Of those infected 
more than 90% of healthy adults will recover from the infection within the first year. 
Approximately 5% of infected adults will develop chronic infections and of these 
individuals, 20-30% will progress to develop cirrhosis and/or hepatocellular carcinoma 
(HCC). Those at greater risk of chronic infection are children below the age of 6, with 
80-90% of infants infected in the first year of life developing chronic infections 
(Schweitzer et al., 2015). HBV is transmitted through multiple routes however, in areas 
where HBV is highly endemic, the most common route is from mother to child. This is 
called perinatal transmission. The second most common route is through exposure to 
infected blood, called horizontal transmission. Blood is the most important vehicle for 
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transmission, but other bodily fluids have been implicated such as semen and saliva 
(Hou et al., 2005). 
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Figure 1.3 Global HBV prevalence (Hou et al., 2005) 
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Transmission from mother to child occurs during the perinatal period. Before HBV 
vaccination was integrated into routine immunisations, the incidence of babies 
becoming HBV positive was between 10-30% for mothers that were HBV S antigen 
(HBsAg) positive and HBV E antigen (HBeAg) negative. These values are important 
because clinical symptoms for HBV are indistinguishable from other forms of viral 
hepatitis, so diagnosis is dependent on serological testing for HBV antigens and 
antibodies against these antigens (Mahoney, 1999). However, transmission rates as 
high as 70-90% were reported in mothers positive for both HBV antigens (Hou et al., 
2005, Kwon and Lee, 2011). There are 3 main routes of HBV transmission from mother 
to baby: transplacental transmission in utero, natal transmission during delivery and 
post-natal infection during care or breastfeeding (Kwon and Lee, 2011, Hou et al., 
2005, Choisy et al., 2017, Manyahi et al., 2017). In many countries where 8-15% of 
children would develop chronic infections; the use of vaccination has reduced the rate 
to less than 1% (WHO, 2017, Gentile et al., 2014). As of 2013, 183 member states of 
the UN have agreed to vaccinate infants against HBV (WHO, 2017). 
Sexual transmission is another common route of infection, particularly in the low 
endemicity regions like North America. Men who have sex with men (MSM) were 
considered at the highest risk of infection with 70% of homosexual men being infected 
within 5 years of beginning sexual activity. However, there has been an increase in the 
level of heterosexual transmission case, such that sexual partners of drug users, 
prostitutes or clients of prostitutes are considered at high risk of infection (Hou et al., 
2005, Lu et al., 2010, Sharifi, 2014). The third route of transmission is through 
parenteral or percutaneous transmission. This includes injection drug use, 
transfusions, dialysis, acupuncture and working as a health worker as examples. 
These routes carry a low risk of developing into chronic infections (<5%) because 
Nicholas Ross Baker Frampton Hepatitis B and Hypoxia Student ID: 1301165 
 
21 
 
individuals at risk generally acquire their infections in adolescence or as early adults. 
Most of these patients will progress to immune clearance and spontaneous recovery 
(Hou et al., 2005, Kwon and Lee, 2011). 
Interestingly HBV infection does not result in a significant host innate immune response 
through proinflammatory cytokine or interferon (IFN) activity. Recent studies have 
shown that HBV infection can result in the downregulation of antiviral effectors such as 
interferon stimulated genes (ISG), Toll-like receptor, and pathogen recognition receptor 
pathways (Lebossé et al., 2016, Luangsay et al., 2015). The lack of innate immune 
stimulation appears to be regulated by high level expression of HBV S antigen (Wang 
et al., 2013, Ortega-Prieto and Dorner, 2017). However, at higher HBV titres, 
macrophages are capable of sensing HBV and stimulating inflammatory cytokine 
expression (Cheng et al., 2017). This process remains poorly understood, because 
high level expression of HBV surface proteins can also act as an immune decoy. This 
is because surface proteins expressed at vast levels have tolerogen behaviour, which 
inhibits corresponding antibody activity through exhaustive binding (Ortega-Prieto and 
Dorner, 2017). The HBV genome is organised onto host-derived histones, which 
results in regulation at an epigenetic level (this will be discussed in more detail in 
Section 1.2.4). It has been shown that host factors can inhibit HBV transcription at this 
point through deacetylation of histones, however, HBV X protein binding to covalently 
closed circular DNA (cccDNA) reverses this inhibition as part of the transcriptional 
activation process (Riviere et al., 2015). This process enables a form of host mimicry 
that prevents activation of host immune responses (Riviere et al., 2015). Additionally, 
HBV transcripts are capped and polyadenylated similar to host mRNAs. This helps to 
prevent innate immune sensing via RIG-I and MDA-5 (Seeger and Mason, 2015, 
Ortega-Prieto and Dorner, 2017). 
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Following acute infection with HBV in adults there are multiple stages to infection 
progression. Approximately 5% of patients with acute HBV will progress into chronic 
HBV infection. Initial infection can result in an immune tolerance phase, in which 
patients demonstrate high levels of HBeAg and HBV DNA expression, however this is 
primarily seen in patients with perinatal or early-childhood infections (Takashima et al., 
1992, Shi and Shi, 2009). 
The next stage in HBV infection is called the immune clearance stage. This stage is 
characterised by high levels of HBeAg, HBV DNA, and active inflammation and fibrosis 
of the liver (Sharma et al., 2005). During this stage patients can undergo HBeAg 
seroconversion, resulting in the expression of anti-HBeAg antibodies (Sharma et al., 
2005). This activity can stimulate the host immune response allowing activation of 
HBeAg and HBcAg specific T cell clones (Milich et al., 1995). This can cause a 
decrease in hepatic inflammation, decreased HBeAg expression, immune-mediated 
hepatocellular injury, and inhibition of viral replication (Sharma et al., 2005, Elgouhari 
et al., 2008). During the immune clearance phase, it has been demonstrated that 
patients can experience flare ups of acute-like HBV infection, which can precede 
remission of hepatitis activity, however, this can also result in cirrhosis progression and 
further HCC development (Furusyo et al., 2002, Shi and Shi, 2009). 
The next phase of chronic HBV infection is the inactive carrier stage. Inactive carriers 
represent the largest group of chronically infected patients. Following seroconversion, 
patients remain negative for HBeAg expression and demonstrate low level expression 
of HBV DNA (Sharma et al., 2005). This stage of infection is usually benign. However, 
patients can undergo spontaneous reactivation of HBV, which results in progressive 
liver damage and can mimic acute HBV infections (Tsai et al., 1992, Shi and Shi, 
2009). Progress to the reactivation stage can occur spontaneously or whilst a patient 
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undergoes immune suppression (Shi and Shi, 2009). Chronic HBV patients who are 
HBeAg negative demonstrate lower levels of HBV DNA, however long-term prognosis 
is poorer and spontaneous recovery is rarer (Shi and Shi, 2009). HBeAg negative 
patients experience the same level of necrotic inflammation but demonstrate higher 
levels of fibrotic activity than patients who are HBeAg positive (Shi and Shi, 2009). 
Currently there is no cure for chronic HBV infections, however there are treatments that 
limit viral replication and reduce the risk of developing complications such as cirrhosis, 
liver failure and HCC. The main treatments recommended by the WHO are Entecavir 
and Tenofovir, particularly when treating infections in high endemic, low-income areas 
because the treatments are easy to implement, just a single pill per day, and represent 
a low risk for developing resistance (Chang et al., 2006, Jenh et al., 2009, Chang et al., 
2010, Gane, 2017). Entecavir is a selective guanosine analogue that has significant 
activity against HBV, specifically through inhibition of reverse transcription, DNA 
synthesis and viral transcription (Chang et al., 2006, Sims and Woodland, 2006). 
Entecavir can suppress viral DNA and maintain normal alanine transaminase (ALT) 
levels in infected individuals over 5 years of therapy (Chang et al., 2010, WHO, 2017). 
Tenofovir is a nucleotide analogue that inhibits HBV reverse transcriptase activity and 
reduces viral replication; it is also regularly used in the treatment of HIV (Jenh et al., 
2009, Gentile et al., 2014, Isorce et al., 2015). The two drugs mentioned above can be 
used in concert to prevent the development of drug resistance. 
Despite the effectiveness of nucleotide analogues, some literature suggests 
peginterferon as a first-line treatment (Isorce et al., 2015). This is due to reportedly 
higher off-treatment response rates due to the added immune-modulatory effects. The 
literature suggests that treatment can result in the development of an inactive HBsAg 
carrier state in 30% of patients (Rijckborst and Janssen, 2010), this represents 
Nicholas Ross Baker Frampton Hepatitis B and Hypoxia Student ID: 1301165 
 
24 
 
chronically infected patients that demonstrate no HBeAg expression, anti-HBe 
antibodies and low or undetectable levels of HBV DNA (Rijckborst and Janssen, 2010, 
Sharma et al., 2005). However, this treatment is expensive and only recommended by 
the WHO for high income, low endemic areas (Perrillo, 2009, Rijckborst and Janssen, 
2010, WHO, 2017). 
As there is no cure and these treatment options are costly and lifelong, the best 
method of controlling HBV is through prevention. One method is simple behaviour 
modifications; practicing safe sex and improving blood-screening practices. However, 
in developing countries where the greatest risk of infection occurs in early childhood; 
the use of immunoprophylaxis and active immunisation are recommended. 
Immunoprophylaxis involves treating patients with Hepatitis B Immune Globulin 
(HBIG): a preparation of anti-HBV Ig isolated from the donors with high levels of anti-
HBV immunity. This is typically given in 4 instances: to new-borns with infected 
mothers; after needle stick exposures; after sexual exposure and following a liver 
transplantation (Hou et al., 2005). The primary method of prevention is through 
immunisation using a HBV vaccine that comprises high concentrations of Hepatitis B 
Surface antigen (HBsAg), with small alterations that prevented spontaneous 
aggregation into 20nm particles. The first generation of vaccines consisted of an 
inactive plasma-derived vaccine. A second-generation vaccine is a DNA recombinant 
HBV vaccine. Both are effective at inducing protective antibody levels in 95% of 
infants, children and young adults. Evidence suggests that vaccination against HBV 
can reduce HCC incidence in HBV endemic area. One study showed that the annual 
incidence in children from Taiwan aged 6-14 dropped 0.70 per 100,000 to 0.57 over a 
4 year period (Chang  et al., 1997). It is suggested that protection lasts for up to 20 
years, perhaps lifelong in some cases. Studies have shown that protection remains 
Nicholas Ross Baker Frampton Hepatitis B and Hypoxia Student ID: 1301165 
 
25 
 
even when anti-HBs levels begin to drop or are undetectable. This suggests long term 
B-cell memory continues to provide protection against HBV (WHO, 2017). Despite the 
existence of the vaccines, of which more than 1 billion doses have been given, HBV is 
responsible for 500,000 to 1.2 million people deaths annually due to HBV related 
morbidity and mortality. HBV represents a substantial portion of the global disease 
burden and warrants further study (Hou et al., 2005). 
1.2.2 HBV Morphology 
Hepatitis B virus (HBV) is a small DNA virus of the Hepadnaviridae family and is 
classified into 7-8 genotypes A-G (and recently described H) with distinct geographical 
locations (Hou et al., 2005, Song et al., 2005). As mentioned briefly, there are related 
viruses that exist within woodchucks, squirrels, ducks and herons. HBV has 3 well 
characterised types of particles that can be visualised using electron microscopy 
(Gerlich, 2013). These are differentiated by the size of the particle and include: 22nm 
spherical non-infectious structures that comprise HBV Surface (S) protein and host 
derived lipids; non-infectious filaments consisting of HBs and host derived lipids, 
however they also contain HBV M and L proteins; finally, infectious HBV virions also 
called Dane particles that are 42nm in diameter, spherical in shape and double shelled. 
This double shell consists of a lipid envelope studded with HBV S proteins (Urban et 
al., 2014, Gerlich, 2013). This contains an inner nucleocapsid of HBV core proteins, 
which are complexed with a viral polymerase and DNA genome. Figures 1.4 and 1.5 
represent the 3 viral particles and a schematic of the HBV genome respectively. 
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Figure 1.4 Hepatitis B viral particles (Gerlich, 2013, Urban et al., 2014) 
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Figure 1.5 Hepatitis B virus DNA genome (adapted from (Lamontagne et 
al., 2016) 
A schematic of HBV genotype D, subtype ayw. This figure shows the partially double-
stranded genome and the positions of attached RNA primer and polymerase protein. 
Coloured arrows represent the HBV open reading frames. The outer black lines 
represent viral transcripts of different sizes that share a polyadenylation site. 
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The HBV genome is partially double stranded circular DNA called relaxed circular DNA 
(rcDNA). This genome is approximately 3.2kb in size. The viral polymerase is 
covalently attached to the 5’ end of the minus strand on DNA. The viral genome 
encodes 4 overlapping open reading frames (ORFs); these are Surface (S), Core (C), 
Polymerase (P) and Hepatitis B X protein (X). The S ORF encodes the viral surface 
proteins S, M and L; these are represented by the S, preS2 and preS1 regions on the 
ORF respectively (Liang, 2009). The C ORF encodes the viral core proteins or 
nucleocapsid and Hepatitis B e antigen (HBeAg) (Milich and Liang, 2003). The P ORF 
encodes the viral polymerase. The X ORF encodes a non-structural protein called HBx, 
this is a multifunctional protein involved in many aspects of the HBV lifecycle. Each of 
these proteins will be discussed in more detail later. In addition to these ORFs, the 
HBV genome includes two direct repeats in the 5’ end of the plus strand called DR1 
and DR2; these are essential for strand specific DNA synthesis. There are also two 
enhancer elements called EnhI and EnhII involved in regulating viral gene expression 
and a glucocorticoid responsive element (GRE). (Su and Yee, 1992, Hatton et al., 
1992, Seeger et al., 1986, Yee, 1989, Tur-Kaspa et al., 1986, Liang, 2009). The viral 
lifecycle has been well studied and is represented in Figure 1.6 and will be discussed 
in more detail in the following sections. 
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Figure 1.6 Hepatitis B lifecycle (Thomas and Liang, 2016) 
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1.2.3 HBV Entry and Nuclear Import 
1.2.3.1 Entry into Hepatocytes 
HBV entry into hepatocytes is the first step on the infection cycle. Until very recently 
this area of the lifecycle was poorly understood and difficult to study with limited cell 
lines available that supported HBV replication. Primary human hepatocytes (PHHs) 
and a specialised and highly differentiated pluripotent stem cell line HepaRG (Glebe 
and Urban, 2007) provided the only successful in vitro model systems (Glebe and 
Urban, 2007, Schulze et al., 2012, Schulze et al., 2007). In addition infection of PHH 
cells could be dependent on source and time since being obtained (Schulze et al., 
2012). Human hepatoma cell lines such as Huh7 and HepG2 cells showed minimal 
evidence of viral replication (Schulze et al., 2012, Li and Urban, 2016). 
However, in 2012, Yan and colleagues identified the bile salt transporter called sodium 
taurocholate co-transportation polypeptide (NTCP), as a binding and entry receptor for 
HBV and by association HDV as well (Ni et al., 2014, Yan et al., 2012, Watashi et al., 
2014, Urban et al., 2014). This receptor is expressed on the basolateral surface of 
hepatocytes and is encoded by the SLC10A1 gene. It belongs to the SLC10 family of 
carrier proteins. While the structure of this transporter has not been fully characterised, 
9 transmembrane domains have been found, these are demonstrated in Figure 1.7 
(Yuen and Lai, 2015). This receptor has been identified as an HBV specific receptor 
and is expressed in PHH cells and DMSO-differentiated HepaRG cells, it is highly 
tissue specific and provides an explanation for the liver tropism of HBV. Importantly, 
expression of NTCP in hepatoma cell lines such as Huh-7 and HepG2 enabled 
infection with both HBV and HDV (Ni et al., 2014, Yan et al., 2014). This discOvary 
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provided the cell culture system to enable effective study of HBV lifecycle in vivo using 
de novo infections (Li and Urban, 2016). 
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Figure 1.7 Cartoon of Sodium Taurocholate Cotransporting Polypeptide 
(NTCP) (Yuen and Lai, 2015) 
A schematic representation of NTCP bile acid transporter, which is involved in 
transporting conjugated bile acids across membranes into Hepatocytes. This 
transporter behaves as a receptor for HBV entry. NTCP receptor function is blocked by 
a variety of different agents such as Myrcludex BTM, a synthetic N-acylated preS1-
derived lipopeptide that inhibits HBV entry in vitro and in vivo with high efficacy, or 
ciclosporin and ezetimibe which are known to inhibit membrane transporter activity. 
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Figure 1.8 Cartoon of HBV entry (adapted from (Lempp and Urban, 2014) 
A cartoon of HBV entry showing HBV initial binding to HSPGs before transitioning to 
the high-affinity entry receptor NTCP. NTCP facilitates the endocytosis of HBV along 
the basolateral surface of hepatocytes. Drugs such as Heparin, Suramin, Myrcludex 
BTM, and Cyclosporin A can inhibit HBV infection by binding to the surface proteins and 
preventing viral interaction. 
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Initial interaction between HBV and hepatocytes occurs via binding cell surface 
expressed heparin sulfate proteoglycans (HSPGs). These are cell surface 
glycoproteins that are ubiquitously expressed on the surface of adherent cells and in 
the extracellular matrix (ECM); they primarily function as coreceptors by regulating 
ligand encounters with receptors. This occurs through high expression of heparin 
sulfate chains binding ligands and increasing concentration around specific signalling 
receptors (Chen et al., 2008). HSPGs have been shown to interact with proteases, 
behave as endocytic receptors, coreceptors for tyrosine-kinase like growth factor 
receptors and as proteoglycans that integrate with integrins and other cell adhesion 
molecules to facilitate cell-cell interactions and motility (Sarrazin et al., 2011). It has 
been demonstrated that numerous microbes including viruses utilise these to bind to 
multiple cell types (Chen et al., 2008). There are approximately 17 different HSPGs 
that can be divided into 3 groups determined by their location. The first of these are 
membrane HSPGs such as syndecans and glycosylphosphatidylinositol-anchored 
proteoglycans (glypicans), evidence suggests that these are some of the initial contact 
receptors for HBV (Verrier et al., 2016a). The second type of HSPGs are secreted 
extracellular HSPGs such as agrin and perlecan (Chen et al., 2008). The last type of 
HSPG is the secretory vesicle proteoglycan serglycin (Sarrazin et al., 2011). 
HBV infection requires an initial interaction with the carbohydrate side chains of 
hepatocyte specific HSPGs and this is mediated via the viral encoded PreS1 (Sureau 
and Salisse, 2013). Figure 1.8 is a cartoon representation of initial binding of the HBV 
particle on HSPGs and subsequent internalisation (Lempp and Urban, 2014). The 
PreS2 domain is not essential for HBV infection and can be removed (Urban et al., 
2014). This was demonstrated with soluble heparin as well as other known inhibitors of 
duck hepatitis infections such as suramin and highly sulfated dextran sulfate that inhibit 
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HBV infection by competitively binding HSPGs (Schulze et al., 2007, Leistner et al., 
2008). This binding provides the initial step to HBV infection, the viral glycoproteins 
recognise specific patterns of hepatic proteoglycans (Schulze et al., 2007, Leistner et 
al., 2008). Using a combination of siRNA treatments against HSPG families, glypican 5 
(GPC5) was shown to bind HBV (Verrier et al., 2016a). This was confirmed through the 
use of anti-GPC5 monoclonal antibodies and soluble recombinant GPC5, both of which 
could neutralise HBV infection . GPC5 is so called because it uses 5 insertion sites into 
the extracellular surface to anchor itself (Li et al., 2011). 
Binding to GPC5 as well as other HSPGs initiates a multistep process of entry depicted 
in Figure 1.8 (Lempp and Urban, 2014); after initial binding, HBV moves to the higher 
affinity receptor NTCP. NTCP is a transporter residing in the basolateral membrane of 
hepatocytes and is involved in the uptake of conjugated bile salts and has been shown 
to be essential for efficient HBV infection, this has been demonstrated using specific 
siRNAs and drugs such as cyclosporin A and Myrcludex B (Figure 1.8) that inhibit virus 
and receptor interactions (Lempp and Urban, 2014, Volz et al., 2013, Lutgehetmann et 
al., 2012). Evidence shows that the PreS1 region of HBV surface protein L binds with 
high specificity to NTCP extracellular loops (Yan et al., 2012, Volz et al., 2013, Urban 
et al., 2014, Colpitts et al., 2015, Li and Urban, 2016). Following binding to NTCP, HBV 
is internalised through endocytosis, although the pathways are not defined (Watashi et 
al., 2014, Cooper and Shaul, 2006). 
1.2.3.2 Nuclear Import 
Following entry into the hepatocyte the mature capsid needs to translocate from the 
cytoplasm into the nucleus. This occurs through interaction with the nuclear pore 
complex (NPC). HBV hijacks the host cellular transportation factors; these facilitate 
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interaction with the NPCs and aid nuclear import. NPCs are macromolecular 
complexes that consist of approximately 30 proteins, called nucleoporins (Nups). 
Together these form a complex with octagonal rotation symmetry that spans the 
nuclear envelope and forms a pore through which HBV can traverse (Gallucci and 
Kann, 2017). There are additional Nups that form asymmetric structures on either side 
of the NPC. Nup358 and Nup214 are examples that have been shown to form part of 
the cytoplasmic filaments around the cytoplasmic face of the NPC (Lim et al., 2007, 
Tran and Wente, 2006, von Appen and Beck, 2016, Gallucci and Kann, 2017). A 
similar structure called the nuclear basket is found on the inside of the nuclear 
envelope. These are formed by numerous Nups; well characterised examples include 
Nup153 and Tpr (Lim et al., 2007, Tran and Wente, 2006). The distribution of Nups 
varies significantly, but they are essential for nuclear import and export, as well as for 
differentiation during other cell cycle, chromatin distribution and embryogenesis 
processes. Nups collectively form a passive diffusion barrier inside the nuclear pore, 
this is characterised by phenylalanine-glycine repeats (FG-repeats) in approximately 
30% of the Nups (Gallucci and Kann, 2017). 
Small molecules with diameters of 5nm or less can passively diffuse through the NPC 
(Ghavami et al., 2016), however larger macromolecules require active transport across 
the nuclear envelope. The channel formed by the NPC is approximately 40nm in 
diameter. This restricts the entry and exit of larger viral capsids. HBV viral capsids are 
approximately 36nm in diameter, which means that they can pass through the NPC. 
This occurs through interaction of the macromolecule nuclear localisation signal (NLS) 
for import or the nuclear export signal (NES) for export, with the nuclear transport 
receptors; these are collectively called importins or exportins (Rabe et al., 2003, Li et 
al., 2010a, Gallucci and Kann, 2017). 
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Figure 1.9 HBV import and export as part of viral lifecycle (Li et al., 
2010a) 
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The pathway regulating HBV import to the nucleus and role of NPC is not well 
understood; currently there are 2 models for transport of the HBV genome. The first of 
these is mediated by binding of the HBV polymerase (Pol) to HBV core (HBc) protein 
dimers and importin α/β at the NPC. In contrast, the second model focuses on whole 
capsid transport through the NPC followed by disassembly while in the nuclear basket 
(Gallucci and Kann, 2017). When considering each of these models it is important to 
discuss the diversity of HBV capsids with mature virions comprising 240 copies of HBc 
that form T4 icosehedral symmetry. Capsid assembly begins with the formation of HBc 
dimers; these form hexamers; which piece together into full capsids. These structures 
are dynamic with HBc subunits able to dissociate and re-associate and had been 
dubbed capsid breathing (Zlotnick et al., 1997). 
Aside from the structure of the capsid, virions can be distinguished by their nucleic acid 
content as shown in Figure 1.9. Mature capsids contain mature rcDNA or double 
stranded linear DNA (dslDNA), these are both enveloped and secreted at later stages 
in the lifecycle or imported into the nucleus. Non-enveloped capsids contain HBV 
pregenomic RNA (pgRNA) and polymerase. The last form of the HBV capsid contains 
all of the HBV genome intermediates from pgRNA to rcDNA and are defined as 
immature virions (Li et al., 2010a). The mature capsids undergo nuclear import, it has 
been reported that capsids are predominantly found in the nucleus (Rabe et al., 2003), 
whereas others (Cui et al., 2015) suggest more cytoplasmic localisation. Evidence 
suggests that both can be true, but that the severity of HBV disease may be 
determined by this localisation (Li et al., 2010a). A more nuclear-based localisation is 
associated with milder disease because there is a higher viral load, but less 
hepatocellular injury. The first model for HBV genome nuclear transport is based on 
interaction of NLS importin α/β with the viral polymerase. This model suggests that 
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mature capsids will destabilise into HBc dimers; releasing the rcDNA-polymerase 
complex at the cytoplasmic face of the NPC. Following destabilisation, the NLS 
importin α/β will bind to the HBV polymerase or the HBc dimers independently and they 
will pass through the NPCs by interacting with nuclear import receptors. The transport 
factors finally dissociate from core protein and HBV polymerase and this can be 
followed by capsid re-assembly. The second model involves the transport of the intact 
capsid via interactions with Importin α/β and Nup153. At this point the capsid 
destabilises into HBc dimers and the rcDNA-polymerase complex is released (Li et al., 
2010a, Li and Urban, 2016, Gallucci and Kann, 2017). 
1.2.4 cccDNA Formation 
Following nuclear import, the HBV genome uses host cell factors to ‘repair’ the rcDNA 
and form covalently closed circular DNA (cccDNA): the viral mini chromosome that 
forms a reservoir for continual replication. Due to the long hepatocyte half-life and lack 
of initiating immune responses, the cccDNA can persist for long periods of time 
(Moraleda et al., 1997, Lutgehetmann et al., 2010, Nassal, 2015). Current treatments 
suppress HBV polymerase activity and reduce viral rcDNA levels but have no impact 
on cccDNA. Therefore, treatment for an established chronic infection is lifelong 
(Quasdorff and Protzer, 2010, Seeger and Mason, 2015). HBV cccDNA formation is 
the first step in the HBV DNA replication process and conversion of rcDNA to cccDNA 
can be detected within the first 24 hours of infection and is indicative of successful 
initiation of viral replication. This process utilises cellular enzymes to repair the DNA 
and complete the rcDNA; however the exact enzymes used are still unknown (Qi et al., 
2016). Two models for cccDNA formation have been suggested; the first model 
proposes that cellular endonucleases remove short terminally redundant sequences 
from the minus strand copy of rcDNA along with the viral DNA polymerase from the 5’ 
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terminus and RNA primer from the plus strand. This is followed by a ligation reaction to 
fill the gaps in each strand of rcDNA. This model is based on the observation that 
nucleotide analogues inhibit reverse transcriptases and do not prevent cccDNA 
formation in duck hepatitis B (DHBV) (Fourel et al., 1994). This would indicate that 
rcDNA is the direct precursor to cccDNA (Qi et al., 2016). Current understanding of the 
model suggests that host cellular DNA repair enzymes catalyse each of these 
reactions. However, the identity of these enzymes is not well understood. An example 
enzyme that has been shown to target rcDNA is tyrosyl-DNA-phosphodiesterase 2 
(Tdp2), however knockout of this gene reduces cccDNA formation in DHBV and has 
minimal impact on cccDNA formation in HBV infection of HepG2 cells (Cortes Ledesma 
et al., 2009, Hu and Seeger, 2015). Tdp2 cleaves tyrosyl-5’ DNA linkages found 
between topoisomerase II and cellular DNA (Cortes Ledesma et al., 2009) and has 
been reported to release covalently linked reverse transcriptase from the 5’ end of 
rcDNA minus strand and cleave the tyrosyl-minus strand DNA linkage of HBV (Cortes 
Ledesma et al., 2009, Jones et al., 2012). Another previously studied example is Ku80, 
a component of the DNA repair pathway, which is involved in non-homologous end 
joining of DNA. In Duck HBV, Ku80 has been shown to be essential for cccDNA 
formation from a dslDNA intermediate but not from rcDNA (Guo et al., 2012). This is 
relevant because it has been demonstrated that cccDNA can be formed from dslDNA 
rather than rcDNA (Yang and Summers, 1995). An alternative model proposes 
polymerase extension of 3’ ends of both plus and minus DNA strands, followed by 
“DNA strand displacement synthesis” that forms a dslDNA containing large terminal 
redundancies. These would span the overlap regions in rcDNA. These would then 
combine through homologous recombination to form cccDNA, however, the evidence 
for this model is limited (Yang et al., 1996, Seeger and Mason, 2015). 
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Using DHBV and woodchuck hepatitis virus (WHV) and viral DNA polymerase 
inhibitors it has been demonstrated that viral DNA polymerases are not essential for 
cccDNA formation . The implication is that viral polymerases are not essential for plus 
strand DNA synthesis (Kock and Schlicht, 1993, Moraleda et al., 1997, Delmas et al., 
2002, Qi et al., 2016); rather the virus utilises host cell DNA polymerases. Qi and 
colleagues utilised de novo infections in HepG2-NTCP cells with HBV deficient in HBc 
production to demonstrate that the viral polymerase is not required for cccDNA 
formation. In addition they used an RNAi screening process to identify the host cell 
DNA polymerase K (POLK) as a crucial factor in HBV cccDNA formation (Qi et al., 
2016). Qi and colleagues confirmed that cccDNA formation occurs within 24 hours of 
infection and demonstrated that approximately 3 copies of cccDNA can be found per 
cell. Further confirmation of cccDNA synthesis being independent of the viral DNA 
polymerase comes from Sohn and colleagues, who showed that a host cell DNA 
polymerase will fill in the 3’ end of both strands (Sohn et al., 2009). However, they also 
observed that inhibiting the polymerase caused a modest reduction in cccDNA levels. 
This implies that either the viral polymerase has a small contributing effect in cccDNA 
formation or that off-target inhibitory effects may have occurred. Qi and colleagues also 
demonstrated that cellular DNA polymerases L and H (POLL/ POLH) may play a minor 
role in cccDNA formation (Qi et al., 2016). Qi and colleagues suggest that POLL and 
POLH might have roles distinct from POLK depending on the size of the plus strand 
gap. Alternatively, the polymerase used could be dependent upon the size of precursor 
rcDNAs. However, different polymerase activities could simply be due to redundancy 
(Qi et al., 2016). 
A previous study by Yeh and colleagues demonstrated that cccDNA synthesis could be 
enhanced by arresting cells in G1 phase (Yeh et al., 1998). Qi and colleagues also 
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demonstrated an increased infection efficiency that associated with the number of G0 
and G1 phases in HepG2-NTCP cultures. This observation supports the theory that 
HBV preferentially infects non-dividing cells and then forms cccDNA (Werle-Lapostolle 
et al., 2004). This is an important observation because POLK activity is at least partly 
regulated by the growth state of cells. Maximal activity of POLK is observed in non-
dividing cells with low levels of deoxynucleotide expression (Qi et al., 2016). Current de 
novo infection protocols treat HepG2-NTCP cells with DMSO to increase expression of 
differentiation markers essential for infection. A by-product of DMSO treatment is to 
arrest the cell cycle, suggesting that DMSO could boost infection through slowing of 
cell cycles. 
Although currently unknown, it is possible that other host cell DNA repair proteins are 
involved in HBV plus-strand DNA synthesis. Qi and colleagues suggest that HBV may 
hijack cellular endonucleases and exonucleases to cleave capped RNA primers on the 
5’ end of the plus strand. They also suggest that other proteins in the host nucleotide 
excision repair (NER) pathway might be involved; XRCC1-hig3 is required for ligation 
in repairing DNA breaks within quiescent cells (Qi et al., 2016). HBV cccDNA formation 
is a complex process, but once complete the cccDNA functions as a mini chromosome 
for HBV and enables the maintenance of chronic HBV infection (Qi et al., 2016). 
The HBV genome is able to integrate into the host genome. This occurs throughout the 
host genome at double strand DNA breaks (Bill and Summers, 2004). The roles and 
clinical implications for this process are unclear because the HBV genome in this form 
is considered replication incompetent. This is because HBV pgRNA cannot be 
transcribed from HBV double stranded linear DNA (dslDNA) (Tu et al., 2017). However, 
it has been demonstrated that dslDNA derived cccDNA can revert back into wild type 
cccDNA, possibly via homologous recombination (Yang and Summers, 1998). The 
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arrangement of the HBV genome following integration can affect the expression of viral 
ORFs. This is due to the position of viral promoters to drive transcription. Whilst HBV 
polymerase, HBeAg and HBV core ORFs typically remain intact, they are separated 
from their corresponding promoters, which prevents expression (Tu et al., 2017). 
Interestingly the HBV surface proteins ORF typically remains intact and expression of 
surface proteins can still occur using the native HBs promoter (Tu et al., 2017). The 
integrated form of HBV is still able to produce transcripts from the HBx ORF through 
activity of Enhancer 1, but the HBx protein is likely to be truncated (Shamay et al., 
2001). However, it has been demonstrated that truncated HBx is still functional in 
transcriptional activations (Kumar et al., 1996). 
1.2.5 cccDNA Transcription and Translation 
1.2.5.1 Transcription and Translation 
HBV cccDNA is assembled in combination with host cell histone proteins; this forms 
the mini chromosome, which is an episomal form of the genome. This structure is 
regulated through post-translational modification (PTM) of the histone proteins in a 
similar manner to that observed with cellular chromatin. These modifications are 
important because they enable access of HBV DNA to host transcriptional machinery 
(Tropberger et al., 2015). HBV cccDNA forms the template for viral mRNA synthesis. 
The episomal form of the genome includes 4 overlapping ORFs that encode 7 proteins; 
these are represented in Figure 1.10. These proteins are translated from the 5 viral 
mRNAs transcribed from HBV cccDNA (Figure 1.10), which are regulated by 4 
promoters called Core, PreS, S and X. Pre-genomic RNA (pgRNA) transcription is 
directed by the core promoter and M/S is regulated by the S promoter. PreS and X are 
regulated by their respective promoters (Seeger and Mason, 2015). Two additional 
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mRNAs are reported to be transcribed from initiation start sites up and downstream of 
an AUG in the Core and S promoters that begin from staggered start sites (Morikawa 
et al., 2016). 
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Figure 1.10 Linear cartoon representation of HBV open reading frames 
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HBV cccDNA serves as the template for mRNA synthesis by host polymerase II. Each 
of the HBV promoters controls the synthesis of specific viral transcripts. HBV mRNAs 
transcribed from cccDNA translate into 7 viral proteins. However, it is important to note 
that HBx is required for efficient transcription of cccDNA (Seeger and Mason, 2015). It 
has been demonstrated that HBx binds directly to cccDNA (Belloni et al., 2009). 
However, interaction of HBx with cccDNA has also been demonstrated via the DNA 
damage binding protein 1 (DDB1) and Cullin4A-RING-DDB1 ubiquitin ligase (Li et al., 
2010b). Specifically, HBx could be involved in regulation of acetylation of histones to 
activate transcription (Seeger and Mason, 2015). Viral mRNAs are transported to the 
host ribosomes and translated into viral proteins. This process relies on post-
transcriptional cis-acting regulatory elements (PREs), which overlap with the HBx 
coding sequence. HBx is translated from the X transcripts; however, unlike other viral 
RNAs it might be produced immediately following cccDNA formation. This is due to the 
previously mentioned activity for HBx in binding to cccDNA, through Cullin4A-DDB1 
interaction with the histones of the mini chromosome (Seeger and Mason, 2015). HBV 
pgRNA forms the template for viral replication by acting as a template for reverse 
transcription; pgRNA is translated to produce the core and viral polymerase proteins; 
the latter is the result of a separate internal initiation of translation. In addition, pgRNA 
acts as a template for genomic DNA formation inside the viral nucleocapsid. PreCore 
RNA is translated into preCore protein or HBeAg, this RNA is colinear with pgRNA with 
the exception of a small 5’ extension which enables translation from an independent 
AUG codon. The M and S surface proteins are translated from the PreS1 and M/ S 
mRNAs (2.4kb and 2.1kb respectively). These also exhibit a colinear relationship with a 
distinct 5’ end on the AUG codon of M mRNA. The L surface protein is translated from 
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the PreS1 mRNA and X is translated from the X transcript (Doitsh and Shaul, 2003, 
Liang, 2009). 
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1.2.5.2 HBV Transcription Factor Interactions 
As mentioned previously the HBV promoter regions include the enhancers EnhI and 
EnhII; these are located upstream of the X promoter and Core promoters respectively. 
These enhancers enable the binding of liver specific transcription factors required for 
promoter activity. cccDNA transcription is regulated in multiple ways. Evidence 
suggests that regulation of this transcriptional activity occurs through host transcription 
factors and some epigenetic factors (Levrero et al., 2009, Quasdorff and Protzer, 2010, 
Belloni et al., 2009). Some of these transcription factors are shown in Figure 1.11, this 
is a linear representation of the HBV genome indicating reported transcription factor 
binding sites. It is interesting to note a mix of ubiquitous and liver specific transcription 
factors actively bind to the HBV genome (Quasdorff and Protzer, 2010). The literature 
suggests that the Nuclear Factor 1 (NF1) family of transcription factors regulates HBV 
transcription. In particular, binding sites for NF1 transcription factors were found at 
three sites in the HBV genome: a site upstream of the S promoter was shown to be 
essential for optimal activity (Shaul et al., 1986, Quasdorff and Protzer, 2010); two 
additional binding sites in EnhI suppress enhancer activity (Spandau and Lee, 1992) 
and a third binding site within EnhI regulates transcription of HBV RNA; specifically, 
inhibiting this site through mutation reduced 3.5kb HBV mRNA (pgRNA) levels (Ori et 
al., 1994). 
Nicholas Ross Baker Frampton Hepatitis B and Hypoxia Student ID: 1301165 
 
49 
 
 
Figure 1.11 Linear HBV genome and transcription factor interactions (Lai, 
A. 2017) 
HNF-1, HNF3α,β,γ, and HNF4α are liver specific transcription factors. Each of these 
transcription factors has demonstrated roles in a number of host cell transcriptional pathways. 
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Other transcription factors include specificity protein 1 (SP1), that binds guanine-
cytosine rich DNA and has been shown to bind within the PreS2/ S, PreS1 and Core 
promoters as well as the EnhII element (Krainc et al., 1998, Raney et al., 1992, Raney 
and McLachlan, 1995, Zhang et al., 1993). Binding to EnhII induced mRNA levels of all 
HBV genes, whereas binding sites in S and X genes resulted in negative regulation of 
each gene (Li and Ou, 2001). This difference in activity supports a regulatory role for 
both NF1 and SP1 at different stages in the HBV lifecycle (Quasdorff and Protzer, 
2010). It has been demonstrated that NF1 inhibits SP1 interaction with the promoter 
(Rafty et al., 2002). Other well-studied transcription factors shown to interact with HBV 
include Activator Protein 1 (AP1); TATA binding protein (TBP), C-AMP response 
element binding protein (CREB) and Nuclear Factor – kappa B (NF-κB) (Ren et al., 
2014, Trierweiler et al., 2016, Tanaka et al., 2005, Tsai et al., 2015, Bogomolski-
Yahalom et al., 1997, Herzig et al., 2003, Herzig et al., 2001, Gilmore, 2006, Lin et al., 
2009, Kim et al., 2010a, Quasdorff and Protzer, 2010). AP1 shows activity in HBx 
regulation (Choi et al., 1998, Hess et al., 2004, Tanaka et al., 2005); TBP binds to 
TATA sequences in the PreS2 promoter and promotes activity (Bogomolski-Yahalom 
et al., 1997). CREB reportedly binds to a region in EnhI that is highly conserved 
amongst HBV genotypes; this factor is involved in glucose and lipid metabolism, as 
well as hepatocyte proliferation (Herzig et al., 2003, Herzig et al., 2001, Tacke et al., 
2005, Cougot et al., 2007, Kim et al., 2008). NF-κB appears to play a negative 
regulatory role through its family members p50 and p65. These form a heterodimer that 
reportedly causes a reduction in all viral mRNAs. This is due to p65 activity in inhibiting 
SP1 and its binding to the HBV genome (Sirma et al., 1998, Lin et al., 2009, Lin et al., 
2017). 
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These ubiquitous transcription factors are essential to HBV promoter and enhancer 
activity; however, they do not account for the hepatocyte tropism observed by HBV. 
This is the result of liver specific transcription factors. Hepatocyte Nuclear Factor 3 
(HNF3) is shown to bind DNA in hepatocyte regulatory regions with roles in 
carbohydrate metabolism and β-oxidation of lipids (Costa et al., 2003). It is shown to 
increase activity of both HBV enhancers and promote PreS1 promoter activity (Chen et 
al., 1994, Li et al., 1995, Raney et al., 1995). HNF3 has been demonstrated to bind to 
chromatin and open nucleosomal domains in the absence of ATP-dependent enzymes. 
Quasdorff and Protzer reasoned that this activity might mean that HNF3 can bind to the 
HBV mini chromosome and enable access to other transcription regulators (Quasdorff 
and Protzer, 2010). Hepatocyte Nuclear Factor 1 (HNF1) is an important factor in 
regulating glucose and amino acid homeostasis (Pontoglio et al., 1996). In addition it 
maintains normal liver structure by regulating hepatocyte differentiation and 
polarisation (Kimata et al., 2006). HNF1 increased PreS1 promoter activity, however 
this activity was dependent on interaction with another ubiquitous transcription factor 
Octamer transcription factor (Oct1) (Raney et al., 1991, Zhou and Yen, 1991). PreS1 is 
part of the L surface envelope protein, suggesting a role for HNF1 in regulating viral 
release. 
Hepatocyte Nuclear Factor 4 alpha (HNF4α) is another host transcription factor with 
important functions in the HBV lifecycle. HNF4α is a nuclear receptor and along with 
retinoic X receptor α (RXRα) can form homo- or heterodimers that regulate many 
hepatocyte functions; these include lipid, carbohydrate, cholesterol and amino acid 
homeostasis (Schrem et al., 2002, Odom et al., 2004). As with HNF1, this transcription 
factor has a role in the development and maintenance of normal liver structure (Kimata 
et al., 2006). HNF4α can promote HBV promoter activity, with increases in PreS1, 
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PreS2/ S and Core promoter activity having been demonstrated (Raney et al., 1997). 
Despite not boosting EnhI and X promoter activity it was shown that HNF4α could bind 
within this region and transactivate the core promoter (Garcia et al., 1993, Raney et al., 
1997). HNF4α was shown to increase the synthesis of pgRNA, possibly linked to 
evidence showing it increased transcription from the pgRNA promoter (Yu and Mertz, 
1997, Yu and Mertz, 1996, Yu and Mertz, 2003). HNF4α plays an essential role in 
regulating the genesis of pgRNA and therefore is important in the production of HBV 
core and polymerase. Quasdorff et al have also demonstrated that high expression 
levels of HNF4α in differentiated hepatocytes increased HBV replication efficiency; in 
addition, they demonstrate that HNF1α regulates expression of HNF4α and therefore 
regulates HBV replication (Quasdorff et al., 2008). As discussed previously, this is 
important to viral replication, these factors are linked to hepatocyte differentiation and 
together have been shown to regulate the efficiency of pgRNA transcription (Tang and 
McLachlan, 2002, Quasdorff and Protzer, 2010). 
The other liver transcription factor that can bind to RXRα and form heterodimers is 
called Peroxisome proliferator-activated receptors (PPARα). PPARα is expressed in 
numerous locations including the heart, kidneys and liver. It plays a significant role in 
regulating cellular development, differentiation and metabolism (Michalik et al., 2006). 
It is know that PPARα-RXRα dimers increase the activity of HBV Core, Pres1 and 
EnhI/ X promoters (Raney et al., 1997). In addition, it has been shown that expression 
of these dimers increases HBV pgRNA expression (Yu and Mertz, 1997, Tang et al., 
2001, Tang and McLachlan, 2001, Quasdorff and Protzer, 2010). Together these 
ubiquitous and hepatocyte specific transcription factors play an important role in the 
viral lifecycle; these represent a small number of a large group of factors that can 
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directly interact with and regulate the HBV genome and replication activity (see Figure 
1.11). 
1.2.5.3 Epigenetic Regulation of cccDNA 
Tropberger et al demonstrated that cccDNA chromatin structure is highly organised 
and regulated by post-translational modifications (PTMs) such as acetylation and 
methylation. The authors identified specific regions at which PTM activity modifies 
cccDNA and showed that PTMs could predict the transcriptional state of viral 
promoters (Tropberger et al., 2015). Four PTMs are known to be involved in active 
transcription; these include H3K4me3, H3K27me3, H3k27ac and H3K122ac (Santos-
Rosa et al., 2002, Tropberger et al., 2013, Creyghton et al., 2010, Tropberger et al., 
2015). H3K4me3 modifications are found at transcription start sites (TSS) of actively 
transcribed genes. Acetylation marks (ac) indicate active TSS and gene enhancers. 
H3K36me3 is also a marker for active transcription, but this marker is located at the 3’ 
end of the host genome. H3K4me3, H3K27ac and H3K122ac PTMs were found highly 
expressed in cccDNA chromatin; however, H3K36me3 expression was lower than 
controls. Two well-characterised PTMs are involved in transcriptional silencing; these 
are H3K9me3 and H3K27me3 (Beisel and Paro, 2011, Tropberger et al., 2015). PTM 
markers for silencing transcriptional activity both had low levels of expression 
(Tropberger et al., 2015). Tropberger and colleagues demonstrated that EnhII and 
basal core promoter regions showed minimal expression of these PTMs. However, a 
spike in expression for H3K4me3, H3K27ac and H3K122ac were found located in the 
precore and pregenomic TSS (Tropberger et al., 2015). This pattern of expression 
closely matches that seen in cellular chromatin. An additional spike in PTMs was 
observed around the EnhI region (Tropberger et al., 2015). This data was gathered 
using de novo infections; a subsequent comparison of PTM expression profiles in PHH 
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cells and HBV positive liver tissue demonstrated different profiles of activity and 
distributions of PTMs. The author suggests that this means cccDNA chromatin is not 
solely regulated by the virus and might adapt to the cellular environment (Tropberger et 
al., 2015). It has been shown that inflammation can play a role in epigenetic regulation 
of gene silencing through the NF-κB pathway and trimethylation of H3K9 (Chen et al., 
2009, Bayarsaihan, 2011, Beisel and Paro, 2011). This pathway has also been linked 
to the acetylation and activation of histones in the promoter regions of inflammatory 
genes (Bayarsaihan, 2011). In addition, a number of pro-inflammatory cytokines are 
regulated through acetylation by CBP/p300 (Villagra et al., 2010). Both pathways have 
been demonstrated to interact with HBV and could therefore modulate the HBV 
epigenome (Cougot et al., 2007, Kim et al., 2010a, Xiang et al., 2015). In addition to 
inflammation, evidence suggests that hypoxia can regulate chromatin and DNA 
modifications through multiple chromatin modifiers such as CBP/p300 and HDACs 
(Tsai and Wu, 2014), however the evidence is limited. Prickaerts and colleagues 
demonstrate that methylation of H3K4me3 and H3K27me3 can be mediated by low 
oxygen and 2-oxoglutarate dioxygenase enzymes (Prickaerts et al., 2016, Hancock et 
al., 2015); the result demonstrated that low oxygen can regulate histone methylation. 
Like inflammation, hypoxic environments within the liver could modulate the HBV 
epigenome. 
It has been demonstrated that interferon alpha (IFNα) can suppress HBV replication by 
targeting the epigenetic regulation of cccDNA transcription (Belloni et al., 2012). 
Specifically, evidence suggests that regulation occurs through modifications to histones 
bound to cccDNA by chromatin-modifying enzymes histone deacetylases (HDACs) 
(Pollicino et al., 2006); these modulate the acetylation status of histones H3 and H4. 
Palumbo and colleagues demonstrate the treatment of infected HepG2-NTCP cells 
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with interleukin-6 (IL6) inhibit viral transcription by reducing HNF1a and 4a interaction 
with cccDNA and subsequent reduction of histone acetylation resulting in reduced 
pgRNA transcription (Palumbo et al., 2015). 
1.2.6 HBV Protein Roles and Functions 
1.2.6.1 HBV Core and Polymerase 
Translation of core and viral polymerase proteins is carefully regulated to ensure the 
correct balance of core subunits to polymerase proteins. The icosahedral shape of the 
HBV capsid is made up of 240 core subunits and contains a single polymerase 
covalently bound to pgRNA (Patel et al., 2017). This interaction between pgRNA and 
viral polymerase is mediated through a specific signal called epsilon (or ε); this signal is 
required for specific packaging of the pgRNA into viral nucleocapsids (Ryu et al., 2008, 
Chen and Brown, 2012, Jones et al., 2012, Patel et al., 2017). This signal is a stemloop 
structure found on the 5’ terminal of pgRNA as shown in Figure 1.12 (Chen and 
Brown, 2012). The epsilon structure is represented at both the 5’ and 3’ ends of the 
pgRNA, but only the 5’ epsilon signal is utilised in the packaging process (Seeger and 
Mason, 2015). This binding triggers packaging and begins the DNA replication process 
in a host-chaperone dependent manner. Evidence suggests that heatshock proteins 
might stabilise the binding (Hu and Seeger, 1996, Hu et al., 1997). Once bound to 
pgRNA, the HBV polymerase initiates the process of reverse transcription by using 
itself as a protein primer and the epsilon signal as a template (Jones et al., 2014, 
Seeger and Mason, 2015). The viral polymerase is made up of 4 separate domains; 
these are the terminal protein (TP) domain, space domain, reverse transcriptase (RT) 
and RNaseH. HBV polymerase primes the reverse transcription process from a 
tyrosine residue in the TP domain. The hydroxyl group of tyrosine Y63 is used to 
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initiate the DNA synthesis. Additionally, the polymerase behaves as a catalyst for 
synthesis. The reverse transcriptase region of polymerase forms a phosphotyrosyl 
linkage between Y63 and the first nucleotide residue of the HBV minus strand DNA 
(Jones et al., 2014). 
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Figure 1.12 Schematic representation of pgRNA including Cis RNA 
elements adapted from (Chen and Brown, 2012) 
Refer to section 1.2.6.1 for details. 
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The Core subunits translated from pgRNA form a nucleocapsid structure. This capsid 
consists of 183-185 amino acids depending on the genotype. These individual subunits 
form homodimers by linking cysteine residues via disulfide bridges (Bruss, 2007). 
These dimers form larger oligomers, via a poorly understood process that results in the 
formation of 2 types of capsid. The first of these is a 30nm structure with T=3 symmetry 
containing 90 core dimers. The second structure is larger at 34nm and consists of a 
T=4 symmetry icosahedral structure comprising 120 core dimers (Patel et al., 2017, 
Zlotnick et al., 1997). While both structures can be found in infectious liver samples, 
the T=4 structure is found in infectious virions. The core protein consists of 2 different 
domains: the N-terminal region between 149-151 amino acids in length and forms the 
primary assembly domain and is sufficient for capsid self-assembly (Bruss, 2007). The 
C-terminal domain is involved in packaging of the pgRNA and RT; this structure is 34 
amino acids in size and is not essential for capsid formation (Gallina et al., 1989). Viral 
DNA synthesis occurs in the lumen of the viral capsid through reverse transcription of 
the pregenome into double stranded DNA, this forms a mature nucleocapsid. 
During the synthesis of viral DNA, the capsid structure becomes a mature 
nucleocapsid containing double stranded DNA. These structures develop the ability to 
bud following envelopment with viral surface proteins. However, another outcome 
involves the re-import of the mature nucleocapsid into the nucleus and amplification of 
cccDNA. This occurs using the import mechanisms previously described. This was 
demonstrated by Tuttleman and colleagues using DHBV (Bruss, 2007, Tuttleman et al., 
1986, Seeger and Mason, 2015). This process has been dubbed intracellular recycling 
(Schreiner and Nassal, 2017) and results in a pool of cccDNA within the nucleus that 
acts as a reservoir for viral persistence and this process can be blocked with nucleotide 
analogues (Hu and Seeger, 2015, Schreiner and Nassal, 2017). 
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1.2.6.2 Reverse Transcription and DNA Synthesis 
Reverse transcription is utilised by HBV through the action of the viral polymerase to 
convert pgRNA into rcDNA for packaging into mature virions (Jones et al., 2012). The 
HBV polymerase has reverse transcriptase activity that initiates the process of binding 
the first nucleotide residue (Ryu et al., 2008, Jones and Hu, 2013). This enzyme is 
capable of catalysing both RNA and DNA dependent DNA polymerisation. HBV DNA 
synthesis can be broken down into roughly 3 processes (Jones and Hu, 2013). These 
include the initial protein priming discussed previously, in which the terminal protein 
domain of viral polymerase binds to pgRNA through interaction with the 5’ epsilon 
signal (Hu and Boyer, 2006, Boregowda et al., 2012, Wang and Seeger, 1992). It has 
been demonstrated that this step inhibits translation of proteins from pgRNA (Ryu et 
al., 2008). The method of repression is not well understood, but the literature suggests 
that polymerase interaction with the epsilon signal prevents ribosomal binding (Ryu et 
al., 2008, Ryu et al., 2010). Following initial protein priming is the DNA polymerisation 
stage, this involves the addition of 2 deoxy-adenosine monophosphate (dAMP) 
residues to the deoxy-guanosine monophosphate (dGMP) attached to the terminal 
protein domain of HBV polymerase (Jones and Hu, 2013, Jones et al., 2012, 
Boregowda et al., 2012). This process is followed by DNA elongation. Protein priming 
results in a three-nucleotide long oligomer attached to the viral polymerase. The 
synthesis of HBV minus strand DNA occurs following transfer of the polymerase 
complex onto the direct repeat 1 (DR1) region at the 3’ end of pgRNA (shown in Figure 
1.12 with the dotted line) (Abraham and Loeb, 2006, Loeb and Tian, 1995, Rieger and 
Nassal, 1996, Jones and Hu, 2013, Hu and Seeger, 2015). 
Minus strand DNA synthesis begins and simultaneously as pgRNA is degraded by the 
RNaseH domain of the viral polymerase (Radziwill et al., 1990, Chen and Marion, 
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1996, Jones and Hu, 2013). HBV plus strand DNA synthesis then occurs in the 
opposite direction and begins at direct repeat 2 (DR2); this utilises an RNaseH 
resistant fragment of the 5’ end of pgRNA for protein priming (Loeb et al., 1991). This 
process all occurs within the viral nucleocapsid, evidence suggests that the 
nucleocapsid regulates the reverse transcription process by phosphorylation activities 
that might regulate the HBV polymerase (Perlman et al., 2005, Basagoudanavar et al., 
2007, Jones and Hu, 2013). 
1.2.6.3 Envelope glycoproteins 
Mature virions that are not imported into the nucleus become enveloped in viral surface 
proteins through a host derived lipid bilayer acquired through budding into the lumen of 
an intracellular membrane thought to represent multivesicular bodies (MVBs) that 
accumulate at late endosomal membranes (Watanabe et al., 2007, Bruss, 2007). Viral 
surface proteins are translated from the PreS1 and M/ S mRNAs. These become 
infectious HBV virions or Dane particles that are subsequently secreted from the cell 
(Watanabe et al., 2007). The S, M and L surface proteins are encoded from a single 
ORF that includes 3 different “in frame” ATG codons for initiation of translation, 
resulting in 3 different proteins that differ in length at the N-terminal region (Figure 
1.10). These proteins are not evenly distributed amongst HBV particles. The major 
component of Dane particles is the S proteins (HBs); L protein is found on the surface 
of both filamentous particles and infectious virions. The M protein is more evenly 
distributed between all types of viral particle. These membrane proteins are 
synthesised at the rough endoplasmic reticulum (Bruss, 2007, Patient et al., 2009). 
Figure 1.13 is a representation of each surface protein and their assembly. 
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Figure 1.13 Cartoon representation of HBV surface proteins 
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HBs is translocated at the ER through activity of the N-terminal first transmembrane 
domain (TM-I), which is directed into the ER lumen (Patient et al., 2009). A 
combination of a cytosolic loop (CYL1) and second transmembrane domain are found 
further downstream; together these behave as a type II signal/ anchor domain (TM-II) 
(Patient et al., 2009). TM-II C-terminal domain directs an antigenic loop 
(AGL)(Peterson et al., 1982); this is composed of two transmembrane α-helices (TM-III 
and TM-IV); which are separated by a short cytosolic sequence (CYL2) (Persson and 
Argos, 1994). This structure contains a large number of cysteine residues involved in 
the formation of disulfide bridges to form a regulated structure. Evidence suggests 
these cysteine residues undergo post-translational modifications by a range of host ER 
chaperones such as protein disulfide isomerase (PDI) (Helenius and Aebi, 2001, 
Huovila et al., 1992). Each of the antigenic loops described earlier contains a single N-
glycosylation site (Bruss, 2007, Schädler and Hildt, 2009). The production of M and L 
proteins is similar with the addition of a 55-amino acid and 108 amino acid sequences 
onto the N-terminal end of HBs respectively. The 55-amino acid sequence is called 
PreS2 and is found in both M and L proteins. This is co-translationally translocated into 
the nucleus by the TM-I sequence (Eble et al., 1990, Heermann et al., 1984). The L 
protein has an additional 108 sequence called PreS1 and the N-terminus of M (Persing 
et al., 1987, Bruss, 2007, Patient et al., 2009). The exact role of the M protein is 
currently unknown because it is not essential to envelop mature virions or subsequent 
secretion. Both S and L are required for envelopment and secretion (Patient et al., 
2009). L has two possible conformations (Figure 1.13) called i-preS (Hildt et al., 1996, 
Bruss, 2007) and e-preS (Urban and Gripon, 2002, Gripon et al., 2005). The first 
conformation i-preS has internal PreS1 and PreS2 chains within the virion and contacts 
the viral nucleocapsid; this has been demonstrated to activate promoter elements (Hildt 
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et al., 1996, Bruss, 2007). The second conformation e-preS has PreS1 and PreS2 
chains exposed on the surface of virions and participates in virus receptor binding 
(Urban and Gripon, 2002, Gripon et al., 2005, Bruss, 2007, Glebe and Urban, 2007). 
1.2.6.4 Envelopment and Secretion 
Other structures called HBsAg spheres and filaments are also formed by the surface 
proteins. These are capsid free subviral particles lacking a viral genome that are 
secreted far in excess of the infectious virions (Gilbert et al., 2005, Patient et al., 2007). 
S protein aggregations can self assemble into 22nm spheres within the ER lumen, 
these then progress through the ER-Golgi intermediate compartment (ERGIC) and are 
released through the general secretory pathway (Patient et al., 2009, Patient et al., 
2007). The incorporation of L protein into these particles forms the filamentous subviral 
particles (Heermann et al., 1984, Roingeard and Sureau, 1998); the secretion of these 
particles and mature virions is a more complex process. The filaments and Dane 
particles utilise a more complex pathway that involves multivesicular bodies (MVBs) of 
the late endosomal pathway and the endosomal sorting complexes required for 
transport (ESCRT)(Patient et al., 2009, Stieler and Prange, 2014, Jiang et al., 2016). 
The mature nucleocapsids acquire host-derived lipid bilayers that are studded with viral 
proteins. These are formed by viral particles budding into the lumen of the late 
endoplasmic compartments (Ueda et al., 1991, Patzer et al., 1986). Dane particles are 
enveloped by a combination of S, M and L proteins; however, L is only found on the 
mature particle and the filaments (Heermann et al., 1984, Patient et al., 2009). The N-
terminal region of PreS1 domain “i-preS” on L proteins is thought to recognise mature 
particles. The process by which this occurs has not been confirmed, but it has been 
suggested that the nucleotide content of the virion (i.e. dsDNA) causes slight 
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conformational changes in the nucleocapsid that act as a maturation signal that recruits 
surface proteins (Hildt et al., 1996, Bruss, 2007). 
Mature virions utilise the ESCRT machinery for secretion and do so through α-taxilin; 
this mediates an interaction between viral surface protein L and ESCRT component 
tsg101 (Jiang et al., 2016, Hoffmann et al., 2013). ESCRT-MVB complex is comprised 
of many subunits; ESCRT I, ESCRT II and ESCRT III. The last component is the core 
complex, this recruits vacuolar protein sorting 4A and 4B (Vsp4A/ 4B). These proteins 
constrict membranes and mediate the splitting off of vesicles (Bishop and Woodman, 
2000, Fujita et al., 2003, Watanabe et al., 2007, Patient et al., 2009). Other literature 
suggests that the endosomal sorting and trafficking adaptor γ2-adaptin and the 
ubiquitin ligase Nedd4 are involved in HBV secretion (Rost et al., 2006, Lambert et al., 
2007); specifically, through interaction with L protein. γ2-adaptin was later shown to 
interact with L protein and it was shown that this interaction was involved in MVB 
dependent release of HBV (Lambert et al., 2007). This applies to L protein in the 
filamentous sub viral particles as well. MVBs are endosomal compartments that 
contain exosomes and, in this case, viral particles. These MVBs facilitate secretion of 
exosomes and viral particles through fusion with the host plasma membrane 
(Watanabe et al., 2007). 
1.2.6.5 Hepatitis B X Protein 
HBx is translated from the X mRNA, which is transcribed from the X ORF (Urban et al., 
2010). It is 17kDa in size and is conserved amongst mammalian hepadnaviruses (van 
Hemert et al., 2011). HBx is essential for the expression of other viral proteins, but HBx 
is not packaged into virions during assembly. A couple of possible hypotheses might 
apply here. First, HBx mRNA is transcribed immediately and then acts to increase 
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transcription of the remaining mRNAs. The second model suggests that HBx is not 
essential for early infection, and is instead expressed alongside each of the other viral 
proteins. In this instance HBx behaves as an inhibitor of cellular responses that would 
control HBV transcription (Lucifora, 2012). HBx is a multifunctional protein and the only 
regulatory protein for HBV. HBx interactions with host proteins have been well studied 
to try and define its role within viral replication (Murakami, 2001, Murakami, 1999). It 
has been demonstrated that HBx is essential for viral replication both in vivo and  
(Tsuge et al., 2010, Lucifora et al., 2011). 
Literature suggests that this regulation of replication occurs through epigenetic 
regulation of cccDNA (Pollicino et al., 2006, Guo et al., 2009, Koumbi and Karayiannis, 
2015). HBV cccDNA is subject to H3 and H4 acetylation during replication in an HBx 
dependent manner. HBx is recruited alongside histone acetyltransferases and 
deacetylases (Belloni et al., 2009, Pollicino et al., 2006) and activates genes on 
episomal templates regardless of promoter or enhancer sequences (Colgrove et al., 
1989); this is because HBx is a non-specific transactivator (Twu and Schloemer, 1987, 
Spandau and Lee, 1988). However, it does not transactivate chromosomal genes (van 
Breugel et al., 2012, Decorsiere et al., 2016). HBx has demonstrated a regulatory role 
over HBV promoter activity by transactivation of EnhI; this occurs despite a lack of 
binding to DNA, through interaction with host transcription factors (NF-κB, AP1, e-EBP, 
ATF/CREB, SP1 etc) (Quasdorff and Protzer, 2010). HBx has also demonstrated 
multiple interactions with host proteins; such as the UV-damaged-DNA-binding protein 
(Sitterlin et al., 1997), mitochondrial hsp60 and hsp70 (Zhang et al., 2005) and the 
mitochondrial antiviral signalling protein (Wei et al., 2010). Research has also 
demonstrated host proteins that bind with HBx and negatively regulate viral 
transcription, such as methyltransferase PRMT1 (Benhenda et al., 2013). 
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However, the HBx interaction with DDB1-Cul4 ubiquitin ligase machinery is of interest 
because inhibition of this interaction negatively regulates HBV infection (Sitterlin et al., 
2000a, Sitterlin et al., 2000b, Li et al., 2010b). DNA binding protein 1 (DDB1) binds to 
Cullin4 (Cul4) as a component of the E3 ubiquitin ligase complex; which is utilised by 
multiple viruses such as HIV-1 or Influenze A virus, to degrade proteins that inhibit viral 
replication, through proteasomal degradation. It has been shown that HBx 
transactivator activity is dependent on interaction between HBx and DDB1-Cul4 (van 
Breugel et al., 2012). This interaction occurs through an H-box binding motif near the 
C-terminal of HBx, which selectively replaces a subset of DCAF proteins in DDB1; this 
has been shown to be essential for HBx function (Yoo et al., 2008). 
Recent evidence has demonstrated that HBx activates episomal gene expression by 
promoting the degradation of the Structural Maintenance of Chromosomes (SMC) 
complex Smc5/6 (Figure 1.14), through DDB1-Cul4 ubiquitin ligase activity (Livingston 
et al., 2017, Murphy et al., 2016). The Smc5/6 subunits of the complex are putative 
HBx substrates and HBx has been demonstrated to reduce expression of the complex 
(Livingston et al., 2017, Murphy et al., 2016). This is important for viral replication 
because the Smc5/6 complex has been shown to bind to cccDNA and silence 
transcription (Livingston et al., 2017, Murphy et al., 2016). It is unclear how Smc5/6 
detects cccDNA; but it is sequence independent and it has been demonstrated that 
Smc5/6 can bind to and block transcription from multiple forms of episomal DNA, 
including plasmids (Kanno et al., 2015). It has been suggested that Smc5/6 interacts 
with components of the Nuclear Domain bodies 10 (ND10) in the nucleus of primary 
human hepatocytes, which traffic towards incoming DNA genomes (Adler et al., 2011, 
Full et al., 2014) and co-localise to repress cccDNA (Everett, 2006, Niu et al., 2017). 
This interaction is inhibited by HBx (Niu et al., 2017). 
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Figure 1.14 Cartoon representation of Smc5/6 pathway (Murphy et al., 
2016) 
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1.3 Hypoxia Inducible Factors 
Hypoxia inducible factors (HIFs) are a group of transcription factors that enable the 
host stress responses and are responsible for regulating the adaptation to low oxygen 
environments. They are found within most cell types and tissues. Typically, stabilisation 
of the transcription factor occurs under low oxygen and indicates that the protein is no 
longer being degraded. There are situations under which the protein may be stabilised 
under normal oxygen, for example mitochondrial stress and the generation of reactive 
oxygen species (Zhao et al., 2014, Solaini et al., 2010, Wilson et al., 2014, Guzy et al., 
2005). Currently there are three known isoforms of HIFs; 1α, 2α and 3α. The last of 
these has a number of different splice variants and is not well studied (Maynard et al., 
2003). HIF1α is ubiquitously expressed in cells and tissues around the body. The other 
isoforms HIF2α and 3α are more tissue-specific. All HIF isoforms are expressed in liver 
parenchymal cells (Nath and Szabo, 2012). Under normal oxygen HIFα subunits are 
degraded through proteosomal degradation. Prolyl-hydroxylases (PHDs) hydroxylate 
two-conserved proline residues found in the oxygen dependent degradation domain 
(ODD)(Berra et al., 2003, Nath and Szabo, 2012). Hydroxylation results in the 
recruitment of the Von Hippel Lindau protein (VHL) protein, which is an E3 ubiquitin 
ligase complex (Wilson et al., 2014). This in turn results in the polyubiquitination of the 
HIFα subunit and targeting to proteasome (Aragones et al., 2008, Kaelin and Ratcliffe, 
2008, Schofield and Ratcliffe, 2004, Tennant et al., 2009, Carroll and Ashcroft, 2006). 
Under hypoxic conditions the HIFα subunit for each isoform binds to a common HIFβ 
subunit, also called ARNT. This subunit is continuously expressed and not regulated 
through oxygen concentrations. This forms a heterodimer that translocates to the 
nucleus and binds hypoxic response elements (HREs) in the promoter regions of target 
genes (Carroll and Ashcroft, 2006). Reportedly, this action enables the regulation of 
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numerous stress response genes (Kaelin and Ratcliffe, 2008, Bertout et al., 2008). HIF 
activity is controlled under hypoxia due to a negative feedback system that upregulates 
PHD1-3 expression and subsequent VHL activity resulting in transient HIF expression 
(Schofield and Ratcliffe, 2004, Aragones et al., 2008, Tennant et al., 2009). Under 
hypoxic conditions the activities of these 2 hydroxylases is inhibited, that results in the 
stabilisation of HIF1α, following which, the protein accumulates and translocates to the 
nucleus where it dimerises with its HIFβ counterpart. This heterodimer can bind co-
activators p300/CBP and bind the HREs found within the regulatory regions of target 
genes, stimulating a wide range of stress responses (Carroll and Ashcroft, 2006, 
Wilson et al., 2014). Evidence suggests that while each isoform may exist within the 
same tissue, these are differentially regulated through multiple mechanisms 
(Majmundar et al., 2010). The different isoforms can control a range of different genes 
at the same time, but have also been shown to enact different responses upon the 
same genes. This may indicate that each isoform regulates the others activities or 
performs opposing functions where required (Majmundar et al., 2010). 
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Figure 1.15 Hypoxia inducible factors, Oxygen dependent and 
independent regulation (Wilson et al., 2014) 
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There is another oxygen sensitive hydroxylase that regulates the activity of HIF1α; this 
is called the factor inhibiting HIF (FIH). FIH activity occurs through hydroxylation of an 
asparaginyl residue in the C-terminal domain of HIF1α. This hydroxylation prevents the 
binding of HIF1α to the transcriptional coactivator p300 (Wilson et al., 2014). HIFs can 
also be stabilised in the absence of a low oxygen environment; this occurs through cell 
surface receptor activity such as G protein-coupled receptors or receptor tyrosine 
kinases promoting HIF1α mRNA translation (Wilson et al., 2014). The 
phosphatidylinositol-3-kinase (PI3K) pathway uses the binding of growth factors to its 
receptors to activate downstream serine/ threonine kinase Akt and mTOR and HIF 
signalling (Agani and Jiang, 2013). Growth factors binding to receptors can activate 
ERK and p70S6K1, two factors important in regulating HIF1α mRNA translation 
(Semenza, 2003, Agani and Jiang, 2013). The ERK can also activate the MAPK 
signalling pathway (Sang et al., 2003). Reactive oxygen species generated through 
mitochondrial dysfunction can also result in HIF1α stabilisation through inhibiting the 
activity of PHDs (Chandel et al., 2000, Guzy et al., 2005, Wilson et al., 2014). Data 
obtained using HIF1 knockout mice models and an ethanol diet suggests that HIFs 
play a regulatory role in hepatic lipogenesis, the results showed an increase in lipid 
accumulation following HIF1 inhibition (Nishiyama et al., 2012). This implies that HIF1 
plays a role in protection against alcoholic liver disease (ALD). Moon and colleagues 
demonstrated that HIF1 deficient mice showed increased levels of liver fibrosis and 
hypothesised that during chronic liver injury, continued expression of HIF1 results in 
increased expression of profibrotic proteins (Moon et al., 2009). This was tested using 
mice subjected to bile duct ligation (BDL) and animal model of fibrosis (Moon et al., 
2009). Another study by Scortegagna and colleagues demonstrated the effect of HIF2 
knockout in mice models; these also demonstrated an increase in lipid accumulation 
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and development of steatosis (Scortegagna et al., 2003). HIFs are involved in 
regulating a number of pathways. 
1.3.1 HIF1α 
HIF1α is involved in glucose metabolism, regulation of lipid metabolism, liver injury and 
tumour-associated angiogenesis, metastasis and inflammation. While under low 
oxygen conditions, this transcription factor regulates the conversion of oxygen-
dependent ATP production to glycolysis. This is achieved by increasing glycolytic 
enzyme activity and lactate dehydrogenase A (LDHA) expression, which leads to 
increased NAD+ production for glycolysis under hypoxia (Shim et al., 1997, Gordan et 
al., 2007b). In addition, PDK1 is up regulated, which enables pyruvate conversion to 
acetyl-CoA and reduces the oxygen consumption within cells (Kim et al., 2006a, 
Papandreou et al., 2006, Simon, 2006). HIF1α uses the pentose phosphate pathway to 
convert glycolytic intermediates into RNA and DNA. These metabolic changes play an 
important role in facilitating cell survival and growth under low oxygen conditions 
(Simon, 2006, Gordan et al., 2007b, Goda and Kanai, 2012). 
Evidence suggests that HIF1α plays a role in cancer metabolism, metastasis and 
invasion. Mutations that inactivate fumerate hydratase (FH) and succinate 
dehydrogenase (SDH) enzymes result in increased ROS generation in tumours after 
fumerate and succinate accumulation (King et al., 2006, Selak et al., 2005, Isaacs et 
al., 2005). This increased inactivation of PHDs, which in turn increases HIF1α 
stabilisastion (King et al., 2006). HIF1α expression can result in a loss of E-cadherin 
(Evans et al., 2007, Krishnamachary et al., 2006, Esteban et al., 2006, Kaelin, 2008). 
Evidence suggests that HIF1α expression is also linked to epithelial to mesenchymal 
transition (EMT)(Yang et al., 2008). However, the mechanism differs between cancers 
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(Kaelin, 2008, Mak et al., 2010). Accumulation of HIF1α is important for the stimulation 
of angiogenesis, glycolysis, erythropoiesis and other targets already discussed. These 
are all involved in cellular tolerance to hypoxia and increasing tissue vascularity. This 
process is commonly utilised by host cells to heal injured tissues. However, 
deregulation of these pathways is commonly used by cancers. Wang and colleagues 
suggest that HIF1α regulates apoptosis via autophagy to destroy compromised cells 
(Wang et al., 2017). Cursio and colleagues demonstrate that HIF1α induces apoptosis 
in liver cells following ischemia-reperfusion injury (Cursio et al., 2008). 
1.3.2 HIF2α 
HIF2α is also responsible for regulating stress response genes in an oxygen 
dependent manner. These include glucose and lipid metabolism, angiogenesis, 
inflammation and redox homeostasis (Leek et al., 2002, Imtiyaz et al., 2010, Qu et al., 
2011, Majmundar et al., 2012). HIF2α can interact with Cytochrome C oxidase to 
increase the electron transport chain efficiency (Gordan et al., 2007b). In addition, 
inhibition of HIF2α results in increased p53 pathway activity and this is linked to 
increased apoptosis of tumour cells; this is regulated through accumulation of ROS by 
anti-oxidant enzyme SOD2 activity (Scortegagna et al., 2003, Gordan et al., 2007a, 
Bertout et al., 2009). HIF2α is essential for pro-inflammatory cytokine expression and 
regulates macrophage migration or chemotaxis in models of acute and tumour 
inflammation (Imtiyaz and Simon, 2010, Imtiyaz et al., 2010), unlike HIF1α this is not 
regulated through ROS (Imtiyaz et al., 2010). High levels of HIF2α expression are 
observed in tumour-associated macrophages (TAMs) (Talks et al., 2000), with 
expression associated with increased tumour grade and vascularity as well as a poorer 
prognosis (Leek et al., 2002, Murdoch et al., 2004, Kawanaka et al., 2008). There is an 
overlap in the genes regulated through action of transcription factors HIF1α and HIF2α, 
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suggesting complementary or opposing functions. It has been shown that knock down 
of one HIFα subunit results in the up regulation of the other (Hu et al., 2003, Kim et al., 
2009, Keith et al., 2011). 
HIF2α regulates EPO production and erythropoiesis and plays a role in regulating 
hepatic lipid metabolism (Scortegagna et al., 2003, Mastrogiannaki et al., 2009). It has 
been demonstrated that continual activation of HIF2α results in severe hepatic 
steatosis; this is combined with impaired fatty acid β-oxidation, decreased lipogenic 
gene expression and an increase in lipid storage capacity(Scortegagna et al., 2003). 
This demonstrated the importance of HIF2α as a lipid metabolism regulator (Rankin et 
al., 2009). HIF2α regulates the expression of liver-enriched gene 1 (leg1), a secretory 
protein involved in hepatogenesis at the final stage called ‘hepatic outgrowth’ (Lin et 
al., 2014). 
1.3.3 HIF3α 
The third known isoform is HIF3α. This is the least well-studied isoform, although 
previous studies have shown expression in kidneys and lung epithelial cells. 
Expression has been reported in the liver; however, the number of studies is limited. 
Most experiments looking into HIF3α activity have been conducted in Chinese Hamster 
Ovary cells (ChoK1). It has been shown that HIF3α is regulated in an oxygen 
dependent manner similar to HIF1α and HIF2α. Unlike the other 2 HIFα subunits, 
HIF3α has 7 identified splice variants, which can be separated by size (Maynard et al., 
2003). It has been reported that HIF3α interaction with the other HIFα subunits can 
prevent nuclear translocation; this suggests a regulatory role over the other HIFα 
subunits (Heikkila et al., 2011). The 3α4 splice variant in particular has been shown to 
interact with HIF1α, HIF2α and HIFβ and act as a negative regulator (Heikkila et al., 
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2011, Ando et al., 2013). HIF3α enacts its negative regulation of HIF1α through 
inhibition of nuclear translocation. In addition, down regulation of HIF3α has been 
shown to reduce HIF target gene expression; perhaps indicating that HIF3α is not 
limited to a negative regulatory role (Augstein et al., 2011, Heikkila et al., 2011). There 
is some evidence to suggest that HIF3α might be a target of HIF2α, it is demonstrated 
that hypoxia does not stimulate HIF3α expression, rather its linked to the expression of 
HIF2α (Liu et al., 2016). 
1.4 HBV and Hypoxia 
Having discussed the HBV lifecycle in detail and talked about HIFs and low oxygen in 
the liver; it is important to discuss how these tow topics intersect. As mentioned 
previously HBV reportedly interacts with a range of ubiquitous and liver specific 
transcription factors (Quasdorff and Protzer, 2010). These interactions occur through 
direct interaction with HBV promoters and enhancers or through binding of the HBx 
protein. As discussed HIFs and HIF1α are associated with regulating a range of stress 
response genes as well as playing roles in glucose and lipid metabolism. These 
transcription factors have been linked to oncogenesis for several cancers such as 
bladder, breast, liver, ovarion, pancreatic, prostate and renal cancers (Harris et al., 
2002, Pilarsky et al., 2004, Bardos and Ashcroft, 2004, Franovic et al., 2009, Semenza, 
2003). Studies have shown that HIF1α is linked to HCC progression and that HIFs 
might be the link to HBV associated HCC pathogenesis. HIF1α activity can be induced 
in a couple of ways, through disruption of oxygen-dependent degradation or through an 
increase in growth factor signalling. Previous studies indicate that this interaction 
between HBV and HIF1α primarily occur through the HBx protein. Interactions have 
primarily been shown through co-immunoprecipitation of HBx and HIFs following 
transfection of HBV or overexpression of HBx and treatment with HIF stabilising agents 
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such as Dimethyloxalylglycine (DMOG) or cobalt chloride (CoCl2). The following 
section will detail some of these previously observed interactions (Figure 1.16). 
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Figure 1.16 Cartoon representation of reported HBV-HIF interactions
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HBx has been identified as a major contributing factor in the development of HBV 
associated HCC (Fallot et al., 2012). Yoo and colleagues showed that HBx induced 
genetic instability and disrupts the normal cell cycle; this occurred simultaneous to 
increased translation of HIF1α mRNA and increased HIF target gene activity. This 
study demonstrated that HBx activation of MAPK signalling may activate HIF1α 
transcription (Figure 1.16 (1)) (Yoo et al., 2003). Yoo and colleagues also 
demonstrated that the C-terminus domain of HBx increased the stability of HIF1α in 
HBx transfected liver and non-liver cells (Yoo et al., 2004). In addition they 
demonstrated that the C-terminus of HBx increased the transactivation function of 
HIF1α by enhancing its association with CBP/p300 (Figure 1.16 (3)) (Yoo et al., 2004). 
The authors showed that the C-terminus of HBx interacts and binds the bHLH/ PAS, 
ODD and C-TAD domains of HIF1α and suggest that this could interfere with PHD and 
VHL interactions with HIFs, thereby preventing proteasomal degradation (Figure 1.16 
(2)) (Yoo et al, 2004). Moon and colleagues reported the same observation and 
suggested that HBx stabilisation of HIFs lead to angiogenesis during 
hepatocarcinogenesis (Moon et al., 2004). Holotnakova and colleagues also showed 
that HBx binding to the bHLH/PAS region stimulated HIF1α interaction with its target 
promoters and resulted in increased carbonic anhydrase 9 (CA9) expression 
(Holotnakova et al., 2010). CA9 is known for roles in pH regulation, which enables 
survival in cells with intracellular acidosis and hypoxia like conditions (Holotnakova et 
al., 2010). 
Liu and colleagues reported that HBx could stabilise HIF1α via activating the human 
epidermal growth factor receptor 2 (HER2) signalling pathway via increased activation 
of PI3K and Akt pathway (Figure 1.16 (4)) (Liu et al., 2009). Hung and colleagues have 
demonstrated that HBx interacts with RNA-binding protein HuR and increases 
Nicholas Ross Baker Frampton Hepatitis B and Hypoxia Student ID: 1301165 
 
79 
 
stabilisation of HER2, which could result in increased activation of the PI3K pathway 
(Figure 1.16 (6)) (Hung et al., 2014). Zhu and colleagues also demonstrated that the 
HBx increases alpha-fetoprotein (AFP) expression that activates PI3K/ Akt signalling 
and promotes mTOR stimulation of HIF expression (Figure 1.16 (5)) (Zhu et al., 2015a, 
Zhu et al., 2015b), possibly through inhibition of 4E-BP1 (Gingras et al., 1998, Uniacke 
et al., 2012). HBV has been shown to interact with eIF-4E previously, through HBV 
polymerase and incorporation into the nucleocapsid (Montero et al., 2015, Kim et al., 
2010b). Yoo and colleagues demonstrated that HBx induced expression of metastasis 
associated protein 1 (MTA1) and histone deacetylase (HDAC) at transcriptional levels. 
These have been shown to physically associate with HIF1α in the presence of HBx. 
HBx interaction with HDAC stimulates deacetylation of the ODD region in HIF1α, this 
prevents hydroxylation by PHDs and subsequent ubiquitination by VHL (Figure 1.16 
(7)) (Yoo et al., 2008). This interaction could be inhibited through siRNA treatment 
against MTA1 (Yoo et al., 2008). 
Hu and colleagues demonstrate the HBx can stimulate the stabilisation of HIF2α, this 
occurs through HBx binding to VHL to prevent alpha subunit degradation and 
simultaneous stimulation of NF-κB, which upregulated expression HIF2α (Figure 1.16 
(8)) (Hu et al., 2016). Alternatively, Li et al recently suggested a new role for HIF1α in 
HBV infections. They demonstrate that HBV L protein can increase the expression of 
multi-drug resistance protein 1 (MDR1) in a HIF1α dependent manner (Figure 1.16 (9)) 
(Li et al., 2017). They argued that this contributed to the pathogenic changes in chronic 
HBV and contributed to chemotherapeutic resistance in HCC. Another argument 
suggests that this activation of MDR1 occurs following accumulation of HBsAg 
(including L protein), which could cause cellular stress responses. Li et al, suggest that 
LHBs might stimulate HIF1α more strongly than HBx (Li et al., 2017). 
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It is clear that there is a relationship between HBV and HIF1α, however the exact 
mechanism of interaction and impact of the interaction requires further study. The use 
of HBx over-expression systems has limited many of the conclusions reached in the 
reports. 
1.5 Aims 
The aim of this study was to further our understanding of the role hypoxia plays in HBV 
viral lifecycle and to expand upon current research using current gold standards for 
modelling native infections and examining the effect of hypoxia at different stages of 
replication. Most studies to date used artificial models of infection and stimulated 
hypoxic responses with drugs rather than true low oxygen environments. First, we 
examined the kinetics of HIF stabilisation and activity in hepatoma cell lines known to 
support HBV infection. We also studied the impact of differentiation status on cellular 
responses to low oxygen. Next, we examined the kinetics of HIF stabilisation and 
activity in chronically infected producer cell lines and artificial transfections of HBV 
genomes. We also studied the effect of differentiation on viral nucleic acids and HIF 
responses in the producer cells. Lastly, we examined the effects of low oxygen on viral 
replication using a de novo infection model that utilises mature Dane particles. Taken 
together these aims provided the basis for experiments that aided in understanding low 
oxygen effects on HBV replication. We hypothesised that low oxygen was promoting 
viral replication. 
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2. MATERIALS AND METHODS 
2.1 Tissue Culture 
All cells used in this study are described in Table 2.1 Cells were maintained in 
Dulbecco’s modified Eagles medium (DMEM) (Gibco, USA) supplemented with 10% 
foetal bovine serum (FBS), 1% v/v penicillin-streptomycin (pen/strep) and  
1% L-Glutamine; from here on referred to as growth media. For normoxic experiments 
cells were incubated at 37oC with 20% O2 and 5% CO2. For hypoxia cells were grown 
under 1% O2 or 3% O2 in a humidified sealed hypoxystation (Don Whitely Scientific, 
UK) calibrated to 5% CO2 and 95% N2. For Non-DMSO differentiation cells were 
maintained in William’s E Medium (Gibco, USA) supplemented with 10% FBS, 1% v/v 
pen/strep, 1% L-Glutamine, inosine 10 μg/ml, 25 mM Glucose, 4.9 μg/ml 
Hydrocortisone and 1μg/ml insulin; from here on referred to as differentiation media. 
2.2 Transfections 
Target cells were seeded into 6-well plates in 10% FBS growth media. Prior to 
transfection the media was removed and replaced with penicillin/streptomycin free 
DMEM containing 3% FBS. Cells were transfected with Fugene6 (Promega, USA) 
according to the manufacturer’s instructions. siRNA transfections were performed with 
Lipofectamine® RNAiMax (Thermo Fisher Scientific, USA) according to the 
manufacturer’s instructions. After transfection in some protocols, cells were reseeded 
into 96 well plates as described in Section 2.3. All plasmids used in this study are 
listed in Table 2.2. 
Nicholas Ross Baker Frampton Hepatitis B and Hypoxia Student ID: 1301165 
 
82 
 
Table 2.1 Cell lines used in this study 
Table detailing the cell lines used throughout this project, including the name of each cell line, 
tissue of origin, a brief description of the cell line, and the source from which we obtained the 
cell lines. 
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Table 2.2 Plasmids used in this study 
Table detailing the plasmids used throughout this project including the vector, specific insert, the 
working concentration and the source from which we obtained the plasmid. 
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2.3 HRE Luciferase Assay 
This assay is performed to ascertain the kinetics of HRE activation in cells exposed to 
hypoxic conditions representing HIF activity. Hepatoma cells were seeded at 2x105 per 
9.6cm2 in 10% FBS growth media. The cells were transfected with 2μg of HRE 
luciferase reporter plasmid. Twenty-four hours after transfection, the cells were 
trypsinised and 2x104 cells were re seeded into each well of 96-well plates for each 
time point and condition in triplicate. The cells are then placed into either normoxic 
(20% O2) or hypoxic (1-3% O2) incubation. A T0 time point is taken at this point. The 
media is removed from each well in the 96-well plate. Samples are lysed using 1x 
luciferase lysis buffer (25mM Tris-phosphate (pH 7.8), 2mM DTT, 2mM 1,2-
diaminocyclohexane-N,N,N ́,N ́-tetra acetic acid, 10% glycerol, 1% Triton X-100) added to 
each well, the plates are then frozen at -20oC until ready for reading. Following lysis of 
all samples, plates are removed from the freezer and thawed. The lysis buffer and 
lysed cells are transferred to the 96 well luminometer plates. Luciferase assay 
substrate (Promega, USA) is added to each well. The plate is read using a 
luminometer (Centro LB 960 Microplate Luminometer) kinetics operation. Data 
demonstrated in graphs represents raw relative light units (RLU) from 3-4 technical 
repeats normalised against cell counts. Data is also represented as relative values of 
hypoxic samples against normoxic controls. 
2.4 Generation of HBV 
This protocol is used to generate full-length genotype D HBV particles from the 
producer cell line HepG2.2.15s. These cells are chronically infected with Hepatitis B. 
HepG2.2.15 cells were seeded into T175 flasks (Corning, USA) coated with collagen 
(Sigma, USA). These cells are maintained in DMEM with 10% FBS and 1% pen/strep. 
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After 72 hours, the media is changed to DMEM with 5% FBS, 2% DMSO and 1% 
pen/strep to DMSO differentiate the cells over an additional 72 hours. Following 
differentiation, discard the media and change to serum free DMEM containing 2% 
DMSO and 1% pen/strep. The media is harvested and replaced every 24 hours. 
Conditioned media contains un-concentrated HBV particles. Virus is concentrated 
using Vivaspin columns (25 mL a time) at 4,000G for 15 minutes in centrifuge. 
Concentrated virus is aliquoted into 1ml Eppendorfs. DNA levels are quantified using 
qPCR (Section 2.9). Dane particles are purified using HiTrap Heparin HP affinity 
columns (GE Healthcare Life Sciences, UK). Concentrated virus was applied to the 
column and washed 5x with wash buffer (20 mM phosphate buffer, 50 mM NaCl, pH  7) 
to remove non-infectious sub viral particles. The virus was then eluted with elution 
buffer (20 mM phosphate buffer, 2 M NaCl, pH  7). Following elution the virus was 
aliquoted into 1mL cryovial tubes and frozen at -80oC. The virus was shipped from 
Munich by secure courier using appropriate containment measures in dry ice. Upon 
receiving the virus, cryovial tubes were stored at -80oC. 
2.4.1 Category 3 containment 
All cell culture and experiments using HBV or chronically infected producer cell lines 
were performed under Category 3 containment. This involved two layers of 
containment. The safety equipment and the laboratory itself. Entry to catergory 3 
laboratory was prohibited until safety training was completed. 
2.5 De Novo Infections 
HepG2-NTCP K7 cells are seeded at 5x104 cells per well in DMEM containing 10% 
FBS, 2% DMSO, 1% pen/strep. The cells are DMSO differentiated over 72 hours in this 
media. Concentrated HBV (MOI of 100) is combined with infection media, DMEM 
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containing 5% FBS, 2% DMSO, 5% PEG8000 and 1% pen/strep. Following 
combination, the virus and media should be mixed for 5 minutes before being added to 
cells. Twenty-four hours later, remove the infection media and wash cells 3x with 
serum-free DMEM (Gibco, USA). Retain the final wash as a T0 time point. This can be 
used as a negative control. The sample can be frozen at -20oC. Replace the serum-
free DMEM with DMEM containing 5% FBS, 2% DMSO and 1% pen/strep. After 96 
hours (5 days post infection), collect the media and replace with fresh media that is 
DMSO free. Store the sample at -20oC. After 24 hours the samples can be treated with 
drugs or transfected. Dependent of whether treatments were applied, infections can be 
placed into hypoxic or normoxic conditions 5-6 days post infection. Collected 
supernatants can be used in HBsAg and HBeAg ELISAs to detect HBV infections. HBV 
RNA and DNA levels quantified by PCR (Sections 2.8 and 2.9). 
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2.6 HBV E and S antigen ELISAs 
Following completion of infection HBV E and S antigen can be detected in the 
conditioned media removed at time points throughout infection using ELISA kits 
(Abnova, USA). Samples were collected as described in section 2.5 and the assays 
performed as per manufacturer’s instructions. Briefly for S antigen ELISAs, add 50 μL 
of sample supernatants into wells of the ELISA plates. Add 50 μL of Anti-HBs 
Peroxidase Solution to each well except the blank. Incubate the reaction plate at 37oC 
in a water bath or incubator for 80 minutes. For E antigen ELISAs, add 100 μL of 
sample supernatants into wells of the ELISA plates. Incubate the reaction plate at 37oC 
in a water bath or incubator for 1 hour. Follow the “plate washing procedure”. Add 100 
μL of Anti-HBe Peroxidase Solution to each well except the blank. Incubate the 
reaction plate at 37oC in a water bath or incubator for 1 hour. Repeat washing 
procedure. Add 100 μL of TMB substrate solution and incubate at room temperature for 
30 minutes. Stop the reaction by adding 100 μL of 2 N H2SO4 to each well except the 
blanks. Following incubations and colour development the plates are read at 490nm 
using a spectrophotometer to determine an OD reading. This is compared to blank 
wells along with positive and negative control samples. The OD readings are 
expressed relative to a cut-off value (s/ c off) (as described in manufacturer’s 
instructions). This value is determined by combining the uninfected cell sample mean 
and two standard deviations around the mean. Any value above the cut-off value is 
considered a true infection. 
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2.7 Western Blotting 
2.7.1 Lysate preparation and sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) 
Cell lysates were prepared from target cells harvested after exposure to hypoxic (1% 
O2) or normoxic conditions (20% O2) using 8M urea lysis buffer (H2O, 8M urea, 8% 
glycerol, 20% sodium dodecyl sulphate [SDS], 1M Tris-HCL, pH7.5) and then 1x 
reducing laemmli buffer (H2O, 30% glycerol, 6% SDS, 0.02% bromophenol blue, 10% 
2-β-mercaptoethanol and 0.2M Tris-HCL; pH6.8) was added at a ratio of 1:3. Protein 
concentration was determined using the NanoDrop 2000 spectrophotometer; 
thereafter, lysates were denatured at 95oC for 10 minutes. Proteins were separated on 
8% SDS polyacrylamide gels using the Mini Protean 3 system (Bio-Rad, USA) 
according to the manufacturer’s instruction. Briefly, 10-20μg of protein was loaded onto 
gels and ran at 350 mAmps constant for 45 minutes in running buffer (0.25M Tris base, 
1.92M glycine, pH 8.4) (National Diagnostics, USA). Proteins were transferred to 
polyvinylidene membranes (Millipore, USA) using a Mini Trans-Blot Electrophoresis 
transfer system (Bio-Rad, USA). Polyvinylidene membranes were activated with 
methanol for 2 minutes followed by incubation in transfer buffer (National Diagnostics, 
USA) for 5 minutes at room temperature. SDS gels were also equilibrated in transfer 
buffer to prevent shrinking and transfer was performed at 350mAmps for 70-80 minutes 
at room temperature. 
2.7.2 Immuno-blotting and chemiluminescent detection of proteins 
After transfer, membranes were incubated in antibody buffer (PBS, 0.1% Tween-20 
and 5% Marvel Dry Milk) for 45 minutes at room temperature to prevent non-specific 
antibody binding. The blocking buffer was removed and membranes incubated in 
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primary antibodies for HIF-1α (BD Biosciences, USA), HIF-2α (Ratcliffe Laboratory, 
University of Oxford) or β-actin (Thermo Fisher Scientific, USA), diluted in antibody 
buffer at 4°C overnight with gentle agitation on a tube roller (Barloworld Scientific, UK). 
The following day membranes were washed in washing buffer (PBS, 0.1% Tween-20) 
4 times for 5 minutes. Incubation with horseradish peroxidase (HRP) conjugated 
secondary antibodies (Dako, Agilent Technologies, USA) was carried out for 60 
minutes at room temperature in antibody buffer followed by excess washing. 
Chemiluminescent detection of HRP-conjugates was achieved with an ECL detection 
system called SuperSignalTM West Dura Extended Duration Substrate (Thermo Fisher 
Scientific, USA). Briefly, membranes were incubated in ECL reagent for 1 minute and 
proteins detected using the PXi Touch Gel Imaging System (Syngene, UK). 
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2.8 Quantitative RT-PCR 
RNA was prepared from target cells. The growth medium was removed and samples 
were washed with PBS, the cells were then lysed using RLT+ lysis buffer (Qiagen, 
Germany). Cellular RNA purification was performed using the Allprep DNA and RNA 
purification kit (see Figure 8.2) (Qiagen, Germany). RNA was amplified using the 
TaqManTM primers (Applied Biosystems, USA) listed in Table 2.3. Reaction master-mix 
was designed using components of the Cells Direct Kit (Invitrogen, USA) according to 
the manufacture’s instructions. Quantitative reverse-transcription PCR (qRT-PCR) was 
carried out in a microAmp 96 well optimal reaction plate (Applied Biosystems, USA) 
using a Mx3000P qPCR system (Agilent Technologies, USA) and data analysed with 
the MXpro software. The PCR cycling conditions are as follows: 30 minutes at 50oC, 5 
minutes at 95oC followed by 50 cycles of 95oC for 15 seconds and 60oC for 60 
seconds. HBV pgRNA data represents copies as determined by a standard curve 
produced using a 10-fold dilution series of concentrated HBV genome (Genotype D – 
plasmid H1.3). Copies are normalized against Beta-2 Microglobulin (B2M) endogenous 
control for extraction efficiency. HIF target genes data represents relative mRNA 
expression as determined by the 2-ΔΔCt method for relative quantification; samples are 
normalized against B2M endogenous control. 
2.9 SYBR Green PCR to amplify HBV nucleic acids 
DNA was prepared from target cells. The growth medium was removed and samples 
were washed with PBS, the cells were then lysed using RLT+ lysis buffer (Qiagen, 
Germany). Cellular DNA purification was performed using the Allprep DNA and RNA 
purification kit (Qiagen, Germany). Quantitative PCR (qPCR) performed using SYBR 
green master mix (Life Technologies, USA) as per manufacturer’s instructions. DNA 
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amplification was performed using primer pairs listed in Table 2.4. The PCR cycling 
conditions are as follows for HBV rcDNA: 5 mins at 95°C; 50 cycles at 95°C for 3s and 
60°C for 60s. The PCR cycling conditions are as follows for HBV cccDNA: 5 mins at 
95°C; 60 cycles at 95°C for 3s, 60°C for 60s and 72°C for 15s. The PCR cycling 
conditions are as follows for ChIP assay: 10 mins at 95°C; 45 cycles at 95°C for 30s 
and 58°C for 30s and 72°C for 30s. HBV rcDNA and cccDNA data represents copies 
as determined by a standard curve produced using a 10 fold dilution series of 
concentrated HBV genome (Genotype D – plasmid H1.3). Copies are normalized 
against cellular prion protein (PrPc) endogenous control. Representative dissociation 
curves for HBV SYBR Green PCRs are displayed in Figure 2.1. 
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Table 2.3 TaqManTM primers used in study 
Table detailing the TaqManTM primers used throughout this project including the name of each 
primer, the source, and the sequence information if available. 
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Table 2.4 SYBR Green primers used in this study 
Table detailing the SYBR Green primers used throughout this project including the name of 
each primer, the source, and the sequence information if available. 
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Figure 2.1 Representative dissociation curves for HBV SYBR Green 
PCRs 
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2.10 PCR Array 
Selected hypoxia signalling PCR arrays consisting of 84 hypoxia regulated genes were 
purchased from (SABiosciences, USA) and performed as per the manufacture’s 
instructions. Briefly, cDNA was synthesized from purified cellular RNA using the RT2 
First Strand Kit components listed in Table 2.5. Followed by reverse transcription of 
cDNA products using the SYBR Green Reverse Transcriptase mix (Qiagen, Germany). 
Reaction mix was added to profiler array 384 well plates and PCR cycling achieved 
with the Applied Biosystems 7900HT machine using the following conditions, 10mins at 
95°C, 40 cycles of 15s at 95°C, and 1 minute at 60°C. Data analysed via the 
SABiosciences online PCR array portal. 
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Table 2.5 PCR array components 
Table detailing reaction components and required volumes for 4 reactions using 
selected hypoxia signalling PCR arrays. 
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2.11 Immunofluorescent Staining of HBV S Antigen 
Following completion of infection, it is possible to stain for the presence of HBV S 
antigen, which is indicative of infection. HepG2.2.15 and uninfected HepG2 NTCP cells 
are used as positive and negative controls in this experiment. After the infection is 
complete the cells are fixed for 25 minutes in 6% paraformaldehyde (PFA) (Sigma, 
USA). The fixative is removed and cells washed with PBS. The cells are permeabilized 
for 10 minutes using a solution of 0.01% Triton X-100 (Sigma, USA) diluted in PBS. 
Following permeabilization, the solution is aspirated and cells washed 3x with PBS. 
The cells are blocked for 30 minutes in PBS containing 0.5% bovine serum albumin 
(BSA). This prevents non-specific antibody binding. The primary antibody (Anti-
Hepatitis B Virus Surface Antigen (ab8636), Abcam, UK) is diluted in PBS containing 
0.5% BSA and 0.5% Saponin. After adding primary antibody to the cells (1:100 or 
2μg/ml), incubate at room temperature for 1 hour. The antibody is removed and cells 
washed 3x in diluent solution. Add the secondary antibody (Goat anti-Mouse Alexa 
Fluor 488, Life Technologies, USA – 1:500 dilution in diluent solution). The cells are 
incubated at room temperature for 1 hour in the dark, wrapped in foil. Following 
incubation, the cells are washed 3x with diluent solution. DAPI (Life Technologies, 
USA) is added to the cells for 1 minute, the cells are subsequently rinsed and can be 
maintained in PBS until imaging. Coverslips are mounted onto microscope slides using 
ProLong® Gold Antifade Reagent (Life Technologies, USA). Images captured using a 
Leica D6000 fluorescence microscope using a 10x and 40x objective. 
2.12 Chromatin Immunoprecipitation (ChIP) 
HepG2.2.15 cells were grown to 80% confluency in T75 culture flasks. After reaching 
80% confluency flasks are placed under 20% and 1% oxygen for 24 hours. Samples 
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are fixed in 1% formaldehyde for 5 minutes at room temperature to cross-link protein to 
DNA. Fixed cells are washed 1x with ice-cold PBS. Fixation is stopped using Glycine 
Stop-Fix solution (Active Motif, USA). Cells are washed 1x with ice-cold PBS. Cells are 
harvested by addition cell scraping solution (Active Motif, USA) and scraping using 
rubber policeman. Harvested cells are pelleted by centrifugation at 2,500 rpm for 10 
minutes at 4oC. The supernatant is discarded. The pellet is resuspended in 1ml of ice-
cold Lysis Buffer (Active Motif, USA) and incubated on ice for 30 minutes. The cells are 
transferred to an ice-cold dounce homogenizer; cells are homogenized with 10 strokes 
to aid nuclei release. Homogenized cells are transferred to microcentrifuge tubes and 
the nuclei are pelleted by centrifugation at 5,000 rpm for 10 minutes at 4oC. 
Supernatants are carefully removed and discarded. Nuclei pellets are resuspended in 
Shearing Buffer (Active Motif, USA). The DNA is sheared by sonication at 25% power 
using 10 pulses of 20 seconds. Sonicated samples are centrifuged at 15,000 rpm for 
10 minutes at 4oC. The supernatants are carefully transferred to fresh tubes. This is the 
sheared chromatin. Chromatin immunoprecipitation (ChIP) is performed as per 
manufacturer’s instructions using ChIP-IT® Express Chromatin Immunoprecipitation kit 
including Protein G Magnetic Beads (Active Motif, USA). Primary antibodies for HIF-1α 
(Ratcliffe Laboratory, University of Oxford) and FLAG (Active Motif) are used in this 
experiment. Following immunoprecipitation, samples amplified by PCR using the 
protocol detailed in section 2.10. Graph represents relative binding as determined by 
the 2-ΔΔCt method for relative quantification against negative control FLAG antibody. 
2.13 Statistical Analysis 
Statistical analyses were performed using One-Way and Two-Way ANOVAs or Multiple 
t tests on grouped data in Prism 7.0 (GraphPad, USA) with P<0.05 being considered 
statistically significant. Significance shown using standardised star rating as follows 
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(*<0.05, **<0.01, ***<0.001, ****<0.0001). Tukey’s multiple comparisons tests were 
used in conjunction with ANOVAto find means that are significantly different from each 
other. This test compares all possible pairs of means. This test identifies any difference 
between two means greater than the expected standard error. Sidak’s multiple 
comparisons tests are also used in conjunction with ANOVA to control the familywise 
error rate that can occur in multiple comparisons tests. The test is designed to correct 
for type 1 errors when performing multiple hypotheses tests. We used the Welch’s 
correction in conjunction with Multiple t tests. This correction is used to test the 
hypothesis that two or more sample means have equal means. This correction is 
considered more reliable than a Student’s t test when samples have unequal sample 
sizes or variance. 
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3. EXAMINING THE HEPATOMA CELL RESPONSE TO LOW 
OXYGEN 
3.1 Introduction 
The majority of hepatocytes within the liver are terminally differentiated (Fausto, 1990, 
Fausto et al., 2006) and exist as part of an oxygen gradient from 11% oxygen at the 
hepatic portal vein to 3% at the hepatic central veins (Jungermann and Kietzmann, 
2000, Adams and Eksteen, 2006). The major cell type in the liver that supports HBV 
infection is the hepatocyte and recent studies show that the hepatocyte derived HepG2 
cell line supports efficient HBV replication in vitro (Meredith et al., 2016, Verrier et al., 
2016b). We therefore studied the response of uninfected HepG2, Huh-7, and Huh-7.5 
human hepatoma lines to low oxygen. Initially we studied the response of Huh-7.5 cells 
to low oxygen; these are derivatives of the parent cell line Huh-7 that contain a single 
point mutation in the dsRNA sensor retinoic acid inducible gene-I (RIG-I); these were 
originally used to study HCV infection because they were highly permissive to infection 
(Blight et al., 2002). Huh-7 cells are an immortalized cell line of epithelial-like, 
tumorigenic cells originally derived from carcinoma cells of differentiated hepatocytes 
(Vecchi et al., 2010). In vitro studies highlight the importance of hepatocellular 
differentiation status for HBV replication and current infection protocols require 
differentiation of the target cells to establish infection. We were therefore interested to 
examine how the differentiation status of hepatoma cells regulated their response to 
low oxygen. 
In this chapter, we examined the hypoxic responses of hepatoma cell lines and study 
the kinetics of HIF activation using a combination of Western blotting, quantitative PCR 
and an HRE luciferase (HRE-Luc) reporter assay. The HRE reporter assay utilises 5 
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tandem repeats of the HIF binding site HRE in the promoter region for luciferase gene 
(Figure 3.1); exposure to low oxygen stabilises HIFα that binds their cognate HRE and 
stimulate transcription and luciferase expression. In addition, we used this model 
system to evaluate the effect of drugs targeting different steps in the HIF degradation 
and signalling pathway for future evaluation in HBV infection systems. 
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Figure 3.1 HRE Luciferase assay for HIF activity 
HRE-Luc reporter plasmid is transfected into the target cell. The cells are exposed to 
normoxic or hypoxic conditions. Under normoxia the alpha subunit is degraded and we 
observed minimal luciferase expression. Under hypoxia, the alpha subunit translocates 
to the nucleus, forms a heterodimer with the beta subunit and binds the co-activator 
P300/CBP. This complex binds to the HRE repeats within the promoter and activates 
transcription and luciferase expression. Inhibiting the prolyl-hydroxylases with FG-4592 
stabilises the alpha subunit and promotes luciferase expression. NSC-134754 
treatment inhibits the HIF signalling pathway, although the method of inhibition is 
currently unknown. 
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Results 
3.2 Huh-7.5 cell response to low oxygen 
We initially focus on 1% oxygen because this oxygen tension is most often used in the 
literature to represent a ‘hypoxic’ environment, this is due to the high Km value for 
PHDs; the lower the oxygen tension, the greater the inhibition of PHD activity 
(Schofield and Ratcliffe, 2004, Jokilehto and Jaakkola, 2010). PHDs are highly 
sensitive oxygen sensors and tightly control HIF-α expression whilst active (Stolze et 
al., 2006). Additionally, 1% oxygen reflects changes in oxygen tension induced during 
viral hepatitis, inflammation and carcinogenesis (Jungermann and Kietzmann, 2000, 
Wilson et al., 2014). We examined the pattern of HIF-1α and HIF-2α expression in 
Huh-7.5 cells over 72 hours of exposure to 1% oxygen using Western blotting (Figure 
3.2a). This demonstrated that both HIF-1α and HIF-2α were expressed within this cell 
type and expression occurred over an extended time period. Additionally, 1% oxygen 
significantly promotes HRE-Luc activity in Huh-7.5s (Figure 3.2c). This data 
demonstrated that the HRE activation continues to increase up to 25 hours compared 
to normoxic controls (Figure 3.2d). 
In addition, we examined the effect of exposure to 3% oxygen, which reportedly 
represents the lower end of the physiological oxygen gradient in healthy liver (Wilson et 
al., 2014).Here we observed a similar pattern of HIF expression with significant 
increases under 3% oxygen over 25 hours (Figure 3.2e), with a peak of activity at 15 
hours post exposure to 3% oxygen (Figure 3.2f). It is important to note that under 1% 
oxygen, the increases in relative HRE activity are higher than those observed under 
3% oxygen. We used a GRE-Luc reporter as a control to demonstrate 1% oxygen does 
not activate luciferase expression in non HRE reporter systems (Figure 3.2b). 
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Figure 3.2 Huh-7.5 response to low oxygen 
Huh-7.5 cells were transfected with a plasmid encoding an HRE-Luc or GRE-Luc 
reporter. Following transfection the cells were reseeded into 96 well plates and placed 
into hypoxic or normoxic conditions. A) A western blot demonstrating HIF-1α and HIF-
2α stabilisation in Huh-7.5 cells over 72 hours. Numbers under actin represent relative 
densitometry. B) GRE-Luc reporter control results demonstrating raw RLU values for 
GRE activation under 1% for 24 hours C) HRE-Luc reporter results demonstrating the 
raw RLU values for HRE activation over 25 hours under 1% oxygen. D) HRE-Luc 
reporter results represented as 1% oxygen values relative to normoxic controls. E) 
HRE-Luc reporter results demonstrating the raw RLU values for HRE activation over 
25 hours under 3% oxygen. F) HRE-Luc reporter results represented as 3% oxygen 
values relative to normoxic controls. Data shows means of 3 biological repeats. 
Multiple T Tests used for raw RLU data and One-Way ANOVA with Tukey’s multiple 
comparisons test for relative HRE activity. 
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3.3 HepG2 cell response to low oxygen 
After demonstrating the effects of two different low oxygen tensions on Huh-7.5 cells; it 
is important to examine the effect in another hepatoma cell line to determine whether 
the observed activity is cell line specific or can be generalized to multiple hepatocyte 
derived lines. HepG2 cells are an immortalized cell line derived from a well-
differentiated hepatocellular carcinoma that exhibits epithelial-like morphology, 
however unlike Huh-7.5 cells they are non-tumorigenic (Costantini et al., 2013, Donato 
et al., 2015). Using the HRE-Luc reporter assay we demonstrated the kinetics of HRE 
activity under 1% oxygen over 25 hours (Figure 3.3a). As observed in Huh-7.5 cells, 
this data demonstrated that exposure to 1% oxygen significantly increases HRE activity 
relative to normoxic controls (Figure 3.3b). Using 3% oxygen we demonstrated the 
kinetics of HRE activation in HepG2 cells (Figure 3.3c) and compared the expression 
relative to normoxic controls (Figure 3.3d). This data shows that 3% oxygen is also 
able to increase HRE activation over the 25 hour time course. However, as observed in 
Huh-7.5 cells the relative activity is increased under 1% oxygen compared to 3% 
oxygen. 
Both cell lines demonstrate a greater relative induction under 1% oxygen compared to 
3% oxygen (Figure 3.4a-b). Importantly the pattern of expression is similar between 
each of the cell lines under both oxygen tensions, although HepG2 cells express higher 
signals under both oxygen tensions. The Huh-7.5 cells demonstrated a greater 
difference in relative fold induction between oxygen tensions (Figure 3.4c). These 
results indicate there is less variance in HRE activity between 1% and 3% oxygen 
tensions in HepG2 cells. Coupled to the fact that HepG2 cells are the basis for many of 
the current model systems used to study HBV, we decided to primarily focus on this 
cell line for infection models. 
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Figure 3.3 HepG2 response to low oxygen 
HepG2 cells were transfected with an HRE-Luc reporter, then reseeded into 96 well 
plates. The cells were then placed into hypoxic or normoxic conditions and lysed every 
5 hours with 1x Luciferase lysis buffer. A) HRE-Luc reporter results demonstrating the 
raw RLU values for HRE activation over 25 hours under 1% oxygen. B) HRE-Luc 
reporter results represented as 1% oxygen values relative to normoxic controls. C) 
HRE-Luc reporter results demonstrating the raw RLU values for HRE activation over 
25 hours under 3% oxygen. D) HRE-Luc reporter results represented as 3% oxygen 
values relative to normoxic controls. Each graph shows means of 3 biological repeats. 
Multiple T Tests used for raw RLU data and One-Way ANOVA with Tukey’s multiple 
comparisons test for relative HRE activity. 
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Figure 3.4 Comparing Huh-7.5 and HepG2 responses to low oxygen 
A) Comparison of raw RLU values for HRE activation in Huh-7.5 and HepG2 cells 
under 3% oxygen. B) Comparison of raw RLU values for HRE activation in Huh-7.5 
and HepG2 cells under 1% oxygen. C) Graph representing the relative increases for 
each oxygen tension in both of the hepatoma cell lines relative to their respective 
normoxic controls. Each graph shows the means of 3 biological repeats per cell line. 
Error bars show SE of 9 technical repeats. 
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3.4 The effect of HIF targeting drugs on hepatoma cell lines 
We had access to three different drugs that regulate the expression and function of 
HIFs. The first of these is called NSC-134754 (NSC) and was kindly provided by 
Margaret Ashcroft (University of Cambridge) and the second is FG-4592. Reports show 
that NSC is a small-molecule HIF pathway inhibitor that prevents the expression of 
HIFs under low oxygen conditions; it has been demonstrated that NSC induces 
metabolic alterations  and reduces the expression of a number of downstream HIF 
targets (Baker et al., 2012). The exact mode of action has not been reported, but this 
could provide a useful tool to study the role of HIFs in HBV replication. The second 
drug is called FG-4592 that targets the prolyl-hydroxylases that regulate HIF 
expression under normoxia. Literature shows that this inhibitor can stabilize the 
expression of HIFs under normal oxygen conditions and boost downstream HIF 
activity; with observed increases in erythropoiesis and regulation of iron metabolism 
(Maxwell and Eckardt, 2016, Provenzano et al., 2016, Chen et al., 2017). The third 
drug is called VH298 that inhibits von Hippel-Lindau (VHL) E3 ubiquitin ligase complex. 
The inhibitor behaves as a competitive inhibitor by binding with high affinity to VHL, this 
results in the accumulation of HIFα (Frost et al., 2016). In this chapter, we 
demonstrated HIF expression and HRE-Luc reporter activity in HepG2 cells; however, 
the primary use of this drug is found in chapter 5. 
We investigated the effect of NSC on each of the hepatoma lines using a combination 
of Western blotting and the HRE-Luc reporter assay. Initially we examined the effect of 
NSC on HIF protein expression under 20% and 1% oxygen by performing a dose 
response from 0.1μM to 1μM NSC in both hepatoma lines and Western blotting 
(Figure3.5a,b). Despite a 10% difference in the loading of the Western blot lanes, we 
selected the 1μM dosage for future experiments because lower doses did not appear 
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to inhibit HIF expression efficiently. We confirmed this result in Huh-7.5 cells by treating 
with 1μM NSC for 24 hours alongside untreated controls. These results demonstrate 
that NSC significantly reduces HRE activation under 1% oxygen (Figure 3.6a). We 
then demonstrated reduced HRE activity in HepG2 cells under 1% oxygen following 
drug treatment (Figure 3.6b). Both cell lines respond to NSC inhibition of HIF in a 
similar way. 
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Figure 3.5 Comparing the effect of NSC on hepatoma HIF expression 
Huh-7.5 and HepG2 cells were were treated with a range of NSC doses. The cells 
were placed into 1% or 20% oxygen for 24 hours, samples lysed with 8M Urea lysis 
buffer. A) A western blot demonstrating a HIF-1α dose response for expression in Huh-
7 cells. Numbers under actin demonstrate the relative densitometry between loading in 
each lane relative to 1μM 20% lane. B) A western blot demonstrating a HIF-1α dose 
response for expression in HepG2 cells. Numbers under actin demonstrate the relative 
densitometry between loading in each lane relative to 1μM 20% lane. Western blots 
representative of 3 biological repeats. 
Nicholas Ross Baker Frampton Hepatitis B and Hypoxia Student ID: 1301165 
 
111 
 
 
Figure 3.6 HRE activity following NSC treatment in hepatoma cells 
Huh-7.5 and HepG2 cells were transfected with an HRE-Luc reporter then reseeded 
into 96 well plates. The cells were then placed into hypoxic or normoxic conditions and 
treated with 0.1μM or 1μM NSC or untreated for 24 hours. Samples were lysed with 1x 
Luciferase lysis buffer. A) HRE-Luc reporter activation in Huh-7.5 cells under 20% and 
1% oxygen. B) HRE-Luc reporter activation in HepG2 cells under 20% and 1% oxygen. 
Each graph shows means of 2 biological repeats and error bars represent SE of 6 
technical repeats. Two-Way ANOVA with Tukey’s multiple comparisons test for HRE 
activity. 
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Next, we tested the efficacy of FG-4592 treatment on HIF stabilisation over a 72 hour 
time course in HepG2 cells (Figure 3.7a). Following demonstration of protein 
expression, we tested the effect of FG-4592 stabilised HIF transcriptional activity using 
our HRE-Luc reporter assay and demonstrate HRE activity similar to that observed in 
1% oxygen controls in both cell types (Figure 3.7b). We followed these data with a 
comparison of FG-4592 stabilisation of HIF-1α expression in both Huh-7 and HepG2 
cells under 20% oxygen conditions following treatment for 24 hours (Figure 3.7c-e). 
FG-4592 treatment up-regulates HRE activation under 20% oxygen. However, 
activation is slightly lower than under 1% oxygen, perhaps reflecting that proteasomal 
degradation is not completely inhibited by treatment with the drug. We demonstrated 
similar results following treatment with VH298. This drug stabilises HIF-1α and HIF-2α 
expression in HepG2 cells for 72 hours (Figure 3.8a). In addition, we demonstrated 
that accumulated HIFα expression results in significantly increased HRE activity using 
the HRE-Luc reporter assay (Figure 3.8b). 
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Figure 3.7 The effect of PHD inhibitor on hepatoma cells 
Huh-7 and HepG2 cells were transfected with an HRE-Luc reporter then reseeded into 96 
well plates. The cells were then placed into 1% or 20% oxygen or treated with 1μM FG-
4592 for 24 hours. A) Western blot demonstrating HIF-α stabilisation in HepG2 cells with 
FG-4592. B) HRE-Luc reporter activation in HepG2 cells over 72 hour with FG-4592 and 
untreated controls under 20% oxygen. C/D) Western blots demonstrating HIF-1α 
stabilisation in Huh-7 cells (C) and HepG2 cells (D) following exposure to 1% oxygen and 
treatment with FG-4592. E) HRE-Luc reporter activation in Huh-7 and HepG2 cells over 24 
hours following various treatments. Each graph shows means of 4 biological repeats (B) 
and 2 biological repeats (E). Error bars represent SE of 6 technical repeats. Two-Way 
ANOVA with Tukey’s multiple comparisons test for HRE-Luc reporter data. (NB, this 
experiment and the one shown in Figure 3.8 were done together and therefore share a 
negative control in Western blots 3.7a and 3.8a). 
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Figure 3.8 The effect of VHL inhibitor on HepG2 cells 
HepG2 cells were transfected with an HRE-Luc reporter, then reseeded into 96 well 
plates (B). The cells were then placed into 20% oxygen and treated with 100μM VH298 
for 72 hours. A) Western blot demonstrating HIF-α stabilisation in HepG2 cells over 72 
hours treatment with VH298 under 20% oxygen, samples were lysed every 24 hours 
post treatment. B) HRE-Luc reporter activation in HepG2 cells over 72 hour treatment 
with VH298 under 20% oxygen, compared against untreated controls. Each graph 
shows means of 4 biological repeats. Error bars show SE of 12 technical repeats. Two-
Way ANOVA with Tukey’s multiple comparisons test. 
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3.5 HIF over expression in hepatoma cells 
After demonstrating the effect of the HIF-regulating drugs on HIF stabilisation and HRE 
activation, it was important to observe the effect of over expressed HIF-1α and HIF-2α 
using plasmids pHIF-1α-FLAG and pHIF-2α-Myc kindly provided by Margaret Ashcroft 
(University of Cambridge). Transfection of these plasmids into target cells results in the 
over expression of HIF-1α and HIF-2α under normoxic conditions. We demonstrated 
that transfection results in protein expression in a dose dependent manner (Figure 
3.9a). Based on the Western blot results we determined the concentration required for 
subsequent HRE-Luc reporter assays. Following transfection with each of the over 
expression plasmids we demonstrated that tagged HIFs are transcriptionally active 
over a 72 hour time course. HIF-1α-FLAG expression increases HRE activity over 72 
hours (Figure 3.9c), demonstrating that the HIF-1α-FLAG is functional and can 
activate downstream HIF signalling. HIF-1α-FLAG causes a significant increase in HRE 
activity under 20% oxygen at 24 hours when compared against 0 hour time point. 
HIF-2α-Myc over expression is also functional and activates downstream HIF 
signalling. Interestingly, the expression of HIF-2α activates the HRE-Luc reporter, but 
exposure to low oxygen only minimally increases the observed HRE activation (Figure 
3.9d). HIF-2α-Myc causes a significant increase in HRE activity under 20% oxygen at 
24 hours when compared against 0 hour time point. HRE is activated by each plasmid 
under normoxia up to 72 hours; both plasmids demonstrate peaks of expression at 24-
48 hours at 20% oxygen that begins to decrease by 72 hours. Perhaps due to the loss 
of transient transfection. These data demonstrate that over expression plasmids can be 
used to examine HIF responses in target cells. 
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Figure 3.9 HIFα over expression and HRE activation 
Huh-7.5 cells were transfected with a dose response of pHIF-1α-FLAG or pHIF-2α-
Myc. A) Western blot demonstrating over expression under normoxic conditions. Huh-
7.5 cells were seeded and transfected with an HRE-Luc reporter (B) and co-
transfected with either pHIF-1α-FLAG (C) or pHIF-2α-Myc (D). The cells were then 
placed into 1% or 20% oxygen for 72 hours. Graph (B) represents means of 2 
biological repeats. Graphs (C-D) represent means of 3 biological repeats. Error bars 
show SE of 9 technical repeats. Data analysed using Two-Way ANOVA with Sidak’s 
multiple comparisons test. 
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3.6 HIF target gene activation in hepatoma cells 
Having demonstrated the effects of over expression and HIF regulating drugs in two 
different hepatoma cell lines, we decided to examine any differences in activity caused 
by these different mechanisms for HIF expression and compare these against a 
normoxic control that demonstrated the transcriptional activity of hepatoma cells under 
20% oxygen. This provides a baseline for comparison when examining HBV stabilised 
HIF. This was achieved using the RT2 profiler PCR array by Qiagen that contains a 
panel of 84 genes commonly associated with the HIF pathway and responses to low 
oxygen. Using this array in combination with the over expression plasmids and HIF 
targeting drugs allowed us to further demonstrate that the observed HIFs can be 
functional and examine any differences in the profile of activated genes. 
The first array compares the activity of HIF target genes in Huh-7.5 samples following 
over expression via plasmid transfection (Figure 3.9). These are compared against 
Normoxic and Hypoxic (1% oxygen) controls (Figure 3.10a). Interestingly, transfecting 
the cells with a HIF-1α and HIF-2α over expression plasmid does not result in the same 
pattern of gene expression (Figure 3.11), perhaps reflecting other activity of other low 
oxygen activated pathways. This heat map demonstrated that the tested hepatoma 
cells exhibit up-regulation of common hypoxic response markers such as solute carrier 
family 2 member 1 (SLC2A1) and solute carrier family 2 member 3 (SLC2A3), carbonic 
anhydrase 9 (CA9) and vascular endothelial growth factor A (VEGFA), making them a 
suitable model for studying infection.  
We organised the expression of genes in the 1% oxygen control samples from highest 
expression to lowest and then compared the expression profile of pHIF-1α-FLAG and 
pHIF-2α-Myc against this (Figure 3.11a,b). These graphs highlight that the expression 
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profile is altered through over expression of pHIF-α, perhaps reflecting the lack of 
hypoxic involvement in HIF-α stabilisation. We compared the transcript up-regulation 
for four different conditions; which are displayed in this heat map. There is a correlation 
between Hypoxic samples and over expressed HIF-1α up-regulated genes indicated by 
the box. A number of these are involved in carbohydrate metabolism, such as glycogen 
synthase (GYS1), glucose-6-phosphate isomerase (GPI), and SLC2A3 (also called 
glucose transporters 3 (GLUT3)). The second heat map represents the HIF 
transcriptional profile for Huh-7 cells treated with the PHD inhibitor FG-4592 and 1% 
oxygen (Figure 3.10b). When comparing the fold change for each gene independently 
we saw a similar profile of activated HIF target genes following FG-4592 treatment 
compared to the 1% oxygen control (Figure 3.12a, b). Artificial stabilisation of HIFs 
demonstrated different profiles of gene expression, however FG-4592 treatment 
exhibits similar levels of regulation. This is an important observation to consider when 
using these drug in future experiments in the context of HBV infection. 
Nicholas Ross Baker Frampton Hepatitis B and Hypoxia Student ID: 1301165 
 
119 
 
 
Figure 3.10 Heatmap of hypoxic gene regulation following HIF stabilising 
treatments 
Legend on following page. 
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Figure 3.10 Heatmap of hypoxic gene regulation following HIF stabilising 
treatments (Cont.) 
A) Huh-7.5 cells were transfected with either HIF-1α-FLAG or HIF-2α-Myc over 
expression constructs over 24 hours under 20% oxygen. Control cells exposed to 20% 
and 1% oxygen for 24 hours were also prepared. Groups are as follows: 20% 
(normoxia), 1% (hypoxia – 1%), 1α (pHIF-1α-FLAG plasmid) and 2α (pHIF-2α-Myc 
plasmid) The red box indicates a region of overlap between hypoxic group and 
overexpression of HIF-1α-FLAG. B) Huh-7 cells were either placed under 1% oxygen 
or treated with FG-4592 (1 μM) for 24 hours. Control cells exposed to 20% oxygen for 
24 hours were also prepared. Groups are as follows: UT (normoxia), 1% (hypoxia – 1% 
oxygen, 24 hours), FG (FG-4592 - 1 μM, 24 hours). Each condition represents 3 
technical repeats. 
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Figure 3.11 Comparing transcript activity following over expression of 
HIF-1 and HIF-2 
Huh-7.5 cells were transfected with either HIF-1α-FLAG or HIF-2α-Myc over 
expression constructs over 24 hours under 20% oxygen. Control cells exposed to 20% 
and 1% oxygen for 24 hours were also prepared. Graphs demonstrate RT2 hypoxic 
gene array results sorted by highest expression for 1% oxygen controls. A) Expression 
profile for hypoxic genes following transfection with pHIF-1α-FLAG. B) Expression 
profile for hypoxic genes following transfection with p HIF-2α-Myc. 
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Figure 3.12 Comparing transcript activity following FG-4592 and hypoxic 
treatment 
Huh-7.5 cells were either placed under 1% oxygen or treated with FG-4592 (1 μM) for 
24 hours. Control cells exposed to 20% oxygen for 24 hours were also prepared. A) 
Graph demonstrates comparison of individual gene expression under 1% oxygen and 
FG-4592 treatment. B) Graph demonstrates comparison of individual gene expression 
under 1% oxygen and FG-4592 treatment with outliers excluded. 
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3.7 Hepatoma cell lines and differentiation 
Current protocols for de novo HBV infections utilise Dimethyl sulfoxide (DMSO) to 
differentiate target cells to enable efficient infection (Huang et al., 2012, Schulze et al., 
2012). Therefore, it is important to study the effect of this differentiation protocol on the 
cellular response to low oxygen. We examined the effect of DMSO differentiation on 
each of the cell lines by examining mRNA transcript levels of four liver specific 
differentiation markers (Figure 3.13a,b): albumin (ALB), alpha fetoprotein (AFP), 
hepatocyte nuclear factor 4 alpha (HNF4α) and cytochrome P450 3A4 (CYP3A4) (Hay 
et al., 2008, Olsavsky Goyak et al., 2010, Holtzinger et al., 2015). DMSO increased the 
expression of all differentiation markers in both cell lines (Figure 3.13). 
For comparison, we utilised an alternative method of differentiation that involved 
culturing the cells with glucose, hydrocortisone and insulin for four weeks and showed 
a similar up-regulation of differentiation markers (Figure 3.13c). Unfortunately, the 
HepG2 cells could not survive this process beyond 2 weeks and the data represented 
in (Figure 3.13c) only demonstrates the process in Huh-7 cells. DMSO differentiation 
increases expression of all four markers in both Huh-7 and HepG2-NTCP cells, these 
cells are HepG2 cells over expressing the bile acid transporter NTCP. This enables 
more efficient HBV infections and so became the cell line of choice for further 
experimentation. Non-DMSO differentiation also causes increases in expression of 
each marker. CYP3A4 and AFP expression are significantly increased using this 
method. However, the increased difficulty and risks of long term culture coupled with 
an inefficient way of maintaining cells for infection makes DMSO protocol a preferable 
method. Considering that HepG2 cells are the primary cells used to study HBV 
infections, this effectively removed the use of this protocol for future study in de novo 
infections. 
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Figure 3.13 Differentiation marker expression in hepatoma cells 
Graphs displays PCR result comparing expression levels of common hepatoma 
differentiation markers relative to un-differentiated Huh-7 and HepG2-NTCP cells. A) 
DMSO differentiated Huh-7 cells. B) DMSO differentiated HepG2-NTCP cells. 
Differentiation status of cells compared using panel of hepatocyte differentiation 
markers. C) Non-DMSO differentiated Huh-7 cells. Each graph represents the means 
of 3 biological repeats. Error bars show SE of 9 technical repeats. 
Nicholas Ross Baker Frampton Hepatitis B and Hypoxia Student ID: 1301165 
 
125 
 
3.8 Cellular differentiation status and response to low oxygen 
When considering the effect of differentiation on hypoxic responses we decided that it 
was important to understand how differentiation affects cellular response to low oxygen 
and HIF expression. We evaluated HIF-1α expression over a 96-hour time in 
differentiated and undifferentiated HepG2 cells under normoxic conditions. 
Dimethyloxalylglycine (DMOG) is a competitive inhibitor of PHDs that is widely used to 
stabilize HIFs under normoxic conditions and was used as a positive control (Zhang et 
al., 2016). Differentiated cells do not express HIF under normoxic conditions over the 
time period studied, however, non-differentiated cells express HIF-1α after 96 hours 
under normoxic conditions (Figure 3.14). This is probably due to cell over-growth that 
limits oxygen availability, whereas DMSO differentiation is known to arrest cell 
proliferation by arresting in G1 phase of the cell cycle (Fiore et al., 2002, Huang et al., 
2004). This data is important to consider when planning HBV infection experiments, 
which typically have a long protocol for infection over 7 days and highlights the 
importance of cell seeding density in subsequent experiments. 
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Figure 3.14 HIF expression in differentiated vs non-differentiated 
hepatoma cells 
HepG2-NTCP cells were either differentiated with 2% DMSO or left untreated and 
incubated at 37oC for 96 hours. Control cells were treated with DMOG (1μM) at T0 and 
lysed every 24 hours. Cells were counted and equal amount of protein lysate were 
analysed by SDS PAGE and screened for HIF-1α expression. 
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3.9 Cell density, differentiation and HIF responses 
After demonstrating HIF expression in over confluent cells we decided to examine the 
effect of cell seeding density and DMSO differentiation on HIF expression and 
downstream signalling more closely. HepG2 cells were seeded at multiple densities to 
reflect a range of confluencies (Figure 3.15a) and we compared HIF-1α expression 
under normoxic and hypoxic conditions in DMSO differentiated and non-differentiated 
HepG2-NTCP cells. DMSO mediated differentiation of HepG2 cells blunts HIF-1α 
expression (Figure 3.15b) under 1% oxygen independent of cell density. The use of 
the HRE-Luc reporter assay enables us to determine whether the reduced levels of 
HIF-1α result in a blunted transcriptional response. HRE-Luc reporter activity is 
independent of cell seeding density in non-differentiated cells. However, following 
DMSO treatment the cells show a blunted HRE-Luc reporter activation that is density 
dependent, consistent with reduced HIF-1α expression by western blotting (Figure 
3.15c). We examined the effect of DMSO differentiation and cell density on HIF-1α 
regulated target genes: PDK1 and SLC16A3 (Figure 3.16). Differentiated cells show a 
blunted HIF gene expression response that is independent of cell density. This builds 
upon the previous result and provides a justification for removing DMSO from our HBV 
infection protocol. 
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Figure 3.15 Hepatoma differentiation blunts HIF-1α expression and 
transcriptional activity 
A) Brightfield microscopy images of HepG2-NTCP cell seeding densities per 1.9cm2 
under 20% oxygen. Western blot (B) and HRE activity (C) of HIF-1α expression in 
HepG2-NTCP cells at a range of densities incubated with DMSO (2%) or untreated for 
72 hours. Cells were cultured under normoxic (20% O2) or hypoxic (1% O2) conditions for 
24 hours, counted to normalise cell lysates before loading or luciferase measurement. 
Hypoxic-dependent RLU activity per 100,000 cells is shown. Two-Way ANOVA with 
Tukey’s multiple comparisons test was used. Graph represents the mean of 2 
biological repeats. Error bars show SE of 4 technical repeats. 
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Figure 3.16 Effect of HepG2 differentiation status on HIF-1α and target 
gene RNA levels 
HepG2-NTCP cells were seeded at a range of densities and incubated with DMSO 
(2%) or untreated for 72 hours. Cells were then cultured under normoxic (20% O2) or 
hypoxic (1% O2) conditions for 24 hours. A/B) qRT-PCR result for HIF-1α mRNA levels 
in un-differentiated (A) and DMSO differentiated (B) HepG2-NTCP cells. C/D) qRT-
PCR result for PDK1 mRNA levels in un-differentiated (C) and DMSO differentiated (D) 
HepG2-NTCP cells. E/F) qRT-PCR result for SLC16A3 mRNA levels in un-
differentiated (E) and DMSO differentiated (F) HepG2-NTCP cells. Data analysed with 
Two-Way ANOVA with Sidak’s multiple comparisons test. Graphs display relative 
mRNA levels normalised against house keeping gene B2M. Each graph represents the 
means of 2 biological repeats. Error bars show SE of 6 technical repeats. 
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Using the same 84-gene PCR array as before, we performed a comparison of common 
HIF-1α target genes in DMSO differentiated versus non-differentiated samples. The 
results are displayed from the highest to lowest gene induction of the DMSO 
differentiated samples. Each sample is compared with the equivalent non-differentiated 
sample induction. This graph clearly shows that DMSO differentiation blunts mRNA 
levels of a wide range of HIF target genes (Figure 3.17a). Plotting the data as two 
groups “DMSO differentiated” vs “Non-differentiated” demonstrating blunted gene 
expression in most genes represented on the array following differentiation (Figure 
3.17b). This graph demonstrates that one gene on the array is up regulated 
significantly through DMSO differentiation, this is EGR1 and is known to be involved 
tendon differentiation, providing an explanation for up-regulation (Guerquin et al., 
2013). Important to note that the examples previously used PDK1 and SLC16A3 
demonstrate the same blunted response in this array. Other important genes that 
typically express highly in hepatocytes exposed to low oxygen are CA9 and EPO; 
these are also blunted significantly in DMSO differentiated samples. 
Nicholas Ross Baker Frampton Hepatitis B and Hypoxia Student ID: 1301165 
 
131 
 
 
Figure 3.17  Non-differentiated vs DMSO differentiated hypoxic gene 
expression 
Huh-7 cells were either DMSO differentiated in 2% DMSO for 72 hours or left 
undifferentiated. The cells were then placed under 1% and 20% oxygen for 24 hours. 
A) Expression profile for hypoxic genes in DMSO differentiated vs non-differentiated 
samples. B) Graph demonstrates comparison of individual gene expression from the 
hypoxic array under 1% oxygen in DMSO differentiated vs non-differentiated samples. 
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3.10 Discussion 
The aim of this results chapter was to develop a better understanding of hepatocellular 
responses to low oxygen in our target cells for HBV infection. So, this chapter aimed to 
establish the baseline for future experiments by examining HIF expression and 
transcriptional activity in Huh-7 and HepG2 cells. This information was used to 
establish a model to examine the effect of low oxygen and HIF on HBV replication. 
We examined the effect of HIFα over expression plasmids and HIF regulating drugs on 
each of the cell lines studied so far. Plasmids were also used to over express HIFs 
under normoxia with the goal of demonstrating functional HIFs in normoxic conditions 
and we confirmed the result demonstrated using FG-4592 treatment (Figure 3.9). 
Using the hypoxic gene array from Qiagen we demonstrated that these treatments 
activate HIF target genes (Figure 3.10), however, the response is different compared 
to hypoxic cells (Figure 3.11). HIF target gene expression is cell context dependent 
and any differences noted are likely to reflect heterogeneous responses between cell 
types. This suggests that there are other variables involved in regulating these 
signalling pathways. In Figure 3.10a we observe a difference in gene expression 
between plasmid HIF-1α (under 20% oxygen) and 1% oxygen samples. Interestingly, 
this suggests that up-regulation of genes is occurring with no associated HIF activation, 
especially because pHIF-2α does not account for observed differences. This suggests 
that either another oxygen sensor is involved (perhaps PHDs themselves) or that the 
low oxygen is capable of activating these genes alone. Perhaps these are activated 
under different kinds of cellular stress (such as mitochondrial) or through growth factor 
interaction with receptors. Literature has shown that HIF-2α plays a role in lipid 
metabolism in particular (Rankin et al., 2009). Considering the genes found in this 
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array (many involved in carbohydrate metabolism), it is not surprising that we saw 
minimal pHIF-2α activation of genes. 
Hepatocytes are highly differentiated (Olsavsky Goyak et al., 2010, Holtzinger et al., 
2015, Meier et al., 2013, Alder et al., 2014) and this is required for efficient infection by 
HBV. Using two independent methods we examined the expression of some reported 
differentiation markers (Hay et al., 2008, Olsavsky Goyak et al., 2010, Holtzinger et al., 
2015). We found a difference in hypoxic responses in differentiated cells; which we 
tested using Western blots and the HRE-Luc reporter assay (Figure 3.14 and Figure 
3.15). 
Cell seeding density and differentiation status are important factors to consider when 
studying HBV infections using de novo infection models. This provides justification for 
our study of the differentiation effects on hypoxic responses. In particular Figure 
3.15b,c suggests that the differentiation state of the cells can determine the level of 
HIF expression and regulate how the HIF signalling pathway responds to low oxygen 
stimulation. Whilst the method of regulation is unclear for HIF signalling, it has 
previously been demonstrated that DMSO can down regulate transcription factor 
activity in the liver, with studies looking at NF-κB and ATF4 (Essani et al., 1997, Song 
et al., 2012). Alternatively, these results could suggest that DMSO up-regulates many 
host genes and masks the effect of hypoxia. 
Further data supporting this conclusion was obtained using PCR to examine the fold 
induction relative to control for HIF-1α mRNA and two genes associated with HIF-1a 
signalling PDK1 and SLC16A3 (Figure 3.16). These hinted at a blunting effect, but a 
further use of the 84-gene array (Figure 3.17a) demonstrated that this effect is 
observed in many genes (Figure 3.17b). 
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Current protocols for studying HBV utilise DMSO differentiation for efficient de novo 
infection. However, to study the effect of low oxygen on HBV replication we should try 
and work around this. We cannot be sure that this is not an off-target effect of DMSO 
or differentiation, the literature does not say. Therefore, we tested another method of 
differentiation to try and confirm this reason. However, the primary cell line for testing 
HBV infections (HepG2 cells) did not survive the process. Therefore, to effectively 
establish an infection model for examining low oxygen effects we had to try and 
remove DMSO from the infection process. 
3.11 Summary 
This chapter establishes low oxygen responses in our target cell line of choice, HepG2 
cells and examines the effect of differentiation on hypoxic responses. This chapter 
primarily identifies tools for use in developing an effective model for infection and low 
oxygen. 
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4. STUDYING HBV AND HIF STABILISATION 
4.1 Introduction 
In the previous chapter we identified a range of tools to study the response of 
hepatoma cells. We showed that HepG2 cells express HIF-1α and HIF-2α and are 
responsive to low oxygen and highlighted a role for differentiation status to regulate 
HIF expression and transcriptional responses to low oxygen. These observations 
provide the foundation for studying the effects of low oxygen on HBV replication. 
HBV has been previously reported to stabilize HIF via interactions with viral encoded X 
protein (HBx), as detailed in the main introduction (See Figure 1.16). However, the 
majority of these reports have studied HBx-HIF interactions in the absence of full 
replicating HBV. Our studies have been performed using a combination of different 
models for HBV infections, including transfections of viral genomes, the chronically 
infected HepG2.2.15 cells and de novo infections using mature HBV particles. In 
addition, we used multiple methods for examining HIF stabilisation and pathway 
activity. These include HIF stabilising agents detailed in chapter 3 and exposure to 1% 
oxygen conditions using specialized hypoxic incubators. These enable a study of HBV-
HIF interaction under less artificial conditions.  
We selected to use HepG2.2.15 cells stably expressing integrated copies of the HBV 
genome (Sells et al., 1987, Lu et al., 2001). These cells express HBV DNA as 
chromosomally integrated sequences, as well as the episomal cccDNA and rcDNA; 
and express the HBV ORFs under the control of wild-type HBV promoters (Sells et al., 
1987, Lu et al., 2001). In addition, these cells have been shown to secrete HBV 
antigens HBs/ HBe and infectious Dane particles (Sells et al., 1987). These cells 
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provide an ideal model to study the effects of low oxygen on HBV replication in the 
absence of any DMSO treatment. In addition, we had an additional HepG2 based line 
that stably expresses HBV genomes - HepAD38 cells express high levels of integrated 
HBV DNA under the control of an artificial CMV promoter that is tetracycline-inducible 
and when the cells are cultured in tetracycline containing media viral transcription is 
inhibited (Ladner et al., 1997, Severi et al., 2006, Jia et al., 2017). These cells are used 
briefly to demonstrate comparable results between producer cell lines. 
The HBV life cycle is depicted in Figure 4.1, the incoming particles contain rcDNA that 
is repaired to form cccDNA, which provides the template for pgRNA transcripts; reverse 
transcription of pgRNA into negative strand DNA and subsequent plus strand DNA 
synthesis (Seeger and Mason, 2015, Thomas and Liang, 2016). These processes have 
been discussed in more detail in the introduction (section 1.2.5). As discussed in the 
main introduction the liver exists under an oxygen gradient with hypoxic zones around 
the hepatic central veins (Figure 4.2a), therefore it is important to consider the impact 
of low oxygen on HBV. HBV core antigen stains kindly provided by the Protzer 
laboratory at TUM. demonstrate significant HBV core expression around the Peri-
central regions of HBV transgenic mice (Figure 4.2b). In this chapter we aimed to 
confirm that HBV infection can stabilize HIFs and to show transcriptional activation of 
this pathway. 
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Figure 4.1 HBV life cycle (Thomas & Liang, 2016) 
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Figure 4.2 Oxygen gradient in the liver and HBV antigen expression in 
mice engineered to express the complete viral genome 
Cartoon displaying the natural oxygen gradient found in the liver ranging from 9% at 
the hepatic portal triad to 3% at the area around the central hepatic vein. (B) HBV Core 
antigen staining around the Peri-central region in HBV transgenic mice liver slices 
(Kindly provided by collaborators at TUM.). 
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Results 
4.2 HBV models and HIF expression 
HBV infection has been reported to stabilize HIFs via an association between the viral 
encoded regulatory protein HBx, however there is no consensus on the mechanism 
and some of the caveats of the studies were discussed in the main introduction (Figure 
1.16). Our initial experiments examined the effect of transfecting HBV genotypes into 
HepG2-NTCP target cells and assessed HIF expression by Western blotting. First, we 
demonstrated that delivery of full-length replication competent HBV genotypes C and D 
into HepG2-NTCP cells via plasmid-based transfection stabilises HIF-1α and HIF-2α 
under normoxic conditions (Figure 4.3a and Figure 4.3b), compared to mock 
transfected controls. We observed comparable levels of HIF expression in the HBV 
transfected cells cultured under normoxia to control cells cultured under 1% oxygen. 
Following this initial experiment, we demonstrated that transfecting HBV into HepG2 
cells can stabilize HIFs over an extended duration using a time course experiment like 
those observed in chapter 3. This demonstrated stable expression of both HIF-1α and 
HIF-2α under normoxic conditions for up to 72 hours (Figure 4.3c). 
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Figure 4.3 Transfection of HBV genomes into hepatoma cells stabilises 
HIFs 
HepG2-NTCP K7 (Sub clone of HepG2-NTCP cells that express higher levels of 
NTCP) cells were transfected with diverse HBV genotypes (1µg per genotype) and 
lysed for Western blotting and PCR 24 hours post transfection. A/B) Western blots 
showing HIF-1α and HIF-2α expression in HepG2-NTCP K7 cells following transfection 
with HBV genotypes C (Gen-C) and D (Gen-D) under 20% oxygen compared to a 1% 
oxygen positive control. C) HepG2-NTCP K7 cells transfected with 1µg of HBV 1.3 
plasmid (Genotype D) and placed under normoxia. Western blots show HIF-1α and 
HIF-2α expression over 72hrs following transfection. 
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4.3 HBV stabilisation of HIF is independent of HBx 
Following the demonstration of stable HIF expression in HBV transfected cells, we 
wanted to confirm previous reports that suggest that the HBx protein is the primary 
target of interaction between the virus and host transcription factor. To achieve this, we 
utilised a combination of plasmid transfections for HBV genotype D. Protzer and 
colleagues kindly provided us with plasmids encoding HBV genotype D with selected 
gene deletions. These include genotype D with HBx deletion (X-), large surface antigen 
deletion (L-) and a double knock out of both HBx and L antigen (X/L-). We examined 
HIF expression following transfection using Western blotting, compared against wild-
type genotype D genome and normoxic and hypoxic controls (Figure 4.4a). This result 
demonstrated that HBV stabilisation of HIF can occur independent of HBx protein. In 
addition, our data demonstrated that stabilisation of HIFs occur independent of the 
large surface antigen as well (Figure 4.4a), perhaps suggesting that stabilisation 
occurs through another HBV protein such as Core or perhaps in response to infection. 
To investigate whether HBx expression cells could stabilize HIF we transfected cells 
with pHBx and compared the stabilisation of HIFs following transfection with HBV 
genotype D, the genome with X deletion and plasmid HBx (Figure 4.4b). Previous 
reports suggest that HBx primarily affects HIFs transcriptional activity, however they 
also suggest that HBx is involved in HIF stabilisation (Yoo et al., 2003, Liu et al., 2014, 
Hu et al., 2016). Figure 4.4b confirms our previous result by demonstrating a lack of 
stabilisation under 20% oxygen following transfection with HBx. To investigate whether 
HBx could affect HRE activation we transfected cells with pHBx or pR96E in 
combination with the HRE-luciferase reporter. R96E is a single point mutation in HBx 
that abrogates interaction with DDB1 and negatively regulates HBV infection by 
preventing HBx interaction with cccDNA and inhibiting viral transcription (Sitterlin et al., 
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2000a, Sitterlin et al., 2000b, Li et al., 2010b), this serves as a control in our 
investigation of the role of HBx in HIF stabilisation and transcriptional activity. This 
result demonstrated that transfection with HBx does not stimulate additional HRE 
activity in HepG2-NTCP K7 cells (Figure 4.4c,d). 
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Figure 4.4 HBV stabilisation of HIF independent of HBx 
HepG2-NTCP K7 cells were transfected with diverse HBV Genotype D and genotype D 
with HBx deletion (X-), large surface antigen deletion (L-), or double knockout of HBx 
and L (X/L-) and lysed for Western blotting (A). Additionally, HepG2-NTCP K7 cells 
were transfected with HBV Genotype D wild type, X deletion, and plasmid HBx, then 
lysed for Western blotting (B). C) HRE luciferase result demonstrating HRE activation 
under 20% and 1% oxygen following co-transfection of HRE and HBx or R96E 
mutation. D) Relative expression of HRE activity following co-transfection of HRE and 
HBx or R96E. One-Way ANOVA (D) and Two-Way ANOVA (C) with Tukey’s multiple 
comparisons test used for analyses. Each graph shows the means of 2 biological 
repeats. Error bars show SE of 6 technical repeats. 
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4.4 HBV producer cells and HIF stabilisation 
Having demonstrated that delivering HBV genomes into HepG2-NTCP cells stabilises 
HIF in a HBx independent manner, we wanted to confirm HIF stabilisation in cell lines 
stably expressing HBV and finally in de novo infections. HepG2.2.15 and HepAD38 
cells provide a model system of chronic infection to study HBV transcription. Of note 
HepAD38 cells are the source of infectious HBV used by most laboratories worldwide 
to purify virus for in vitro infection studies. Both HepG2.2.15 and HepAD38 cells 
express HIF-1α under both 20% and 1% oxygen conditions, whereas uninfected 
HepG2-NTCP K7 cells only express HIF-1a under hypoxic conditions (Figure 4.5a), 
confirming our earlier observations with transfected HBV genomes. We observed 
increased expression of HIF-1α in both HBV expressing cells cultured under low 
oxygen conditions, demonstrating that the cells can still respond to low oxygen stress 
and consistent with additive pathways to stabilize HIF in the infected cells. Culturing 
the producer cells under 20% oxygen and lysing the samples for Western blotting 
every 24 hours demonstrated that stabilisation of HIF occurs over a prolonged period, 
up to 72 hours (Figure 4.5b). 
We examined HIF target genes CA9 and VEGF expression within the cells using 
quantitative PCR demonstrating that the HepG2.2.15 cells still respond to low oxygen 
and show increased transcription of HIF target genes compared to uninfected HepG2-
NTCP K7 cells (Figure 4.5c). Following this result, we performed PCR to determine the 
effect of the HIF stabilising drug FG-4592 on HBV infected cells. We examined the 
expression of CA9 and VEGFA following drug treatment and exposure to low oxygen 
(Figure 4.5 d,e). This result confirms the response to low oxygen in HepG2.2.15 cells 
and demonstrated that FG-4592 is effective at increasing HIF target gene expression in 
HBV infected cells relative to normoxic controls. 
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Figure 4.5 HBV and HIF stabilisation 
A) HepG2-NTCP K7, HepG2.2.15 and HepAD38 cells were placed under normoxic or 
hypoxic conditions or treated with 1μM FG-4592 for 24 hours, samples were blotted for 
HIF-1α. B) HepG2.2.15 cells were placed under normoxic conditions for 72 hours. Cell 
counting of comparable wells was utilised for equal loading, samples were blotted for 
HIF-1α. C) Relative CA9 and VEGFA induction in uninfected HepG2-NTCP K7 cells 
and HepG2.2.15 cells under 1% oxygen, Two-Way ANOVA with Sidak’s multiple 
comparisons test. D) CA9 and VEGFA up-regulation relative to uninfected cells in 
HepG2.2.15 cells, Unpaired t test with Welch’s correction. Each graph shows the 
means of 4 biological repeats. Error bars show SE of 12 technical repeats. 
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After demonstrating increased CA9 and VEGF mRNA levels in HepG2.2.15 cells we 
extended these results to study additional HIF regulated genes using a selected 
hypoxia PCR array (Figure 4.6), HIF stabilisation previously confirmed in Figure 4.5a. 
This result demonstrated that HBV infected cells under normoxic conditions promote 
the expression of multiple hypoxic response genes. Of note HBV infected cells show a 
different profile of hypoxic gene expression compared to uninfected hypoxic HepG2-
NTCP K7 cells or following treatment with FG-4592 (Figure 4.7a,b). 
As discussed previously, FG-4592 treatment stimulates HIF expression through 
inhibition of PHDs (Figure 3.1), this result demonstrated that FG-4592 treatment 
stimulates a fewer genes compared to 1% oxygen incubation in HepG2-NTCP K7 cells, 
however for most genes demonstrated with the array, the expression is more limited 
(Figure 4.8a). A comparison of 1% oxygen and HBV stimulated gene expression 
demonstrated very similar levels of expression in up-regulated genes (Figure 4.8b). A 
comparison of commonly up-regulated genes in HBV positive and 1% oxygen samples 
reveals some differences in expression (Figure 4.8c). Expression is lower in HBV 
positive samples, this could reflect continued degradation under 20% oxygen or simply 
cell type specific differences. HBV positive HepG2.2.15 cells specifically demonstrate 
increased up-regulation of numerous genes involved in regulating cell growth, 
proliferation, apoptosis and cellular metabolism (Figure 4.8c). 
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Figure 4.6 HIF transcript activity in HBV expressing HepG2 cells 
compared to PHD inhibitor treated HepG2 cells 
Legend on following page. 
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Figure 4.6 HIF transcript activity in HBV expressing HepG2 cells 
compared to PHD inhibitor treated HepG2 cells (Cont.) 
HepG2-NTCP K7 cells were treated with FG-4592 (1µM) (FG - group) under 20% 
oxygen or placed into 20% or 1% oxygen (1% - group) for 24 hours untreated. 
HepG2.2.15 cells were placed under 20% oxygen for 24 hours (HBV – group). 
Heatmap was generated by Qiagen RT2 software. 
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Figure 4.7 HIF transcript activity in chronic HBV producer cells 
compared to PHD inhibitor treated cells 
Legend on following page. 
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Figure 4.7 HIF transcript activity in chronic HBV producer cells 
compared to PHD inhibitor treated cells (Cont.) 
HepG2-NTCP K7 cells were treated with FG-4592 (1µM) under 20% oxygen or placed 
into 20% or 1% oxygen for 24 hours untreated. HepG2.2.15 cells were placed under 
20% oxygen for 24 hours. A) Comparison of hypoxia and FG-4592 treated samples 
regulated genes, sorted against hypoxic samples. B) Comparison of hypoxia and HBV 
positive samples regulated genes, sorted against hypoxic samples. 
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Figure 4.8 Comparing HIF transcript activity in HBV positive versus drug 
stabilised HIF 
HepG2-NTCP K7 cells were treated with FG-4592 (10µM) under 20% oxygen for 24 
hours or placed into 20% or 1% oxygen for 24 hours untreated. HepG2.2.15 cells were 
placed under 20% oxygen for 24 hours. A) Comparison of fold regulation between 
sample conditions. B) Comparison of up-regulated genes ordered highest to lowest 
using 1% oxygen controls. C) Comparison of fold difference in up-regulated genes for 
HBV positive and 1% oxygen samples. 
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4.5 HIF stabilisation in de novo infections 
After demonstrating HIF stability and downstream pathway stimulation in HepG2.2.15 
cells, we decided to model HBV low oxygen responses using more authentic de novo 
infection protocols. In the previous chapter we demonstrated HIF kinetics in Huh-7 and 
HepG2 cells; however, gold standard HBV infection protocols currently use HepG2-
NTCP K7 cells that over express the viral entry receptor NTCP. Our initial experiments 
analysed HIF expression in HepG2-NTCP K7 cells under 20% and 1% oxygen over a 
72 hour time course (Figure 4.9a). This result demonstrated a similar pattern of 
expression observed in previously tested cell lines. In addition, we examined the 
kinetics of HRE activation using the HRE-Luc reporter assay (Figure 4.9b). This cell 
line demonstrated a peak of HRE activity after 24 hours under 1% oxygen, which 
decreased by 72 hours, matching HIF protein expression. Following a de novo infection 
we examined the expression of HIF-1α and HIF-2α after 24 hours exposure to 20% and 
1% oxygen conditions (Figure 4.9c), this result demonstrated that HBV stabilises HIFs 
under both oxygen tensions, although inhibition of the degradation pathway under 1% 
oxygen clearly demonstrated increased expression. 
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Figure 4.9 HIF kinetics in HepG2-NTCP K7 cells and de novo HBV 
stabilisation of HIFs 
HepG2-NTCP K7 cells were either untransfected (A) or transfected with HRE-Luc 
reporter (B). Cells are incubated at 20% or 1% oxygen for 24 hours post transfection. 
Cells are lysed every 24 hours, over 72 hours with 8M Urea lysis buffer or 1x luciferase 
lysis buffer for Western blotting (A) and HRE-Luc reporter assay (B). Multiple t tests (* 
= P<0.0001). C) Western blot demonstrating HIF stabilisation under 20% and 1% 
oxygen in HBV de novo infection. Infected cells are placed under 20% or 1% oxygen 
over 24 hours. Data represents the means of 6 biological repeats. Error bars show SE 
of 18 technical repeats. 
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Following demonstration of HIF stabilisation by HBV infection we examined the effect 
of infection on HIF transcript expression and HRE activation (Figure 4.10a,b). These 
results demonstrate that infection increases the expression of HIF-1α and VEGF 
mRNA levels relative to uninfected cells (Figure 4.10a). Following these results we 
examined the expression of CA9 during HBV infection over a 72 hour time course 
(Figure 4.10b). This result demonstrated an increased expression under 20% and 1% 
oxygen in HBV infected samples, although the difference was only significant at the 1% 
oxygen tension. This result combined with the previous demonstration of up-regulated 
hypoxic genes in HepG2.2.15 cells prompted examination of the hypoxic gene 
expression profile during de novo infections (Figure 4.11b). We examined the 
expression of HIF transcripts during early HBV infection by preparing RNA at 24h and 
72h post infection. The experiment was performed in this way to compare the response 
to uninfected HepG2-NTCP K7 cells without adding stress from an extended HBV 
infection. This result indicated that activation of HIF transcripts occurs after only 24 
hours of infection. Interestingly the pattern of expression changes between 24 and 72 
hours of infection, suggesting changes in HBV lifecycle. A comparison of gene profiles 
at 24 and 72 hours demonstrated a profile of up-regulated genes change over time 
during early infection (Figure 4.12). Additionally we compared the levels of up-
regulation against 1% oxygen controls from this experiment and HepG2.2.15 results 
demonstrated in (Figure 4.6) in a table (Supplementary Table 8.1). The differences 
noted in this table could reflect the stage of the HBV lifecycle over time and the 
difference between episomal DNA in the de novo infection and integrated HBV 
genomes in HepG2.2.15 cells. 
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Figure 4.10 HIF transcriptional activity in de novo HBV infection 
HepG2-NTCP K7 cells were infected with HBV (MOI 100) over 24 hours. A) PCR result 
demonstrating HIF-1α, HIF-2α and VEGF mRNA expression relative to uninfected 
controls. B) Cells are placed under 20% or 1% oxygen over 72 hours. Graph 
represents CA9 induction in uninfected and HBV infected cells under 20% and 1% 
oxygen, Two-Way ANOVA with Tukey’s multiple comparison’s test. Each graph shows 
the means of 2 biological repeats. Error bars show SE of 6 technical repeats. Analyses 
performed using Multiple T Tests (A) and Two-Way ANOVA with Tukey’s multiple 
comparison’s test (B). 
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Figure 4.11 De novo HBV infection and HIF transcript activity 
Legend on following page. 
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Figure 4.11  De novo HBV infection and HIF transcript activity (Cont.) 
HepG2-NTCP K7 cells were differentiated over 72 hours in 2% DMSO and then 
infected with HBV (MOI 100). Uninfected cells are seeded 1 day post infection. A) 
Supernatants were collected after 24 hours. Graph represents HBeAg ELISA result to 
demonstrate successful infection, Unpaired t test (P 0.0014), Error bars show SD of 3 
technical repeats. B) Samples are lysed 24 and 72 hours post infection for Qiagen RT2 
hypoxic gene PCR array. Heatmap was generated by Qiagen RT2 software. 
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Figure 4.12  Comparisons of de novo infection time points on HIF 
transcript activity 
Legend on following page. 
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Figure 4.12 Comparisons of de novo infection time points on HIF 
transcript activity (Cont.) 
HepG2-NTCP K7 cells were differentiated over 72 hours in 2% DMSO and then 
infected with HBV (MOI 100). Uninfected cells are seeded 1 day post infection. A) 
Graph representing HBV samples 24h post-infection compared against hypoxic 
controls. B) Graph representing HBV samples 72h post-infection compared against 
hypoxic controls. 
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4.6 Studying HBV-HIF interaction 
Having demonstrated that HBV can stabilise HIF and that it is transcriptionally active, 
we were interested to know whether the viral genome contained any putative HIF 
binding sites. We identified a conserved HRE binding motif 38 bases upstream from 
the EnhI and X promoter region that was conserved in diverse HBV genotypes (Figure 
4.13a). This provided a potential point of direct interaction between the HBV genome 
and HIFs, we examined the binding of HIF-1α using chromatin immunoprecipitation 
(ChIP) in combination with a specific HIF-1α antibody, HepG2.2.15 cells and primer 
pairs that spanned the entire HBV genome. We used HepG2.2.15 cells because 100% 
of cells contain integrated copies of the HBV genome. This experiment demonstrated 
an interaction between HIF-1α and the HBV genome between 1580 and 1700 
nucleotides (Figure 4.13c); this coincides with the EnhI and X promoter regions 
identified in our bio-informatic screen. It is important to discuss that interaction occurs 
under both 20% and 1% oxygen (Figure 4.13b). Increases under 1% oxygen are likely 
due to the increased expression of HIF-1α protein under low oxygen, that occurs 
through normal inhibition of the cellular degradation pathway as observed in Figure 
4.9c. This data represents relative binding to the HBV genome compared against a 
non-specific antibody control. We utilised primers against SEMA4B that is known to 
bind HIF-1α as a positive control for successful chromatin immunoprecipitation of HIF-
1α (Figure 4.13c) (Schodel et al., 2011). 
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Figure 4.13 Conserved HIF binding site within the HBV genome 
HepG2.2.15 cells were placed under 20% and 1% oxygen for 24 hours and used to 
generate samples for ChIP using the protocol found in section 2.12. A) GenBlast 
search of selected region demonstrates conserved HRE core motif in all HBV 
genotypes. B) Graphs demonstrating HBV-HIF binding and SEMA4B-HIF binding 
under 20% and 1% oxygen. C) PCR results for primers that span HBV genome, graph 
demonstrates that HIF-1α binds to HBV genome. Data represents means of 2 
biological repeats. Error bars show SE of 3 technical repeats. Data analyses performed 
using Unpaired t test with Welch’s corrections (B). 
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4.7 Discussion 
In the previous chapter we established tools for studying low oxygen effects on 
hepatoma cells. This chapter aimed to examine the effect of HBV infection on the host 
transcription factor HIF. As discussed, the literature reports an association between 
HBx and HIF-1α and HIF-2α (Liu et al., 2014, Kim, 2014, Yang et al., 2017, Hu et al., 
2016). However, we wanted to pursue this idea further within the context of full 
replicating HBV. We examined the effect of HBV on HIF stabilisation using multiple 
models of infection, including plasmid transfections, stable HBV producer cell lines and 
de novo infections. We transfected HepG2-NTCP K7 cells with the HBV genotypes C 
and D. Genotype D is used frequently in the literature and was the basis for generation 
of both the stable producer lines. Genotype C is used for comparative purposes, and 
together these plasmids are used to establish that HBV can stabilize HIFs under 
normoxic conditions (Figure 4.3a). Using plasmids for Genotype D with selected 
deletions in the X and L genes, or containing a double knock out of X and L showed 
that HBV stabilisation of HIFs is not dependent on HBx (Figure 4.4a). Additionally, this 
data suggests that the L protein is not involved, this has previously been implicated in 
facilitating interaction between MDR1 and HBV through HIF-1α (Li et al., 2017). 
Despite demonstrating that HBx and large surface antigen are not essential for HBV 
HIF stabilisation, there are other HBV proteins that could be involved, perhaps the 
Core protein. Alternatively, HIF stabilisation could occur as a stress response to HBV 
infection, which the virus exploits, this however is speculation. 
Using a plasmid to express HBx enabled a comparison against the X-minus Genotype 
D plasmid. Transfection of this plasmid alone under normoxic conditions failed to 
stabilise HIFs (Figure 4.4b). Of course, this does not mean there is no interaction with 
the HIF pathway; HBx can apparently transactivate a wide range of episomal reporters 
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by targeting Smc5/6 for degradation.We examined HBx and HRE co-transfections in 
hepatoma cells following exposure to both 20% and 1% oxygen (Figure 4.4c). This 
demonstrated no significant change in relative HRE activity when compared to HRE 
alone; this suggests that the pHBx was not functionally active with our reporter (Figure 
4.4d) However, it is important to note that we were unable to confirm HBx expression 
in our lab via Western blotting following transfection due to time limitations, instead we 
relied on HBx reporter activity provided by our collaborators (data not shown). This 
means that a lack of HRE effect could be due to a lack of HBx protein expression. 
Previous literature suggests that HBx potentiates HIF stability and increases 
transcriptional activity following HIF stabilisation under low oxygen (Yoo et al., 2003, 
Liu et al., 2014). This data suggests that HBx effects on HIF transcriptional activity 
could be further downstream in the HIF response pathways rather than a direct 
interaction with HIF and HRE binding sites. 
We confirmed these results using HepG2.2.15 and HepAD38 HBV producer cells by 
demonstrating HIF stabilisation over a 72 hour time course (Figure 4.5). A comparison 
of CA9 and VEGFA expression under 1% oxygen relative to normoxic controls in 
HepG2-NTCP K7 and HepG2.2.15 cells (Figure 4.5) demonstrated that HBV positive 
cells expressed higher relative HIF transcript expression. CA9 and VEGFA are both 
strongly induced by hypoxia (Olive et al., 2001, Lin et al., 2004) and are therefore 
commonly used as markers for HIF transcription. In addition, they are associated with 
poor therapeutic outcomes in cancers because they promote cancer cell survival 
(McIntyre et al., 2012, Ledaki et al., 2015). CA9 catalyses the reversible hydration of 
carbon dioxide and in cancers this enables the maintenance of neutral pH within the 
tumour microenvironment (Ledaki et al., 2015). VEGFA induces angiogenesis and 
vasculogenesis, which helps oxygenate the tumour microenvironment, promotes cell 
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migration and inhibits apoptosis (Yang et al., 2009, Matsumoto et al., 2005). 
Importantly, a study in our laboratory has shown that CA9 is highly up-regulated in 
HBV associated HCC and correlates with poor prognosis (Jane McKeating personal 
communication). This suggests that HBV up-regulated CA9 and VEGFA expression 
observed in our experiments could be contributing to eventual development of HCC. 
We demonstrated that HepG2.2.15 cells under 20% oxygen increase the expression of 
multiple genes using the hypoxic gene array (Figure 4.6). When comparing the profile 
against uninfected cells under 1% oxygen, we demonstrated differential expression of 
multiple genes (Figure 4.7), whereas FG-4592 treatment exhibits a similar profile for 
gene expression, but the level of induction is reduced. Interestingly, FG-4592 produces 
a different response in HepG2 cells when compared against Huh-7 cells, which 
demonstrated expression beyond 1% oxygen controls. HepG2.2.15 cells do specifically 
demonstrate increased up-regulation of numerous genes involved in regulating cell 
growth, proliferation, apoptosis and cellular metabolism often as part of stress 
responses, examples include; DNA damage-inducible transcript 4 protein (DDIT4) 
(Sofer et al., 2005), N-Myc Downstream Regulated 1 protein (NDRG1) (Kovacevic and 
Richardson, 2006), Angiopoietin like 4 (ANGPTL4) (Zhu et al., 2011) and 6-
phosphofructo-2-kinase/ Fructose-2,6-Bisphosphatase 3 (PFKFB3) (Kim et al., 2006b) 
(Figure 4.7). These results demonstrate that HBV is stimulating expression of multiple 
HIF associated genes. However, many of the genes that are up-regulated are stress 
response genes and could be increased in response to an HBV infection. 
We performed a test of HepG2-NTCP K7 cells normal low oxygen responses using 
Western blotting and the HRE-Luc reporter before further experimentation (Figure 4.9). 
This result demonstrated HIF protein expression from 24 to 72 hours and HRE 
activation under 1% oxygen at 24 and 48 hours. We observed an increasing activation 
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of HRE over the 72 hour time course under 20% oxygen, despite declining protein 
expression. This could be due to cellular stress and activation of the stress response 
pathways independent of HIFs. Alternatively, the luminometer can detect bright 
luciferase signals in adjacent wells if the signal is particularly bright. The bars observed 
at 20% oxygen could be a result of bleeding signal from the 24 and 48 hour signals at 
1% oxygen. 
Next, we examined the effect of de novo infections on HIF stabilisation. HBV infection 
stabilises HIF-1α and HIF-2α; however, expression was further increased under 1% 
oxygen. We examined HBV infection effects on downstream HIF transcript expression 
by demonstrating an increase in HIF-1α, HIF-2α, and VEGFA mRNA levels relative to 
uninfected cells (Figure 4.10a). A time course of CA9 expression in uninfected and 
HBV infected samples demonstrated that HBV causes an increase in activation under 
20% oxygen and 1% oxygen but this is not a significant difference under either 
condition (Figure 4.10b). We examined the effect of de novo infections on hypoxic 
gene expression using the hypoxic gene array (Figure 4.11), this result demonstrated 
expression profiles for early de novo infections at 24 and 72 hours post infection. 
Interestingly, there is a change in the expression of up-regulated genes between 24 
and 72 hours. Perhaps reflecting a different stage of the HBV lifecycle. Early infection 
involves the translocation of rcDNA to the nucleus and formation of cccDNA before 
transcription of pgRNA begins. This process has been discussed in more detail in the 
main introduction (section 1.2.4). Alterations in gene expression at this time suggest 
that different stages of the HBV lifecycle differentially regulate HIF expression. 
Following this result, we tested whether HIF-1α interacted with HBV using anti-HIF-1α 
targeted chromatin immunoprecipitation (Figure 4.13a,c). This result demonstrated 
that HIF-1α is interacting directly with the HBV genome at an HRE site located within 
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the EnhI/X promoter region; this result has not been shown previously and has some 
interesting implications, this suggests that HIF-1α may be directly involved in regulating 
HBV transcription. Combined, these data provide justification for examining the effect 
of HIFs and low oxygen on HBV replication. 
4.8 Summary 
This chapter presents results that establish the effect of HBV infection on HIF 
stabilisation and transcript activity in two model systems. In addition, these results 
demonstrate a direct interaction between HIF-1α and the HBV genome. The results 
obtained here provide a model for understanding HBV-HIF interactions and a 
justification for further study into low oxygen effects on HBV replication. 
Nicholas Ross Baker Frampton Hepatitis B and Hypoxia Student ID: 1301165 
 
167 
 
5. EXAMINING THE EFFECT OF LOW OXYGEN ON HBV 
REPLICATION 
5.1 Introduction 
In the previous chapter we demonstrated that HBV infection stabilised HIF expression 
and associated transcriptional activity. Furthermore, we showed evidence that HIF 
binds the viral genome under low oxygen conditions, suggesting a direct role for this 
transcriptional activator to positively regulate viral replication at the transcriptional level. 
We noted that HBV infected cells showed increased HIF expression under low oxygen, 
suggesting additive pathways stabilising HIFs. In this chapter, we investigated the 
effect of low oxygen on viral specific transcription and replication. HBV transcription is 
dependent on host cellular transcription factors that bind defined motifs within the 
promoter and enhancer elements, as represented in figure 5.1 (Quasdorff and Protzer, 
2010). These interactions have been discussed in detail in the main introduction 
(section 1.2.5.2). 
In this chapter, we examined the effect of low oxygen on HBV promoter activity using a 
panel of transcriptional reporter assays (Kim et al., 2016, Ko et al., 2014) depicted in 
figure 5.2. We followed these studies with experiments to examine the effect of low 
oxygen on HBV replication using both HepG2.2.15 cells and de novo infections to 
confirm these results in a more authentic infection model (Figure 5.3). Finally, we 
examined the HIF dependency of the effect of low oxygen on HBV replication using 
siRNAs and the HIF pathway inhibitor NSC. 
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Figure 5.1 HBV genome representations and transcription factor 
interactions (Lai, A. 2017) 
(Top) Schematic representation of HBV partially double-stranded circular genome 
including open reading frames (ORFs), direct repeats (DR1 and DR2) and viral RNAs. 
(Bottom) Cartoon representation of linear HBV genome including promoter and 
enhancer regions, displaying host transcription factor interaction sites. 
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Results 
5.2 Effect of low oxygen on HBV promoter activity 
Following the ChIP result in the last chapter, it is clear that HIF-1α interacts with the 
HBV genome in HepG2.2.15 cells. The HRE site is located close to the X promoter 
region. This suggests that the host transcription factor interacts with HBV promoters 
and could stimulate activity. We used the HBV promoter constructs to investigate this 
further. Following transfection, the cells are placed under normoxic and hypoxic 
conditions and samples are collected every 24 hours over a 72 hour time period 
(Figure 5.2). These results indicate that low oxygen increases the activity of all 
promoter constructs. The EnhI/ HBx promoter demonstrated increases under 1% 
oxygen at all time points, however the only significant difference is observed after 72 
hours (Figure 5.2c). In comparison, all of the other three HBV promoters demonstrate 
a significant increase relative to normoxic controls at all time points (Figure 5.2b,d,e), 
demonstrating that low oxygen up-regulates HBV promoter activity. In addition we see 
significant increases in promoter activity between 24-48 and 24-72 hours (Figure 
5.2b,d,e). To assess the dependency of the transcription reporters on low oxygen we 
investigated the effect of HIF stabilising drugs FG-4592 and VH298 previously 
described in chapters 3 and 4. Following transfection, the cells were either treated with 
FG-4592 or VH298 and cultured under normoxia. 
Our results demonstrate that HIF stabilising drugs increase HBV promoter activity 
(Figure 5.3) significantly compared to 20% oxygen controls. Treatment with VH298 
produces similar levels of up-regulation to incubation under 1% oxygen in each of the 
promoters; whereas treatment with FG-4592 results in a significant increase (Figure 
5.3a-d). These results were obtained alongside HRE-Luciferase reporter control 
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demonstrating increased HRE activity under each condition (Figure 5.3e). Relative 
expression of promoter activity against normoxic controls demonstrated that each of 
the promoters is increased through treatment with FG-4592 and VH298 (Figure 5.3f-
g). However, under each condition, we saw significantly higher up-regulation of the 
EnhI/ X promoter activity. This coincided with the ChIP data and suggested that HIF-1α 
binding caused increased promoter activity. Interestingly, HRE is only present with 
EnhI/X promoter and yet all promoters show a boost under low oxygen, suggesting 
direct and indirect effects. 
Following these results, we investigated whether viral transcriptional activity is HIF-
dependent by co-transfecting promoter plasmids with HIF1a and HIF2a expression 
vectors. Since over-expression of wild-type HIFs under normoxic conditions are 
targeted for proteosomal degradation we expressed HIFs containing a double proline 
mutation within their ODD domains that are stably expressed under normoxia (Figure 
5.4a,b). We noted increased expression of the double proline HIF mutants and 
associated activation of HRE-Luc reporter. We therefore investigated the effect of the 
double proline HIF mutants on HBV reporter activity and observed that EnhI/ X and 
EnhII/ BCP promoters are significantly increased by co-expressing HIF1α and HIF2α 
(Figure 5.4c-f). Interestingly, the S1 and S2 promoters appear to be primarily 
regulated by HIF2α, with significant increases observed in promoter activation following 
co-transfection (Figure 5.4e,f). Together these results demonstrate a role for low 
oxygen and HIFs to up-regulate HBV promoter activity. 
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Figure 5.2 HBV promoter activity under 1% oxygen over time 
A) HBV reporter constructs for studying promoter activity. From top to bottom: 
Enhancer 1 and Enhancer 2 with the basal core promoter (EnhI/ II + BCP); Enhancer 1 
and HBx (EnhI/ HBx); S1 promoter and S2 promoter. HepG2-NTCP K7 cells were 
transfected with HBV-promoter-luciferase reporters, after transfection the cells were re-
seeded into 96 well plates and placed into hypoxic or normoxic conditions. B) Raw 
RLU values for EnhII/ BCP promoter activation over 72 hours. C) Raw RLU values for 
EnhI/ X promoter activation over 72 hours. D) Raw RLU values for S1 promoter 
activation over 72 hours. E) Raw RLU values for S2 promoter activation over 72 hours. 
F) Raw RLU values for HRE activation over 72 hours. Each graph shows the means of 
4 biological repeats. Error bars show SE of 12 technical repeats. Data analyses using 
Two-Way ANOVA with Tukey’s multiple comparison’s test. 
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Figure 5.3 HBV promoter activity and HIF stabilising agents 
Legend on following page. 
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Figure 5.3 HBV promoter activity and HIF stabilising agents (Cont.) 
HepG2-NTCP K7 cells were transfected with HBV-promoter-luciferase reporters, after 
transfection the cells were re-seeded into 96 well plates. The cells were then placed 
into 20% or 1% oxygen. Normoxic samples are either treated with VH298 (100μM) or 
FG-4592 (1μM) or left untreated. A) Raw RLU values for EnhII/ BCP promoter 
activation over 72 hours. B) Raw RLU values for EnhI/ X promoter activation over 72 
hours. C) Raw RLU values for S1 promoter activation over 72 hours. D) Raw RLU 
values for S2 promoter activation over 72 hours. E) Raw RLU values for HRE 
activation over 72 hours. F) Relative activation of HBV promoters following FG-4592 
treatment relative to normoxic controls. G) Relative activation of HBV promoters 
following VH298 treatment relative to normoxic controls. Each graph shows the means 
of 4 biological repeats. Error bars show SE of 12 technical repeats. Data analysed 
using Two-Way ANOVA with Tukey’s multiple comparisons test 
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Figure 5.4 Effect of HIF on HBV promoter activity 
HepG2-NTCP K7 cells were transfected with pHIF-1α, pHIF-2α, pHIF-1α-2P or pHIF-
2α-2P. A) Western blot demonstrating HIF over expression under normoxic conditions. 
B) HRE-Luc reporter and the HIF over expression plasmids. C-F) HepG2-NTCP K7 
cells were co-transfected with an HBV-Luc reporters EnhI/II + BCP (C), EnhI/ HBx (D), 
S1 (E), S2 (F) and the HIF over expression plasmids (double proline mutants); 
following transfection the cells were reseeded into 96 well plates. Each graph shows 
the means of 2 biological repeats. Error bars show SE of 6 technical repeats. Data 
analysed with One-Way ANOVA with Tukey’s multiple comparison’s test. 
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5.3 Effect of low oxygen on HBV replication 
To investigate the effect of low oxygen on HBV replication we quantified viral pgRNA, 
rcDNA and cccDNA by PCR. Low oxygen increases HBV pgRNA over a 72 hour time 
course, with significant increases observed after 48 and 72 hours (Figure 5.5a). The 
increased pgRNA could reflect an increase in promoter activity or an increase in 
template for transcription. This is important when considering the result in HepG2.2.15 
cells, which contain both stably integrated viral genomes and cccDNA. Considering this 
we examined the expression of cccDNA and demonstrated significant increases under 
low oxygen (Figure 5.5b). This was performed alongside PCRs for HBV rcDNA, which 
demonstrated a similar pattern of expression, however there was only a significant 
difference at the 24 and 72 hour time points (Figure 5.5c). Interestingly this value 
appears to have declined from the 24 hour mark, perhaps because intracellular rcDNA 
has been converted into cccDNA. The pattern of rcDNA expression over 72 hours 
suggests a possible increased effect of reverse transcription on pgRNA to rcDNA 
synthesis. Using a PCR designed to amplify secreted and packaged rcDNA we 
observed no significant change in this parameter under 1% oxygen over any of the 
time points studied (Figure 5.5d). Taken together these results suggest that low 
oxygen promotes viral transcription. This could also be the result of increased 
transcription of pgRNA from cccDNA. The increased cccDNA levels under low oxygen 
could be the result of multiple pathways. Firstly, low oxygen could be increasing 
infectious spreading, however HepG2.2.15 cells lack NTCP and so this seems unlikely. 
Alternatively, this could be through an increase in the reimport of encapsidated rcDNA 
into the nucleus and subsequent conversion into cccDNA. Lastly, this could be the 
result of reduced Smc5/6 associated degradation of cccDNA through an HBx-HIF 
interaction. 
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Figure 5.5 Low oxygen effects on HBV replication 
HepG2.2.15 cells were placed under 20% or 1% oxygen for 24-72 hours. Samples 
were lysed every 24hrs for RNA and DNA preparation with RLT+ buffer, supernatants 
were harvested at every time point for ELISAs and extracellular HBV DNA PCR. qPCR 
was performed to examine HBV pgRNA (A), cccDNA (B), rcDNA (C), and supernatant 
rcDNA (D). Each graph shows means of 3 biological repeats. Error bars show SE of 9 
technical repeats. Data analysed using Two-Way ANOVA with Tukey’s multiple 
comparison’s test. 
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5.4 Effect of hepatocellular differentiation on HBV replication under 
low oxygen 
It is important to consider that these experiments with HepG2.2.15 cells that carry 
integrated copies of HBV are performed in the absence of any DMSO treatment. To 
confirm these observations with de novo infected cells it is necessary to continuously 
treat the cells with DMSO to establish and maintain a productive infection. Since we 
previously observed a blunted response to DMSO-differentiated HepG2 cells to low 
oxygen in terms of HIF signalling (Figure 3.15) we were interested to evaluate the 
impact of DMSO on low oxygen stimulated viral transcription. 
We examined the effect of DMSO mediated differentiation on HepG2.2.15 expression 
of HIF and stimulatory effect of low oxygen on pgRNA and rcDNA levels using Western 
blotting and quantitative PCR (Figure 5.6). Previous studies have demonstrated that 
DMSO differentiation increases HBV transcription and replication at multiple stages in 
the viral life cycle (Verrier et al., 2016b, Urban et al., 2014). Our data showed a 
significant increase in HBV RNA and DNA levels under 1% oxygen (Figure 5.6b,c). 
DMSO differentiation significantly increased the expression of both pgRNA and rcDNA 
under normoxic conditions, however it blunts the effect of low oxygen priming of viral 
transcription. This demonstrated more evidence that pgRNA and rcDNA regulation are 
regulated by low oxygen, potentially through HIF expression which, we have previously 
shown is blunted under DMSO differentiation. 
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Figure 5.6 Differentiation status of HBV infected cells blunts their 
response to low oxygen 
A) HepG2.2.15 cells were either differentiated using 2% DMSO or untreated and 
placed under 20% oxygen. Equal protein loading for Western blot determined by 
counting control wells. qPCR was used to measure HBV pgRNA (B) and rcDNA (C). 
Each graph shows the means of 3 biological repeats. Error bars show SE of 9 technical 
repeats. Two-Way ANOVA with Tukey’s multiple comparison’s test. 
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5.5 Removing DMSO from the de novo infection protocol 
Considering the effect that DMSO has on HIF expression, the hypoxic gene array and 
on HBV nucleic acid expression, we decided it was important to remove DMSO from 
our infection protocols to accurately study the effect of low oxygen on HBV replication. 
We therefore evaluated the effect of removing DMSO from differentiated HepG2 cells 
on viral transcripts under normoxic and hypoxic conditions (Figure 5.7). Cells were 
treated or not with 2% DMSO for three days and differentiation media removed and 
replaced with DMEM. The cells were then incubated under 20% or 1% oxygen and 
lysed for RNA preparation every 24 hours. A T0 sample was lysed at the point of 
DMSO removal as a control (Figure 5.7a). This experiment shows that non-
differentiated cells show an increase in pgRNA levels under low oxygen over 72 hours 
(Figure 5.7b). Interestingly, removing DMSO restores pgRNA expression to levels 
observed in un-differentiated cells. However, the levels are still elevated initially 
(Figure 5.7c). After 72 hours, we saw pgRNA levels return to those comparable with 
control cells in Figure 5.7b (Figure 5.7c). These results were repeated successfully, 
and it was demonstrated that rcDNA expression responds to DMSO treatment and 
removal in the same pattern (data not shown). These data provide the justification for 
developing a de novo infection protocol in the absence of DMSO. 
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Figure 5.7 HBV nucleic acids expression in the DMSO escape assay 
Legend on following page. 
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Figure 5.7 HBV nucleic acids expression in the DMSO escape assay 
A) Schematic representation of DMSO “Escape” assay using HepG2.2.15 cells. Seed 
cells into 12-well plates 5x104 cells per well. Differentiate in 2% DMSO over 8 days. 
After 6 days, seed out non-DMSO differentiated controls for confluence on day 8 
(1.5x105 cells per well). After 8-day differentiation, remove DMSO from appropriate 
samples. Place samples under 20% and 1% oxygen for 72 hours. B/C) HepG2.2.15 
cells were either differentiated over 72hrs with 2% DMSO or left undifferentiated. B) 
Undifferentiated cells were placed under 20% or 1% oxygen and lysed every 24 hours. 
C) DMSO differentiated cells had media replaced with DMSO free media and placed 
under 20% or 1% oxygen, samples were lysed every 24 hours following DMSO 
removal for RNA. T0 controls represent cells at start of incubation. Each graph shows 
the means of 2 biological repeats. Error bars show SE of 8 technical repeats. Analyses 
performed using Two-Way ANOVA with Sidak’s multiple comparison’s test. 
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5.6 Studying viral replication in de novo infections under low 
oxygen 
Results obtained in chapter 3 combined with results using HepG2.2.15 cells indicate a 
need to remove DMSO from our infection protocol if we wanted to accurately study the 
effect of low oxygen on viral replication. 
Having demonstrated that pgRNA and rcDNA levels could return to levels observed in 
un-differentiated cells, we altered the protocol standardly used for de novo infections 
by removing DMSO once the infection has been established (Figure 5.8a). Following 
this protocol, we examined the effect of low oxygen on HBV nucleic acid levels in the 
absence of DMSO (Figure 5.8b-d). These results demonstrate significant increases 
after 24 hours in pgRNA, cccDNA and rcDNA following exposure to 1% oxygen. This 
result confirms the previous result obtained using HepG2.2.15 cells. 
An independent repeat using a 72 hour time course demonstrated that HBV pgRNA 
increases under low oxygen (Figure 5.9a), up-regulated expression remains constant 
over 72 hours perhaps indicating an increase in promoter activity or template for 
transcription. In addition, we demonstrated that cccDNA and rcDNA expression 
increased significantly over time (Figure 5.9b,c). This would suggest an increase in 
template for viral transcription. As stated previously, this could indicate an increase in 
virus spread, reimport of rcDNA or inhibition of degradation through Smc5/6. 
Additionally, we demonstrated that HBsAg levels are increasing over time in a similar 
manner to viral nucleic acids (Figure 5.9d). We confirmed this result using 
immunofluorescent staining for HBsAg in HepG2-NTCP K7 cells following de novo 
infection (Figure 5.10a), counting HBsAg positive cells demonstrated that the 
percentage of HBs positive cells increases over time and under low oxygen (Figure 
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5.10b) and this effect is not caused by increasing cell number caused by continued 
proliferation after DMSO removal (Figure 5.10c). Together these results confirm data 
obtained using HepG2.2.15 producer cells, and we conclude that low oxygen promotes 
HBV replication. 
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Figure 5.8 Low oxygen effect on HBV replication in de novo infection 
model 
A) Schematic representation of de novo infection in HepG2-NTCP K7 cells. HepG2-
NTCP K7 cells were differentiated over 72 hours in 2% DMSO. Cells were infected with 
HBV (MOI 100) over 24 hours in media containing 5% PEG and 2% DMSO. Fresh 
media without PEG added after 24 hours. Infection is left for 5 days. DMSO is removed 
from infected cells 5 days post infection. Cells can be treated with drugs and siRNAs at 
this point. Cells are placed under 20% or 1% oxygen over 24 hours. B) Graph 
demonstrating pgRNA PCR result. C) Graph demonstrating cccDNA PCR result. D) 
Graph demonstrating rcDNA PCR result. Each graph represents the means of 6 
biological repeats. Error bars show SE of the mean of 18 technical repeats. Data 
analysed using Unpaired t test with Welch’s correction. 
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Figure 5.9 Time course of HBV nucleic acid expression under low 
oxygen 
HepG2-NTCP K7 cells were differentiated over 72 hours in 2% DMSO. Cells were 
infected with HBV (MOI 100). Following infection cells were placed under 20% or 1% 
oxygen over 72 hours. A) Graph demonstrating pgRNA PCR result. B) Graph 
demonstrating cccDNA PCR result. C) Graph demonstrating rcDNA PCR result. D) 
Graph demonstrating HBsAg ELISA result as signal/ cut-off (described in methods 
section). Each graphs shows the means of 6 biological repeats. Error bars show SE of 
18 technical repeats. Data analysed using Two-Way ANOVA with Tukey’s and Sidak’s 
multiple comparison’s tests. 
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Figure 5.10a Immunofluorescent staining of HBsAg 
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Fig 5.10 Continued 
A) HepG2-NTCP K7 cells were infected with HBV (MOI 100) on collagen coated 
coverslips. Infections were placed under 20% or 1% oxygen over 72 hours. Cells were 
fixed in 6% PFA and stained with an anti-HBs antibody and DAPI, images taken with a 
Leica DM6000 microscope. Scale bars represent 100μm in x10 images and 25μm in 
x40 images. B) Graph representing the percentage of HBs positive cells in anti-HBs 
immunofluorescent stained samples. C) Cell counts were determined by counting DAPI 
stains using ImageJ. HBs counts performed manually. Graph represents average HBs 
counts obtained from 9 images per condition at 40x magnification. Data analysed using 
Multiple t tests within time points and Two-Way ANOVA with Tukey’s multiple 
comparison’s test between timepoints. 
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5.7 HBV replication and HIFs 
Having demonstrated that low oxygen promotes viral replication using HepG2.2.15 
producer cells and a de novo infection model, we investigated whether the effect is HIF 
dependent. Data gathered using ChIP and HBV promoter constructs argues for low 
oxygen regulation of replication being HIF dependent, however, we have yet to 
demonstrate this using the de novo infection model. Following initial infection, we 
treated HepG2-NTCP K7 cells with the HIF pathway inhibitor NSC and incubated the 
cells under 20% and 1% oxygen for 72 hours. 
As previously demonstrated in Chapter 3, NSC treatment results in inhibition of HIF 
expression. This causes a significant reduction in pgRNA, cccDNA, rcDNA and HBsAg 
expression under 1% oxygen over 72 hours (Figure 5.11). A similar experiment 
utilising siRNAs to reduce expression of HIF-1α and HIF-2α after initial infection 
confirms this result. We utilised Western blotting to demonstrate effective silencing of 
protein expression and subsequent PCRs to show that reduced HIF expression causes 
a reduction in HBV replication; specifically, we saw significantly reduced pgRNA 
expression following HIF-1α silencing (Figure 5.12b) and significant decreases in 
cccDNA expression using HIF-1α and HIF-2α siRNAs (Figure 5.12c). This indicated 
HIFs are involved in the expression of pgRNA and cccDNA, perhaps through regulation 
of HBV transcription. However, siRNA treatment did not reduce expression of all 
nucleic acids. HBV rcDNA levels are decreased following treatment with NSC, but we 
did not see a decrease in expression following transfection with siRNAs (Figure 5.11c 
and Figure 5.12d). This could suggest a HIF independent effect of low oxygen on 
rcDNA expression. 
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Figure 5.11 Time course of HBV nucleic acid expression with NSC 
treatment 
HepG2-NTCP K7 cells were infected with HBV (MOI 100). Followign infection, cells 
were treated with 1μM NSC or left untreated. Cells are placed under 20% or 1% 
oxygen over 72 hours. A) Graph demonstrating pgRNA PCR results. B) Graph 
demonstrating cccDNA PCR results. C) Graph demonstrating rcDNA PCR results. D) 
Graph demonstrating HBs ELISA results. Each graph shows the means of 2 biological 
repeats. Error bars show SE of 6 technical repeats. Data analysed using Two-Way 
ANOVA with Tukey’s multiple comparison’s test. 
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Figure 5.12 Time course of HBV nucleic acid expression with siRNA 
transfections 
HepG2-NTCP K7 cells were infected with HBV (MOI 100). Following infection, cells 
transfected with siRNAs against HIF-1α or HIF-2α or left untreated. Cells are placed 
under 20% or 1% oxygen over 72 hours. A) Western blot demonstrating HIF 
stabilisation in infected HepG2-NTCP K7 cells under 20% and 1% oxygen following 
transfection with siRNAs. B) Graph demonstrating pgRNA PCR results. C) Graph 
demonstrating cccDNA PCR results. D) Graph demonstrating rcDNA PCR results. 
Each graph shows the means of 3 biological repeats. Error bars show SE of 9 technical 
repeats. Data analysed using Two-Way ANOVA with Sidak’s multiple comparison’s 
test. 
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5.8 Discussion 
Having established that HBV stabilises HIFs in the previous chapter we moved onto 
examining the effect of low oxygen effects on viral life cycle. We observed increased 
activity for all HBV promoters (Figures 5.2 and 5.3) using HBV promoter constructs 
and HIF stabilising agents, which indicated that low oxygen is regulating viral 
transcription. Treatment with FG-4592 increased promoter activity significantly when 
compared to 1% oxygen controls. Plotting the data for each condition relative to 20% 
oxygen controls reveals that increased activity is not dependent on time, just low 
oxygen and HIF expression. This difference in effect could be due to the method of HIF 
stabilisation. As discussed previously, VH298 inhibits the VHL protein as part of the 
proteasomal degradation pathway, whereas FG-4592 inhibits PHDs, perhaps indicating 
a role for other parts of the low oxygen response in target cells. However, neither of 
these drugs specifically targets a single HIF isoform. Therefore, we utilised plasmids to 
over express both HIF-1α and HIF-2α that contain mutations in the double proline 
residues within the oxygen-dependent degradation (ODD) domain. These mutations 
prevent hydroxylation by PHDs and therefore prevent degradation. These plasmids 
were utilised in conjunction with HBV reporter plasmids to demonstrate which isoform 
was affecting HBV promoter activity (Figure 5.4). This result demonstrated that 
promoter activities are differentially regulated by HIF-1α and HIF-2α. HIF-1α 
specifically increased activity in the EnhI/ X promoter and EnhII/ BCP promoter. 
Activation in the EnhII/ BCP promoter could be attributed to the EnhI/ X promoter within 
the construct. Interestingly, the S1 and S2 promoters see increased activity following 
HIF-2α stabilisation. Collectively these results indicate that low oxygen has a role in 
increasing HBV transcription and provide justification for examining different steps in 
the viral lifecycle more closely. Specifically, this was achieved by exposing HepG2.2.15 
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cells and de novo infections to low oxygen environments. So, we examined the effect 
of low oxygen on different steps of the replication cycle using PCR and ELISAs. 
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Figure 5.13 HBV lifecycle (Thomas & Liang, 2016) 
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Initial experiments were conducted using HepG2.2.15 cells, the PCRs demonstrate an 
increase in pgRNA, cccDNA and rcDNA under low oxygen (Figure 5.5). Each of the 
HBV nucleic acids are increased after 24 hours, although pgRNA is not increased 
significantly. Increased expression of cccDNA could indicate a couple of different 
effects under low oxygen (Figure 5.5b). First, this could indicate that low oxygen is 
promoting conversion from rcDNA to cccDNA as shown in Figure 5.13. Secondly, this 
could indicate that low oxygen promotes the re-import of rcDNA into the nucleus rather 
than secretion following DNA synthesis (Li et al., 2010a, Gallucci and Kann, 2017). 
This possibility is supported by PCR data demonstrating no increase in the secretion of 
HBV virions following low oxygen exposure, as demonstrated using PCR to test for 
supernatant rcDNA levels (Figure 5.5d). Lastly, increases in cccDNA could indicate an 
increase in spreading infection and therefore greater percentage of HBV positive cells. 
However, in HepG2.2.15 cells, each cell contains integrated copies of the HBV 
genome and lack NTCP. To test this, we utilised immunofluorescent staining of HBs in 
de novo infected HepG2-NTCP K7 cells (Figure 5.10a). This result indicated an 
increase in the percentage of HBs positive cells (Figure 5.10b) and provides some 
support for the increase of spreading infection under low oxygen. 
So, increases in pgRNA suggest that low oxygen is promoting HBV transcription from 
cccDNA, this supports the data we obtained using the HBV reporter plasmids (Figure 
5.2). Increased pgRNA expression could subsequently increase expression of rcDNA 
and cccDNA by providing more template for DNA synthesis and increased rcDNA for 
re-import into the nucleus. Increased levels of cccDNA following re-import of mature 
virions has been reported previously (Nassal, 2015), and our data suggests that low 
oxygen causes an increase in this behaviour. HBV pgRNA and cccDNA are increased 
immediately following 24 hour exposure to hypoxia, this then remains stable and even 
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increased further over 48 and 72 hours (Figure 5.5a, b). HBV rcDNA showed 
significant increases initially, that diminished over 48 hours and then increased again 
after 72 hours (Figure 5.5c). The implications of this are not fully understood, but it 
could be the result of reverse transcription from pgRNA and subsequent positive strand 
synthesis. HBV rcDNA drops as it is converted into cccDNA and then increases again 
as replication builds up. However, when examining the ratio of expression for rcDNA to 
pgRNA under each oxygen tension, we saw increased rcDNA expression early on 
suggesting an increase in production from pgRNA (Table 5.1). At this stage, this is just 
speculation and it is important to consider that HIF signalling is dynamic and 
fluctuations in activity could change the response in HBV infections. 
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Table 5.1 Ratios of rcDNA to pgRNA expression 
Table detailing the ratio of rcDNA to pgRNA expression under 20% and 1 % oxygen over 72 
hours during de novo infection experiment. 
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We demonstrated no difference in supernatant rcDNA expression between 20% and 
1% oxygen using PCR. This implies that low oxygen does not affect secretion of 
virions; this has been shown to occur through MVBs and the ESCRT pathway, 
discussed in detail in section 1.2.7. This provides a possible explanation for observed 
increased in cccDNA; the rcDNA produced via reverse transcription could be 
translocated to the nucleus and re-imported for an increased cccDNA pool (Nassal, 
2015).  
Considering the HBV S1 and S2 promoter data obtained demonstrating increased 
activity under low oxygen, we would expect an increase in HBsAg expression. We 
demonstrated that antigen secretion (or expression) is increased under low oxygen 
using ELISAs against HBs and anti-HBs immunofluorescent staining (Figure 5.9d and 
Figure 5.10a), this however does not contradict the supernatant rcDNA result. HBV 
antigens are secreted via the Golgi general secretory pathway. This implies that low 
oxygen might play a regulatory role in the endoplasmic reticulum (ER) and Golgi during 
HBV infections. It has been demonstrated previously that hypoxia inhibits the adaptive 
unfolded-protein response (UPR) in Beta cells and reduces ER to Golgi trafficking of 
proteins (Bensellam et al., 2016); however another report demonstrated that hypoxia 
played a role in increasing trafficking of copper through the biosynthesis secretory 
pathway in the Golgi (White, 2009). If hypoxia typically inhibits secretion then this 
suggests that HBV can overcome the inhibitory effect of low oxygen. 
Having demonstrated the effect of low oxygen on the HepG2.2.15 cells it became 
important to confirm these results using de novo infections. However, as we 
demonstrated previously, DMSO blunts the HIF response in uninfected cells. This is 
problematic because the current gold standard de novo infection protocols require the 
differentiation of target cells in 2% DMSO for 72 hours proceeding infection. We 
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decided to examine the effect of DMSO differentiation on HBV nucleic acids expression 
and HIF responses in HepG2.2.15 cells. Our data demonstrated that HepG2.2.15 cells 
exhibit blunted HIF expression and altered pgRNA and rcDNA leves following DMSO 
differentiation and so we developed the DMSO “escape” assay to test the effects of 
DMSO removal following differentiation. We demonstrated that removing the DMSO 
can result in the return of pgRNA and rcDNA expression to levels observed in 
undifferentiated cells after 72 hours (Figure 5.7b,c). This is important when 
considering the study of HBV in low oxygen environments. This result provided the 
justification for removal of DMSO from our de novo infection protocol following initial 
infection. Using this protocol, we performed de novo infection and examine the effect of 
24 hour low oxygen exposure on a more authentic infection model. This confirmed our 
results in HepG2.2.15 cells, demonstrating significant increases in pgRNA, cccDNA 
and rcDNA expression after 24 hour incubation under 1% oxygen (Figure 5.8). We 
performed a repeat experiment including a time course of incubation under 1% oxygen, 
this demonstrated increased cccDNA at all time points, but this was only significant at 
72 hours (Figure 5.9). HBV pgRNA and rcDNA levels were increased significantly at all 
time points. These results suggest that low oxygen is up-regulating cccDNA, however 
the response is delayed. Perhaps suggesting that low oxygen is increasing 
transcription of pgRNA from cccDNA, which subsequently causes increased rcDNA 
expression, which is then re-imported. Both models for HBV infection have 
demonstrated the same effect of low oxygen on viral replication, data demonstrated in 
earlier chapters showed that HBV stabilised HIFs and treatment with HIF stabilising 
agents resulted in increased promoter activity. This provides strong evidence that the 
effects on HBV replication are mediated through HIFs. To confirm this result, we 
performed a de novo infection and treated infected cells with the HIF pathway inhibitor 
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NSC and siRNAs against HIF-1α or HIF-2α (Figures 5.11 and Figure 5.12 
respectively) and examined the effect on viral nucleic acids following exposure to low 
oxygen. A combination of these data suggest that the increased viral replication 
observed under low oxygen is likely due to HIF-1α specifically. 
Taken together the results in this chapter imply that low oxygen boosted HBV 
replication at several stages in the viral life cycle: transcription and cccDNA genesis. 
We also establish that differentiation is altering normal hypoxic responses and 
determined that removing DMSO from the equation post infection is a viable method of 
maintaining efficient infection but not impairing the hypoxic responses. 
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5.9 Summary 
This chapter presents results demonstrating that low oxygen increased HBV promoter 
activity. Further experimentation using HIF stabilising agents and over expression 
plasmids suggests that this effect is mediated primarily through HIF-1α. In addition, we 
demonstrated that HBV nucleic acids are up-regulated in HepG2.2.15 cells following 
exposure to low oxygen. We confirmed this result using de novo infections and 
demonstrate that increasing expression under 1% oxygen is indicative of spreading 
infection rather than re-import and amplification of viral DNA. We further demonstrated 
the effect of low oxygen on HBV replication and specifically identify HIFs in this 
process using NSC and siRNAs to down regulate HBV nucleic acid expression. 
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6. DISCUSSION 
In this thesis, we aimed to study the role hypoxia plays in HBV viral replication. To 
achieve this, we examined the low oxygen responses within target cells and included 
examination of differentiated cells. These results provided the basis for HBV infection 
models. We followed this with an examination of HBV and HIF stabilisation using 
HepG2.2.15 producer cells and de novo infection models. Whilst the de novo infection 
protocol we used is considered the “gold standard” for modelling HBV infections, there 
are some limitations that are important to consider. Firstly, this model is reliant on 
artificial differentiation using DMSO. Treatment with this chemical could result in 
multiple off target effects that affect the observed results. Further testing of DMSO 
effects on HBV infections would be required to be sure no off target effects are 
occurring. We tested an alternative method of differentiation for hepatocytes and found 
that HepG2 cells could not tolerate the differentiation process enough for efficient use 
in experimentation. It would be interesting to consider the use of pluripotent stem cells 
as progenitors for differentiated hepatocytes as the basis for future models of infection. 
Secondly, this infection model relies on the overexpression of NTCP and polyethylene 
glycol treatment to enable efficient infection. This is incredibly artificial and therefore 
results obtained using this model could be affected by multiple cell manipulations that 
have occurred. The model system could potentially be improved by trying to remove 
each of these treatments. However, this could significantly reduce the level of HBV 
infections. The model could be improved by altering the cell types used for infection. 
The use of primary human hepatocytes would provide a more realistic model for 
infections. We established that stabilisation occurs under both 20% and 1% oxygen; 
and that stabilisation is not dependent upon X and L proteins. Considering this result it 
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is unclear how HBV infection results in HIF stabilisation, perhaps through HBV induced 
reactive oxygen species (ROS) accumulation (Mishra et al., 2017). ROS have 
demonstrated a role in regulation of HIF-1 through altered activity of PHD2 (Niecknig et 
al., 2012). Further testing revealed an HRE binding motif within the HBV genome, and 
the use of a ChIP assay demonstrated a direct interaction between HIF-1α and the 
HBV EnhI/ X promoter. In the final results chapter, we examined the effects of low 
oxygen on HBV transcription and replication using a combination of HBV-promoter-
luciferase constructs and PCRs targeting HBV nucleic acids. These data demonstrated 
that low oxygen up-regulated viral transcription and replication. Further investigation 
using the HIF inhibitor NSC and specific siRNAs demonstrated that low oxygen effects 
on HBV infection are HIF dependent. Together our results argue a role for HIFs in viral 
transcription that impacts upon replication and demonstrate that this effect is 
independent of low oxygen. However, the effect is potentially accentuated in hypoxic or 
inflammatory environments. 
The biological relevance of our observations may be reflected in the oxygen gradient 
associated with normal blood flow in the liver, and inflammation associated with 
infection, liver disease and hepatocellular carcinoma (Jungermann and Kietzmann, 
2000, Gebhardt et al., 2007, Wilson et al., 2014). These all result in hypoxic 
environments within the liver of varying oxygen tensions. Our collaborators from the 
Protzer laboratory at T.U.M in Munich, have demonstrated that HBV will predominantly 
localize to low oxygen regions in the livers of HBV transgenic mice. Our data suggests 
a pro-viral role for HIFs in viral replication. These transcription factors are reported to 
act as part of multiple stress response pathways; and through binding of promoter 
regions regulate a number of genes involved in glucose metabolism, regulation of lipid 
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metabolism, liver injury and tumour-associated angiogenesis, metastasis and 
inflammation. This was discussed in more detail in the main introduction. 
A number of reports have demonstrated interactions between HIFs and other viruses. 
For example, it was demonstrated that the HPV protein E6 inhibits p53, which inhibits 
HIF-1α expression (Ravi et al., 2000). In addition, it has been shown that HPV E7 
protein can stabilise HIF-1α through direct interaction with the protein (Bodily et al., 
2011). Other reports demonstrate that EBV can increase HIF-1α synthesis through 
LMP-1 protein enhancing the ERK1/2 MAPK signalling pathway (Wakisaka et al., 
2004). Additionally, EBV proteins EBNA 3 and 5 have been demonstrated to inhibit 
PHD activity and therefore prevent degradation of HIFs (Darekar et al., 2012). Reports 
also demonstrate KSHV stabilisation of HIF-1α through the vGPCR protein, which 
stimulates the secretion of multiple cytokines that enhance the synthesis of HIF-1α 
(Jham et al., 2011). Our lab has previously demonstrated a role for HIFs in the lifecycle 
of HCV and demonstrated that hypoxic exposure results in increased viral replication 
(Wilson et al., 2012). Colleagues within our lab have also recently demonstrated 
inhibition of HIV-1 replication following exposure to low oxygen (Unpublished, Jane 
McKeating personal communication). Previous reports have demonstrated a link 
between HIFs and HBV through the HBx protein (Yoo et al., 2003, Yoo et al., 2004, 
Yoo et al., 2008). Specifically, these papers demonstrate increased MAPK signalling 
resulting in increased HIF-1α expression; increased HDAC1 transcription and binding 
of PHDs/ VHL to prevent HIF-1α degradation. Another study by Li and colleagues 
demonstrated an interaction between LHB and HIFs resulting in increased MDR1 
expression (Li et al., 2017). Our data demonstrated that HBV interactions with HIFs are 
not dependent on HBx or LHB. This was an interesting result and motivated further 
examination of other interactions. We examined the interaction between HIF-1α and 
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the HBV genome using anti-HIF-1α ChIP and primers spanning the HBV genome; this 
revealing a direct interaction between HIF-1α and the viral genome at an HRE motif 
found in the EnhI/ X promoter region. This interaction has not been previously shown. 
This result does not preclude the interaction of viral proteins with HIFs but 
demonstrated a role for the host transcription factor in regulating viral transcription. 
Previous studies have shown multiple transcription factors that will interact with the 
HBV and regulate the virus (Quasdorff and Protzer, 2010), these have been discussed 
in more detail in the main introduction. We demonstrated low oxygen and HIF effects 
on HBV promoter activation using the HBV luciferase reporters. These data 
demonstrate the reverse of previous research, which primarily focuses on HBx 
regulation of HIF activity. The implication is that HBV is modifying host behaviour. Our 
models suggest that HBV is actively stabilising HIFs even under 20% oxygen 
conditions and through interaction with the viral genome stimulate transcription. This in 
turn results in increased replication. We propose a model in which HBV ordinarily 
utilises HIFs, and this effect is accentuated under low oxygen or inflammatory 
conditions. 
A study by Song and colleagues examined the effect of inflammation on miR-210 
activity under low oxygen during HBV infection. They concluded that low oxygen was 
reducing viral replication through miR-210 activity (Song et al., 2014). These results 
seem to directly contradict those found in our studies. However, they only use the 
HepG2.2.15 cell model of infection and only measure the levels of HBsAg, HBeAg and 
HBV DNA found in harvested supernatants following hypoxic exposure. Our data is 
based upon multiple models of infections and more stringent experimental techniques 
that measure the levels of HBV nucleic acid expression harvested from cell lysates of 
infected cells. Importantly, Song and colleagues suggest that low oxygen and 
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inflammation increase miR-210 activity, which causes reduced viral replication (Song et 
al., 2014). If our data is correct, then HBV is overcoming this down regulation whilst in 
low oxygen regions. Zhang and colleagues also demonstrate a role for miR-210 and 
miR-199a-3p in reducing viral replication following up-regulation during inflammation 
(Zhang et al., 2010), however they do not utilise low oxygen in their study. This result 
suggests that up-regulation of micro RNAs is part of an anti-viral response that is at 
least partly controlled through HIF stabilisation. 
Our studies highlight the need for further study into low oxygen and inflammatory 
effects on HBV replication. The data shown in this thesis indicates that cccDNA, rcDNA 
and pgRNA levels are increased under low oxygen. We have studied the effect of low 
oxygen on viral entry and demonstrated no change following hypoxic incubation (data 
not shown). This implies that either low oxygen is promoting nuclear import of virions 
following infection, or more likely, low oxygen is promoting transcription from cccDNA. 
This would result in up-regulation of pgRNA and generate more template for rcDNA 
synthesis. Increased synthesis of rcDNA results in increased levels of re-import and 
therefore increased cccDNA levels. Especially considering our data suggests that low 
oxygen was not increasing the level of secreted rcDNA. Multiple repeat infections 
demonstrated different patterns of viral replication up-regulation. Up-regulation is not 
consistently at any one timepoint. This suggests that the process is controlled by the 
virus and that up-regulation is regulated to reflect different stages of infection lifecycles. 
This could suggest that HBV infections occur preferentially under low oxygen 
conditions before spreading through the liver. In addition, low oxygen induced 
expression of viral nucleic acids, perhaps suggesting that HBV pathogenesis is 
increased under low oxygen environments. Alternatively, this could represent the 
dynamic nature of HIF signalling. In conclusion, the virus is likely utilising a host 
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transcription factor to regulate viral transcription and replication. Considering the 
challenges with treating HBV due to the formation of cccDNA and a reservoir for 
replication, a better understanding of these host-viral interactions and the effect on 
infection progression, could reduce the burden of infectious disease on human health. 
In addition, our findings highlight a potential role for HIF inhibitors as therapeutics in the 
treatment of HBV. 
6.1 Future Work 
While these data have uncovered a role for low oxygen in the HBV lifecycle, more 
investigation is necessary to validate the involvement of HIF-1α and HIF-2α; and 
determine the circumstances under which each isoform is utilised. It would be valuable 
to perform additional ChIP experiments to confirm whether all HIF isoforms can bind to 
the HRE motif within the genome. These interactions have only been demonstrated 
using the HepG2.2.15 cell model so far, it would be important to expand upon this 
result and demonstrate interactions using a de novo infection model. Additionally, it 
would be interesting to examine the effect of low oxygen on the epigenetics of cccDNA. 
It is well known that low oxygen can induce epigenetic changes through the recruitment 
of HDACs to chromosomes (Kim et al., 2007, Liang et al., 2006), and previous 
research has shown that cccDNA behaves as a mini chromosome and undergoes 
epigenetic changes (Yoo et al., 2008, Belloni et al., 2009). However, there is no 
research that examines the role hypoxia might play on cccDNA. It would be interesting 
to examine epigenetic changes in cccDNA following hypoxic exposure; and investigate 
the impact of any epigenetic changes on HIF binding to the genome. Additionally, it has 
been shown that specific PHD activities are determined by the oxygen tension with 
each PHD being regulated by a different effective Km (Schofield and Ratcliffe, 2004). 
This in turn determines the HIF isoform that is expressed depending on the cell type 
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(Schofield and Ratcliffe, 2004, Berchner-Pfannschmidt et al., 2008). It would be 
interesting to examine whether the oxygen tension can alter the isoform of HIF that 
bind the HBV genome. We demonstrated that different promoters are regulated 
through the expression of HIF-1α or HIF-2α using over expression plasmids; promoter 
activation seems to occur despite only finding an HRE binding site in the EnhI/ X 
promoter. A study of HIF isoform binding to HBV promoters under varying hypoxic 
oxygen tensions would be interesting and would complement our data using HIF over 
expression plasmids. 
Although we observed a decrease in viral replication through inhibition of cccDNA, 
rcDNA and pgRNA levels following transfection with siRNAs or treatment with NSC; the 
role of HIFs in viral replication could be further studied using knockout cell lines 
generated with the CRISPR knockout system or perhaps an inducible knockout 
system. This is important because whilst the siRNAs and HIF inhibitor are effective, 
their reduction of HIF expression is not 100%. It would be interesting to examine an 
HBV infection in cells with complete knockout, would an HBV infection be viable 
independent of HIFs? Having demonstrated that HBV-HIF interactions are not 
necessarily through HBx and that stabilisation is independent of HBx and LHB, it would 
be interesting to examine the interaction between HIFs and other viral proteins. 
Considering the observed increase in replication, it is possible that HIFs are interacting 
with the Core protein or the viral polymerase. This could be achieved using GST bound 
agarose affinity beads and a pulldown assay. 
Another interesting direction for future study, would be the examination of HBV induced 
HIF stabilisation on host metabolism and the impact on HBV. Previous reports have 
demonstrated that HBV alters the hexosamine biosynthetic and phosphatidylcholine 
pathways (Li et al., 2015). Other studies also demonstrate that these pathways are 
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regulated by low oxygen (Guillaumond et al., 2013). Hexosamine is specifically 
involved in post-translational modifications (Taparra et al., 2016, Ferrer et al., 2014) 
and could be utilised by HBV to induce changes in cccDNA structure. In addition, HIFs 
are strongly associated with glucose metabolism changes, through HRE activation and 
regulation of genes such as GLUT1 and GLUT3 amongst others (Semenza, 2003, Kim 
et al., 2006a). It would be interesting to study the impact of viral infection on host 
metabolism and how these changes affect the virus. 
HBV is strongly associated with the development of HCC; however, the pathogenesis 
of HBV-related HCC is currently not clear. Evidence suggests that HBV could induce 
malignant transformation through direct integration of the viral genome into host 
chromosome or HBx associated activation of the MAPK pathway and inhibition of the 
p53 tumour suppressor (Ueda et al., 1995, Wang et al., 1994). It is also suggested that 
chronic infections induce HCC formation through cycles of inflammation and 
regeneration; and as a consequence of cirrhosis development (El-Serag, 2012). HIFs 
are known to affect most of the hallmarks of cancer (Wigerup et al., 2016) and we 
demonstrated that HBV can stabilise HIF expression over extended time periods. It 
would be interesting to investigate the contribution of HBV stabilised HIFs on the 
process of HCC development. In addition, hypoxia induces epigenetic changes through 
recruitment of HDACs, which modify chromosomes and reportedly cccDNA (Yoo et al., 
2008). Epigenetic changes are associated with improved infection outcome (Koumbi 
2015). These in turn could cumulatively be responsible for the development of HCC in 
chronic infections. 
Our results indicate that low oxygen does not increase secreted rcDNA levels, but we 
did observe an increase in the percentage of HBs positive cells over time, indicating an 
increase in the number of infected cells. It would be interesting to examine how low 
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oxygen is increasing viral replication. This increase could be due to vertical spreading, 
whilst cells are dividing or perhaps increasing susceptibility to infection. This could be 
tested through the use of cell cycle inhibitors such as RO-3306 (Vassilev, 2006) or cell 
cycle arrest using gamma-irradiation (O'Connell et al., 1998). Following treatment with 
each of these methods, examination of viral spread under 20% and 1% oxygen would 
provide more evidence to determine how low oxygen is affecting spread. 
Lastly, this thesis has demonstrated the pro-viral effect of low oxygen in the HBV life 
cycle, specifically showing a role for HIF-1α and HIF-2α. It will be important to expand 
this research to include HIF-independent low oxygen signalling pathways because 
hypoxic responses are dynamic and subject to fluctuation. In addition, it would be 
interesting to further investigate the role of HIF3α in the viral lifecycle, to date, there are 
very few studies that investigate the role of this protein in uninfected cells and even 
less for viral infections. 
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8. SUPPLEMENTARY FIGURES 
 
Figure 8.1A Comparison of up-regulated hypoxic genes in HBV de novo 
infection 
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Figure 8.1B Comparison of up-regulated hypoxic genes in HBV de novo 
infection (Cont.) 
Legend on next page 
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Figure 8.1B Comparison of up-regulated hypoxic genes in HBV de novo 
infection (Cont.) 
A/B) Table summarising up-regulated genes on hypoxic gene array and comparing 
changes between 24 and 72 hours of early infection. De novo infection of HepG2-
NTCP K7 cells with HBV (MOI 100). For comparison, table includes genes up-
regulated by hypoxic control (1% oxygen) and HepG2.2.15 cells. 
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Figure 8.2 Cartoon representation of DNA/ RNA purification process 
(adapted from Qiagen, USA) 
